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Due to climate change and uncertainties in global fuel prices, there is a need to adopt 
biomass derived feed stocks for sustainable manufacturing of fuels, chemicals and 
pharmaceuticals. As a result, many major industrial manufacturers are now seeking 
routes to their products that are sustainable, more efficient, and less waste or energy 
intensive. While bioprocesses to produce compounds ranging from therapeutic drugs 
to fuels have already been widely implemented, the current microbes being 
employed are often relatively inefficient and limited in the feedstocks they can 
utilise. Inherent to successful bioprocess development is the ability to rapidly and 
predictably engineer microbes for the efficient flux of simple biomass towards 
compounds of industrial significance. Current iterative and empirical processes for 
microbial strain improvement are limited and therefore improved enabling 
technologies to accelerate these processes are required. 
  
To address these issues, this thesis describes the development of a platform for the 
rapid and predictable engineering of microbes for industrial bioprocesses.  This has 
been achieved through complementing an accelerated DNA assembly technique for 
biosynthetic pathway construction with quantitative proteomics to identify pathway 
bottlenecks and guide subsequent rounds of pathway optimisation.  Only through the 
ability to rapidly construct biosynthetic pathways and then assess the failure or 
success of the introduced pathways can microbes be engineered in an intuitive and 
predictable manner.   
 
A central theme of this thesis is the optimisation and implementation of a DNA 
assembly technique for the construction of multicomponent pathways. Despite being 
a fundamental aspect of strain engineering, DNA assembly is often unreliable and 
time consuming. One limitation of this technique is the reduced efficiency observed 
in the assembly of multiple DNA fragments (as is often the case when constructing a 
heterologous pathway). To overcome this issue a ‘nested’ DNA assembly 
methodology has been developed for the predictable construction of combinatorial 
vector libraries and complex vectors resulting in the successful assembly of up to 10 
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fragments.  Appropriate shake flask and microtiter plate assays were additionally 
developed to characterise these constructs. A parallel strand of this work has been the 
optimisation of the methodology to maximise throughput and efficiency whilst also 
ensuring the method is amenable to process automation. 
 
To exemplify the power of proteomics in guiding strain engineering the reverse 
glyoxylate shunt was selected as a simple benchmark heterologous pathway in the 
commonly used host, Escherichia coli.  This pathway allows for the conversion of 
tricarboxylic acid cycle intermediates malate and succinate to oxaloacetate and two 
molecules of acetyl-CoA.  Strains have been engineered to overexpress the pathway 
genes and tryptic digestions of cell lysates carried out. Liquid chromatography, mass 
spectrometry and data analysis methods have been developed for the identification of 
over 100 proteins from these lysates. Work was then focused on developing 
quantitative acquisitions which will allow for the identification of pathway 
bottlenecks. The coupling of techniques for pathway engineering and pathway 
analysis will create a step change in the speed and predictability with which microbes 
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Industrial biotechnology provides an opportunity to decrease the current reliance on 
fossil fuels through the development of bioprocesses to convert renewable carbon 
sources into industrially useful compounds. These products include, but are not 
limited to, fine and bulk chemicals, polymer intermediates, therapeutics, consumer 
products or renewable fuels. 
This approach generally involves the engineering of a microbial host to efficiently 
catalyse the conversion of a sustainable feedstocks into the product of interest. This 
can be achieved – for example - through manipulating the microbial host to over-
produce native and heterologous (foreign) enzymes through the introduction of DNA 
and reducing or eliminating competing reactions through the removal of native DNA.  
A key bottleneck in the implementation of this approach, however, is the speed and 
predictability with which microbes can be engineered to produce the product of 
interest. This results in the development of a bioprocess becoming a costly and time 
consuming endeavour for the end user.  
In this thesis I will develop suite of techniques which aim to bring increasing 
predictability and overcome persistent limitations associated with today’s iterative and 













Mass Spectrometry  
ACN – Acetonitrile 
CID – Collision Induced Dissociation 
Da – Dalton 
DDA – Data dependent acquisition 
DIA – Data independent acquisition 
ESI – Electrospray Ionisation 
FA – Formic acid 
ICAT - Isotope-coded affinity tagging 
iTRAQ - Isobaric tags for relative and absolute quantification 
kDa – Kilodalton 
LC – Liquid chromatography  
m/z – Mass to charge ratio 
MALDI – Matrix assisted laser desorption ionisation 
MS – Mass spectrometry 
MS/MS – Tandem mass spectrometry 
MSE - Data independent acquisition which alternates between high energy and low 
energy scans 
 
RT – Retention time 
SILAC- Stable isotope labelling by amino acids in cell culture 





ABTS – 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)  
bp – base pair 
CFU – Colony forming unit 
CRISPR - Clustered regularly interspaced short palindromic repeats 
DNA – Deoxyribonucleic acid 
dsDNA – Double stranded DNA 
dNTPs - Deoxyribonucleotides 
ELISA - Enzyme-linked immunosorbent assay 
eGFP – Enhanced green fluorescent protein 
ExoIII – Exonuclease III 
LOl – Linker oligo long 
LOs – Linker oligo short 
LOA – Linker oligo annealed 
MAGE – Multiplex automated genomic engineering 
ORF – Open reading frame 
Ori – Origin of replication 
PCR – Polymerase chain reaction 
PAGE - Polyacrylamide gel electrophoresis 
PEG – Polyethylene glycol 
POl – Part oligo long 
POs – Part oligo short 
POA – Part oligo annealed 
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PS – Phosphorothioate 
RBS- - Ribosome binding site 
mRNA – Messenger ribonucleic acid 
TP – Truncated part 
UTR – Untranslated region 
 
General 
°C – Degrees Celsius 
µg – Microgram 
µl – Microlitre 
µM - Micromolar 
ADH – Alcohol dehydrogenase 
ATP – Adenosine triphosphate 
BSA – Bovine serum albumin 
CFE – Cell free extract 
CoA – Coenzyme A 
Da – Dalton 
ddH2O – Double distilled H2O 
DTT - dithiothreitol 
E. coli – Escherichia coli 
HRP – Horseradish peroxidase 
g – Gram 
IPTG - Isopropyl β-D-1-thiogalactopyranoside 
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Kb –Kilobase pair 
L – Litre 
LB – Luria-Bertani 
mg – Milligram 
mM – Millimolar 
mRNA – Messenger ribonucleic acid 
ng – Nanogram 
nm – Nanometre 
OD600 - Optical density at 600 nm 
pg – Picogram 
Reverse osmosis - RO 
rGS – Reverse glyoxylate shunt 
Room temperature – RT 
RPM – Revolutions per minute  
S. cerevisiae – Saccharomyces cerevisiae 
SOC – Super optimal culture 
SD – Standard deviation 
SDS-PAGE - Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
U – Enzyme unit 
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1.1 Production of chemicals through bioprocesses 
 
The development of sustainable bioprocesses for the conversion of renewable 
feedstocks into fuels, chemicals and pharmaceuticals offers an attractive solution to 
the current reliance on petrochemical based routes1, 2. The current linear utilisation of 
carbon relies on taking petrochemical feedstocks from the earth for use, after which 
they end up as carbon dioxide in the atmosphere. In contrast a bioprocess can be 
defined as one which harnesses the power and diversity of nature via a micro-
organism to convert a biological feedstock into an industrially relevant product. In 
this process carbon dioxide and water are converted to sugar by plants which can 
then be converted to the chemical of interest by microbial fermentation. These 
chemicals can then be used in the desired application and if they cannot be re-used, 
are converted back to CO2 completing a closed loop cycle. Concerns over climate 
change and global fuel prices are driving the move towards a bio-based economy.  
Despite the relatively recent initiative to move away from petrochemical feedstocks 
the industrial fermentation of microbes for chemical production predates the 
utilisation of petroleum based feedstock. Lactic acid fermentation was the first 
industrial fermentation processes for the production of a pure chemical. Initially 
described as a component of sour milk by Carl Wilhelm Scheele in 1780 it was not 
until 1858 when Louis Pasteur discovered that it was not a component of the milk but 
rather a metabolite generated through the fermentation of certain microorganisms, 
which he called lactic yeast3. By 1883 the process had been industrialised by Charles 
Avery who opened a lactate fermentation plant in Littleton, USA. Around the same 
time the German chemist Carl Wehmer was developing an industrial process for the 
production of citric acid through fermentation. Despite this process not progressing 
beyond pilot scale due to a combination of technical and sterility issues it laid the 
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ground work for the first commercial citric acid plant using the microorganism 
Aspergillus niger by Pfizer Inc. in 19234. 
A further fermentation process with a long history is the use of Clostridium 
acetobutylicum for the production of acetone, butanol and ethanol (referred to as 
ABE fermentation)5. This process first rose to prominence during the 1st world war 
when acetone was a much sought after chemical due to its use as a solvent for the 
manufacturing of the smokeless explosive cordite. This resulted in Chaim Weizmann 
patenting his process utilising Clostridium acetobutylicum for industrialisation of the 
process. However, during the 1950’s the process was superseded by cheaper 
petrochemical based production processes. The recent drive for renewable chemical 
production with a reduced carbon footprint has resulted in a renewed interest in the 
process from a number of companies6, 7. 
The following decades saw a focus on the development of a number of processes 
utilising microbes to produce natural products of pharmaceutical interest including, 
antibiotics, cholesterol lowering agents, anti-cancer drugs and immunosuppressants8. 
The improvement of these processes relied primarily on identification of a natural 
producer followed by strain mutagenesis and the screening of the resulting library for 
improved producers. This approach was particularly successful for antibiotics where 
a number of powerful screens were available with penicillin production using 
Penicillin chrysogenum increased by over 1,000-fold9. Today the development of 
strains for production of recombinant biopharmaceuticals proteins is a market with 
sales exceeding $100 billion10. 
 
1.2 Metabolic engineering 
 
The advent of recombinant DNA technology during the 1970s and 1980s provided 
the tools for researchers to engineer microbial strains specifically for industrial 
bioprocesses11, 12, 13.  This allowed researchers to use recombinant DNA techniques 
to either increase the production of native metabolites or to re-route metabolism for 
the production of new industrial compounds not natively produced by the chosen 
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host organism. This initially focussed on the production of proteins through the 
introduction of a single gene.  Early success such as the engineering of Escherichia 
coli to produce human insulin14, an idea which became feasible following the 
engineering of E. coli to produce human growth hormone15, highlighted the ability to 
produce a chemically complex molecule through the overexpression of a single gene. 
This resulted in the conception of the first “molecular biology based” biotechnology 
company, Genentech, who licensed the technology to produce human insulin from a 
gene cloned in E. coli to the insulin producer Eli Lilly.   
Since then the engineering of microbes through the introduction and deletion of 
genes to enable and maximise the production of a plethora of fuels, chemicals and 
pharmaceuticals from plant based renewable feedstocks such as starch, cellulose and 
lignocellulose as opposed to petrochemical feedstocks has been a primary goal of the 




Despite there being many published reports of microbial strains being engineered for 
the heterologous production of fuels16, chemicals17 and pharmaceuticals18, 19 
relatively few have been progressed to an industrial scale (Table 1), whilst those that 
have, have proved to be extremely cost, time and labour intensive. These difficulties 
are directly linked to the efficiency and predictability with which microorganisms 
can be adapted for use in industrial bio-processes, a key issue this work aims to 
address. 
Product Host Status Companies Reference 
1,3 Propanediol E. coli Commercialised DuPont, Tate & Lyle www.duponttateandlyle.com  
1,3 Butanediol E. coli Demonstration Genomatica and Versalis www.genomatica.com 
1,4 Butanediol E. coli Commercialised Genomatica and Dupont www.genomatica.com 
Isoprene S. cerevisiae Preparing commercialisation Amyris, Braskem, Michelin www.amyris.com  
Isobutene E. coli Demonstration Global Bioenergies www.global-bioenergies.com  
Squalene S. cerevisiae Commercialised  Amyris www.amyris.com  
PHA E. coli Commercialised  Metabolix www.metabolix.com 
Farnesene S. cerevisiae Commercialised  Amyris www.amyris.com  
Isobutanol S. cerevisiae Commercialised  Gevo www.gevo.com  
Table 1: Production of platform chemicals through the utilisation of engineered microbes in industrial bioprocesses (PHA – polyhydroxyalkanoate). 
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Gevo have commercialised a bioprocess utilising a genetically engineered yeast 
strain to produce isobutanol from renewable feedstocks. The branched chain higher 
alcohol isobutanol is commercially attractive both as a next generation biofuel due to 




Figure 1: The metabolic pathway utilised for the production of isobutanol from pyruvate:  ADH, alcohol 
dehydrogenase; ALS, acetolactate synthase; DHAD, dihydroxy-acid dehydratase; KAR, ketol-acid 
reductoisomerase; KDC, keto-acid decarboxylase. 
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Engineering of S. cerevisiae to produce isobutanol at high yields is achieved through 
diversion of carbon from the branched chain amino acid biosynthesis intermediate 
ketoisovalerate (KIV). The engineering of the strain to express a 2-keto acid 
decarboxylase21 and alcohol dehydrogenase activity22 results in isobutanol 
production from KIV (Figure 1). Further engineering of the strain to overproduce 
KIV and limit the formation of ethanol and acetic acid increased strain productivity 
under anaerobic conditions. Gevo has coupled this engineered strain to a process 
involving continuous stripping of isobutanol from the culture broth through flash 
evaporation resulting in the commercialisation of a bio-based process approaching 




Production of chemical building block 1,3-propanediol through engineering of E. 
coli by DuPont, in collaboration with Genencor and Tate and Lyle was industrialised 
with reported titers of up to 135 g l -1 24. The production of 1,3-propanediol was 
achieved via the glycolytic triose dihydroxyacetone phosphate (DHAP) which is 
reduced and dephosphorylated to glycerol. As E. coli is intrinsically a poor glycerol 
producer the team first introduced a glycerol production pathway from S. cerevisiae. 
This was followed by two genes from Klebsiella pneumoniae to dehydrate and 
reduce glycerol to 1,3-propanediol (Figure 2). Further optimisation of the strain was 
achieved through the elimination of E. coli pathways competing for consumption of 
glycerol, optimisation of glucose import and the use of a previously uncharacterised 
endogenous E. coli enzyme for the final reduction of 3-hydroxypropanal to 1,3-
propanediol. This process continues to be used by DuPont for the bio-based 




Figure 2: Metabolic engineering of E. coli for the production of 1,3-propanediol. Engineering focussed on the 
conversion of dihydroxyacetone phosphate (DHAP) to 1,3-propanediol. Glycerol production via glyceraldehyde 3-
phosphate (G3P) was achieved through the introduction of glycerol 3-phosphate dehydrogenase (DAR1) and 
glycerol 3-phosphate phosphatase (GPP2) genes from Saccharomyces cerevisiae. Introduction of glycerol 
dehydratase (dhaB) from K. pneumoniae enabled the conversion of glycerol to 3-hydroxyproponal with the final 
reduction to 1,3-propanediol catalysed by an endogenous E. coli oxioreductase (yqhD).  
 
1.3.3 Artemisinic acid 
 
Jay Keasling’s team at the University of California, Berkley were able to introduce in 
Saccharomyces cerevisiae a metabolic pathway responsible for the production of a 
precursor for the anti-malaria drug artemisinin, artemisinic acid25. Malaria affects 
over 200 million people annually26 and disease control is hampered by the 
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occurrence of drug resistant strains of the malaria parasite Plasmodium falciparum. 
Whilst synthetic antimalarial drugs and vaccines are in development they are 
awaiting clinical trials27. Artemisinin is a sesquiterpene lactone endoperoxide 
extracted from the plant Artemisia annua which is a highly effective treatment 
however it can be in short supply28 due to relatively low extraction yields and 
subjection to year to year variations in crop performance. Whilst the full chemical 
synthesis of artemisinin was achieved in 1983 it has proven too complex and costly 
for commercialisation29. Therefore, the semi-synthesis from microbially sourced 




Figure 3: The biosynthetic production of artemisinic acid from renewable feedstocks overview. Artemisinic acid is 
produced from the mevalonate pathway intermediate farnesyl-pyrophosphate (FPP). In blue are the genes of the 
upper mevalonate pathway which converts acetyl-CoA to mevalonate. In red are the genes of the lower 
mevalonate pathway for the production of FPP. These genes were overexpressed in the production strain. In 
yellow is the amorphadiene synthase gene from A. annua which was heterologously expressed in the production 
strain. In yellow are the P450 enzyme (CYP71AV1) and its redox partner (CPR) from A. annua which catalyse the 
three step oxidation of amorphadiene to artmesinic acid. 
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During the development of this process both E. coli and S. cerevisiae were explored 
as well understood and genetically tractable potential hosts for artemisinic acid 
production. Strain engineering was initially focused on the accumulation of the 
precursor amorphadiene. To achieve this the group focussed on the native isoprenoid 
production pathways in both E. coli and S. cerevisiae, the 1-deoxy-D-xylulose 5-
phosphate (DXP) and mevalonate pathways respectively. Initial efforts to 
overexpress rate limiting enzymes within the DXP pathway in E. coli only had 
limited success with terpenes produced in the low mg per L range30. Production in E. 
coli was improved through the heterologous expression of the S. cerevisiae 
mevalonate pathway and the introduction of a synthetic codon optimised 
amorphadiene synthase (ADS) from A. annua31 which is responsible for the 
conversion of farnesyl pyrophosphate from the mevalonate pathway to 
amorphadiene, however the levels following optimisation of the fermentation process 
were still 50-fold lower than the estimated concentration required for an 
economically viable process32.  
 
Analysis of the limitations of this strain highlighted that when the upper part of the 
mevalonate pathway was overexpressed growth was inhibited. It was hypothesised 
that this inhibition in growth was the result of the accumulation of a pathway 
intermediate. A combination of operon optimisation through a combinatorial 
approach using tuneable intergenic regions33 and targeted transcriptome and 
metabolite analysis showed that the accumulation of hydroxymethylglutaryl (HMG)-
CoA resulted in the observed growth inhibition. The optimisation of this node to 
alleviate pathway bottlenecking coupled to process optimisation resulted in strain 
capable of producing 25 g per L amorphadiene34.  
 
The conversion of amorphadiene to artemisinic acid was found to be catalysed in the 
native host by a cytochrome P450 enzyme through the analysis of cell free extracts35. 
E. coli has typically been a poor expression host for eukaryotic P450 enzymes32 and 
therefore the expression of the P450 and its cognate reductase was first tested in an 
amorphadiene producing S. cerevisiae strain resulting in 100 mg per L artemisinic 
acid25. This resulted in a change in host organism, despite the lower amorphadiene 
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yields produced in S. cerevisiae - 150 mg per L compared to E. coli 25 g per L - the 
inability of E. coli to efficiently express the P450 enzymes resulted in S. cerevisiae 
being identified as the optimal host. Further pathway and fermentation optimisation 
using the engineered S. cerevisiae strain resulted in a strain producing the 25 g per L 
artemisinic acid targeted at the beginning of the project35. This project is one of the 
first examples of engineering a strain for the use in a bioprocess using tools such as 
combinatorial DNA assembly and codon optimised gene synthesis for pathway 
construction coupled to transcriptomics and metabolomics analysis for heterologous 
pathway optimisation. 
 
Despite the successes described above it took 10 years to take the proof of concept 
Saccharomyces cerevisiae artemisinin production strain through to one that was 
scaled to industrially relevant levels at an estimated cost of 50 M USD. It is believed 
to have taken 15 years at a cost of 130M USD for the development of the 1,3-
propanediol process8. This highlights the difficulty and extensive time required in the 
optimisation of a proof of principle strain into an industrially applicable strain.  
 
Using traditional approaches each stage of engineering is carried out sequentially 
adding to time and cost. The implementation of new technologies has the potential to 
decease this time and accelerate the implementation of the industrial bioprocess 
(Figure 4). This PhD focusses on addressing limitations in both the construction and 
characterisation of the microbes engineered for industrial applications. 
 
 
Figure 4: Development of an industrial strain from proof of principle can be a long and costly processes. As a 
result, the implementation of new technologies to accelerate this process is required (adapted from8). 
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1.4 Synthetic Biology 
 
The field of synthetic biology has grown rapidly from 2004 when the first synthetic 
biology conference, Synthetic Biology 1.0, was held at Massachusetts Institute of 
Technology (MIT). A year later, Drew Endy published a review entitled Foundations 
for engineering biology36 in which the application of three engineering principles 
(standardisation, decoupling and abstraction) to biotechnology were outlined: the use 
of DNA in the form of standardised biological parts which are well defined, 
described and characterised; reducing the complexity of engineering a system 
through splitting it into a number of smaller tasks which are eventually combined; 
and reduction of complexity through the use of parts which interact with each other 
in a known fashion, thus making them easier to model and combine. This review was 
one of the first to suggest the application of engineering principles to genetic 
engineering and has shaped the evolution of a rapidly growing field since37,38,39,40. 
Despite the field of synthetic biology spanning a broad range of topics including ones 
which are not directly related to the engineering of organisms for biotechnology, key 
synergies exist. Critically, this includes the predictable engineering of biological 
hosts. 
 
The field has been driven by a number of technological breakthroughs particularly 
relevant to strain engineering, including: (i) Advance in the development of robust 
genetic parts such as those that provide tight control over gene transcription through 
synthetic promoter design41 and the ability to rapidly combine multiple genetic 
fragments42. (ii) Reduction in the cost of DNA sequencing43 – allowing for whole 
microbial genomes to be sequenced relatively cheaply - and the continued reduction 
in DNA synthesis cost44,45 have not only allowed researchers to develop synthetic 
pathways which go beyond merely redirecting carbon flux through the host’s natural 
pathways but also to select and introduce enzymatic functions through the 
identification of the appropriate genes from the abundance of sequenced organisms. 
(iii) The development and implementation of transcriptomics46,47 , metabolomics48, 49 
and proteomics50 techniques, known collectively as “omics”, which provide a level 
of understanding of limitations in cell engineering not previously achievable. In 
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addition to these techniques efforts have been focused on the construction of genome 
scale metabolic models, commonly generated from omics data, which describe the 
inter-conversion of metabolites through enzyme catalysed chemical 
transformations51. These models have been used to characterise biological production 
systems and identify non-intuitive engineering strategies to optimise strain 
productivity52 . 
 
The tools developed in the field of synthetic biology can be combined to accelerate 
not only the engineering of microbes for industrial bioprocesses but also enhance the 
level of understanding of the engineered organism’s limitations and guide subsequent 
rounds of strain improvement.  
 
1.5 The design build test learn cycle - accelerating engineering of cellular 
metabolism 
 
With the advent of synthetic biology, the engineering of microbes for use in a 
bioprocess can be considered less of a one off ad hoc process and instead can be 
thought of as a repeating cycle split into four primary components, design (D) of the 
biological system, building (B) of the necessary genetic constructs, test (T) of the 
generated cell system and learn (L) to generate information on the successes or 
failures of the cycle to feed into the next turn of the cycle. Through the utilisation of 
enabling tools developed in the field of synthetic biology each stage of this process - 
known as the design-test-build-learn cycle - can be optimised to accelerate microbe 




Figure 5: The design, build, test, learn cycle for the engineering of microbes for industrial bioprocesses. 
 
1.5.1 Design  
 
The engineering of a microbe standardly begins with the design stage during which a 
chemical of industrial interest is targeted. This is followed by the identification either 
of metabolic pathways present in nature to produce this target or the identification of 
genes from throughout nature that can be stitched together into a pathway to produce 
the chemical from an intracellular metabolite.  
The simplest strategy typically relies on a classical strain engineering approach in 
which a natural producer of the target chemical is identified and exploited for further 
improvement through mutagenesis coupled to high throughput screening. This 
approach has proven to be been extremely efficient and has resulted in the bio-based 
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production of multiple biopharmaceuticals as mentioned previously. Implementation 
of a more rational engineering approach from a native producer for the 
overproduction of the compound of interest relies on several parameters including, 
ease of handling and culturing of the organism, in-depth knowledge of host 
metabolism and regulation, efficient procedures in genetic material transfer, 
availability of molecular biology tools and of genomic sequence data. Each of these 
parameters would be considered before engineering the native producer to enhance 
production of the desired compound. 
In absence of a characterised natural producer or in the case of a genetically 
intractable host, the genes involved in the generation of the product of interest 
require to be transferred into a heterologous host. This approach usually utilises a 
well characterised host for which standard molecular biology tools are available such 
as E. coli53, S. cerevisiae54, 55 , Bacillus subtilis56, Corynebacterium glutamicum57 or 
Pseudomonas putida58, 59 . Each of those micro-organisms has specific advantages 
which would guide the choice of host for specific applications. P. putida for example 
is extremely solvent tolerant60 making it an attractive host for the production of 
certain chemicals whilst B. subtilis has very efficient protein secretion machinery61 
making it a promising choice for the industrial production of enzymes due to the 
savings associated with reduced downstream processing.  
This stage also involves the engineering of the host strain to maximise target 
production, which can involve: (1) modulation of substrate uptake (2) down 
regulation of cellular pathways competing with the desired heterologous pathway; 
(3) enhancing cellular tolerance to the chemical of interest62, 63 , through for example 
transporter and membrane engineering; (4) balancing of reducing power to drive flux 




Following the choice of host and the definition of the required reactions to produce 
the compound of interest the required biosynthetic pathway is standardly constructed 
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in vitro. This involves the synthesis (and potentially host specific codon 
optimisation) or amplification of the genes required to encode the enzymes involved 
in the metabolic pathway and the combination with associated regulatory regions 
such as promoters, terminators and ribosome binding sites which can be used to 
modulate the amount of enzyme production at each stage of the pathway.  The goal 
of this modulation is to balance pathway enzyme production levels, ensuring flux 
through the pathway avoiding any build up potentially toxic pathway 
intermediates65,66 without putting an unnecessary burden on cellular metabolism67. 
The ability to rapidly construct these biosynthetic pathways in a combinatorial 
manner is an area which has seen significant growth recently and is reviewed later in 




The test stage of engineering an industrial microbe involves the utilisation of 
analytical techniques which allow for determination of the success of the design and 
build stages. This can include, confirmation of the success of the build stage 
(including successful biosynthetic pathway construction and implementation of gene 
knockouts), growth and physiological characterisation of the engineered strains and 
analysis of product formation. 
The analysis of product formation often relies on techniques such as gas or liquid 
chromatography coupled to either UV absorbance or mass spectrometry (MS) based 
detection. Whilst these approaches combine reliable target identifications with 
accurate and precise target compound quantification, they lack the required 
throughput for the screening of large strain variant libraries. Consequently, a higher 
throughput screen or selection could be implemented as a preliminary step. Examples 
of high throughput screening methods include solid-phase assays in which product 
formation can be coupled to growth or a colorometric response and liquid-phase 
assays which are based on spectroscopic measurements such as colorimetric, UV 
absorbance or fluorescence in microtiter plates68, 69. As specific assays for target 
molecules are often lacking there has been a recent focus on the development of 
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biosensors70, 71, 72.  A biosensor standardly functions through protein or transcript 
based sensing the of target molecule coupled to the expression of a reporter such as 
green fluorescent protein (GFP). The combination of this approach with fluorescent-
activated cell sorting (FACS) can result in an extremely high-throughput screening 
platform.  
Recent advances in the analysis of transcript, metabolite or protein abundance using 
mass spectrometry based omics’ approaches for the optimisation of industrial 




The learn stage is arguably the least systematic in metabolic engineering strategies 
and often relies on ad hoc observations and the intuition of individual researchers 
who define the next stages of engineering. With the increasing amount of data 
generated during the test cycle, techniques such as principal component analysis 
(PCA) have been used to analyse small proteomics dataset from engineered 
organisms and deduce patterns or trends to guide subsequent rounds of engineering73. 
In the future sophisticated data analysis tools such as machine learning74 will likely 
be necessary to process the large diverse datasets collected during the learn cycle and 
deduce strain limitations to guide subsequent rounds of engineering 
 
1.6 Accelerating the build stage 
 
As metabolic engineers looked to accelerate the engineering of microbes for 
bioprocesses, it quickly became apparent that the inability to assemble multiple DNA 
fragments was one bottleneck which was holding the field back. Despite advances in 
the ability to construct DNA vectors, from the 1970s when the construction of a 
bacterial plasmid would be worthy of a high profile publication75, standard 
techniques involving the digestion of DNA with a restriction enzyme followed by 
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subsequent ligation still only allow for the combination of two or three DNA 
fragments. When multiple pathway genes and their respective regulatory regions – 
promoters, ribosome binding site (RBS), terminators - required to be combined this 
involved laborious multi-stage cloning experiments which proved to be time 
consuming, unpredictable and expensive. This realisation coupled to decrease in the 
cost of synthetic DNA resulted in the development of techniques for the rapid and 
combinatorial assembly of genetic constructs.  
 
1.6.1 DNA assembly methodologies 
 
1.6.1.1 Traditional digestion and ligation methodology 
 
Molecular cloning utilising DNA ligase and type II restriction enzymes has been the 
foundation of metabolic engineering for the past 40 years76. This “cut and paste” 
strategy relies on cleaving of DNA using restriction endonucleases to generate 
compatible sticky-ends. The DNA fragments are then co-incubated in a buffer which 
allows the compatible ends to anneal and in the presence of a DNA ligase which 
covalently seals nicks in the constructed vector. This approach is limited to assembly 
of a maximum three fragments of DNA, with each fragment requiring to be void of 
recognition sites for the restriction enzymes being used. This strategy is also difficult 
to standardise and automate. The limitations of this approach resulted in the 
development of several DNA assembly technologies, each with the goal of allowing 
the assembly of multiple DNA fragments in one reaction thus accelerating the 




BioBricks77 was the first standardised assembly technique to gain traction amongst 
the scientific community. BioBricks are standardised fragments of DNA (known in 
DNA assembly nomenclature as parts) which can be joined together in a Lego-like 
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fashion. The BioBrick approach allows for the combination of up to three BioBricks 
with the resulting construct becoming a new BioBrick, thus allowing subsequent 
rounds of assembly. Both the assembly method and parts are standardised in the 
sense that the enzymes used are constant and therefore the 5’ and 3’ terminal 
sequences are constant. Large databases of these parts have been built up including 
the BioBricks foundation and MIT’s Registry of Standardised Biological Parts. 
BioBricks require to be flanked by two specific restriction sites which cannot be 
present within the part itself (Figure 6). Through digestion and ligation two 
BioBricks can be combined - separated by a 6 base pair (bp) scar – with the resulting 
construct flanked by the original recognition sites meaning that this construct 
becomes a BioBrick in its own right. The main limitation of this approach is the time 
consuming construction of complex vectors due to the stepwise nature of the 
assembly process. A further potential limitation is that the introduction of 6 bp scars 
could be problematic if they occur within certain regions, for example within coding 
sequences in the case of protein domain assembly or between the ribosome binding 





Figure 6: Assembly of two DNA fragments using the BioBricks technology. In this example, DNA assembly is 
achieved through digestion of Part A and B with BamHI/XhoI and BglII/XhoI respectively. This generates 
compatible overhangs allowing ligation of the two BioBricks. As the product of the BioBricks assembly is flanked 
by the original restriction sites further BioBricks can be added in a stepwise manner. 
 
1.6.1.3 Gibson Assembly 
 
Building on the success of BioBricks as a standardised system for DNA assembly, 
Gibson et al78 described a method for the enzymatic assembly of over ten fragments 
of DNA. This technique falls into the category of long overlap DNA assembly 
methods. It differs from techniques which rely on digestion and ligation because the 
complementary overhangs between fragments are usually 15 nucleotides or more in 
comparison to the standard 4 nucleotide generated through restriction endonuclease 
digestion.  
 
Gibson DNA assembly relies on a one pot reaction in which linear DNA parts with 
approximately 25 bp homology, a 5’ exonuclease, a DNA polymerase and a DNA 
ligase are combined (Figure 7). Initially the exonuclease degrades the linear parts in 
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a 5’ to 3’ direction resulting in the generation of single stranded overhangs enabling 
complementary regions to anneal to each other. Next a high fidelity DNA 
polymerase fills in any gaps before the nicks in the final construct are sealed by a 
DNA ligase. The advantages of this technique in comparison to BioBricks are the 
increased number of parts which can be combined, the fact it is largely sequence 
independent in the sense that no specific restriction sites require to be omitted from 
part sequences and that it results in a scarless assembly. It is also extremely simple 
and amenable to automation as all three enzymes and the DNA to be assembled are 
mixed in one reaction, which is incubated at 50 °C for one hour after which the 
resultant constructs are directly transformed. All enzymes act simultaneously during 
the incubation, however the T5 exonuclease is the only temperature sensitive enzyme 
in the reaction resulting in slow heat inactivation through the reaction. Consequently, 
only the polymerase and ligase remain active towards the end of the reaction 
ensuring complete repair of the DNA construct.  
 
 
Figure 7: Assembly of two DNA fragments by Gibson assembly. Sequence overlaps depicted by black boxes. DNA 
assembly is achieved through the action of three enzymes. First a DNA exonuclease degrades the DNA fragments 
in a 5’ to 3’ direction generating single stranded overhangs which are complementary between the parts to be 
assembled. A DNA polymerase then fills in any gaps before a DNA ligase seals nicks in the final construct. 
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The part length, which is restricted to at least 250 bp and the incompatibility of the 
technique with repeated sequences represent the main limitations associated to the 
Gibson assembly technology. A minimum part length of 250 bp is required due to the 
potential degradation of the full length DNA fragment by the exonuclease prior to 
overhang annealing and polymerase-catalysed strand extension. Repeated sequences, 
for instance terminator elements located downstream of each gene in a pathway, are 
problematic as Gibson assembly relies on sequence homology which could result in 
aberrant constructs with missing parts. In order to circumvent this issue, sequential 
assemblies can be performed so that the part junctions including repeated sequences 
are not involved in the same reaction.  However, this procedure adds time and 
complexity to the construction process. Torella et al 79 described a technique in 
which DNA parts were flanked by unique 40 bp nucleotide sequences thus limiting 
the potential for misassembly due to repeated sequences. However, this technique 
requires either an initial cloning or PCR step to attach these sequences to the parts. 
 
1.6.1.4 Golden Gate assembly 
 
A number of the issues encountered with Gibson assembly were addressed in the 
development of the Golden Gate assembly methodology and its variants 80, 81, . This 
technique relies on type IIs endonucleases which are restriction enzymes that 
recognize asymmetric DNA sequences and cleave outside of their recognition 
sequence. Although several type IIs endonucleases are available BsaI is commonly 
used for Golden Gate assembly and will be used as the endonuclease for this 
description (Figure 8). Parts to be assembled using Golden Gate assembly are 
amplified, flanked by BsaI recognition sites (GGTCTCN^NNNN_). The PCR 
products are mixed with BsaI and ligase in a one pot reaction. An initial stage of 
digestion results in the part being liberated from the flanking BsaI sites resulting in 4 
bp overhang sites allowing ligation between the parts to take place in a second stage. 
The initial digestion from the donor amplified fragment is reversible in that it is 
possible to ligate the BsaI containing sequences back onto the part, however once the 
parts are ligated to each other there are no longer any BsaI recognition sites present, 
this meaning that through cycles of digestion and ligation you can enrich towards the 
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formation of the desired product. In comparison to Gibson assembly this technique is 
less sequence independent as it requires the parts to be void of BsaI recognition sites. 
A second limitation is that with overhangs of only four base pairs in length and a 
desire to have at least two bp difference between each set of overhangs there is the 
potential that in complex assemblies it may not be possible to find specific overhangs 
for assembly.  
 
 
Figure 8: Assembly of two DNA fragments by Golden Gate assembly. Homology between parts highlight in boxes. 
DNA assembly is achieved through cycles of digestion and ligation. First, a type IIs restriction enzyme is used to 
digest the target DNA generating compatible four nucleotide overhangs which allow target parts to be ligated. 
To enrich the product of interest the digestion and ligation reactions are repeated multiple times in a cyclic 
manner. 
 
1.6.1.5 Alternative strategies 
 
Despite BioBricks, Golden Gate, Gibson assembly and their variants being the most 
widely implemented DNA assembly strategies several other approaches are 
available, each with associated advantages and disadvantages. In vivo homologous 
recombination based approaches to assemble DNA have been implemented in a 
number of organisms but most widely in S. cerevisiae. The strategy is based on 
transformation of S. cerevisiae with DNA fragments flanked by regions of homology 
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defining the order the parts assemble. The efficient homologous recombination 
machinery of S. cerevisiae is then responsible for the assembly of the genetic 
construct.  This approach has been shown to be extremely efficient and used for the 
construction of eight gene biosynthetic pathways82 and even full synthetic 
genomes83. The main limitations associated with this strategy are the difficulty in S. 
cerevisiae competent cell preparation, the relatively low competency that can be 
achieved in comparison to E. coli (around 105 compared to 109 cfu/µg DNA) and the 
slower growth rate of S. cerevisiae in comparison to E. coli requiring transformation 
plates to incubated for up to four days compared to just one for E. coli.  
 
Site specific recombinases, which are enzymes catalysing the introduction, removal, 
swapping or inversion of DNA fragments through specific recognition sites have also 
been implemented for DNA assembly84.  Unlike the previously described approaches 
which rely on homology between DNA fragments, this strategy is reliant on the 
recombinase enzyme and its associated recognition sites which mediate the DNA 
assembly. A major advantage of such an approach is that fragments can be removed 
or swapped from previously built constructs. For example, when building a 
biosynthetic pathway, a suboptimal gene could be swapped for a more suitable 
variant without having to completely rebuild the genetic construct. Much study in 
this area has been based on the PhiC31 recombinase85, with the focus on increasing 
the number of orthogonal recognition sites available and thus the number of parts 
which can be assembled. One limitation of recombinase based strategies is the length 
of the recombinase recognition sites, which are usually approximately 50bp inverted 
repeats which flank each assembled fragment as scar sequence and may negatively 
impact part performance.  
 
1.6.1.6 inABLE®  
 
Ingenza Ltd. currently uses a combinatorial genetic assembly technology (known 
commercially as inABLE®) for the efficient and selective assembly of complex DNA 
expression vectors encoding, for example, the enzymes responsible for multiple 
biosynthetic transformations within a pathway to produce chemical targets.  
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The inABLE® technology can be split into three stages, part design and preparation, 
part linker fusion and the assembly reaction (Figure 9).  
 
Figure 9: Overview of the assembly of DNA fragments using the inABLE technology. 
 
The part is defined by the researcher and the only sequence constraints are that it is 
over 100bp in length and that it does not contain any EarI or SapI recognition sites. 
Once the part sequence has been defined computer aided design is implemented to 
define the most appropriate region to split the part into the part oligo, the linker oligo 
and the truncated part (Figure 10).  
 
The splits are calculated to ensure that linker oligonucleotides have a melting 
temperature between 35 °C and 45 °C. A scar sequence of GCC is predefined as a 
high GC content is desirable during the ligation stage of the part linker fusion 
reaction. GCC also codes for alanine (or glycine in reverse) so if the introduction of 
the scar sequence within a coding region cannot be avoided a relatively innocuous 
amino acid will be introduced.  
 
The truncated part is cloned into a compatible backbone flanked by recognition sites 
for the type IIs endonucleases EarI and SapI, allowing excision of truncated parts 
devoid of enzyme recognition sites. The part and linker oligonucleotides are split into 
part oligo short (POs), part oligo long (POl), linker oligo short (LOs) and linker oligo 
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long (LOl) and ordered as oligonucleotides. POl and POs are then annealed and 5’ 
phosphorylated to create the “part oligo annealed” (POA). This is repeated for the 
linker oligonucleotides to produce the “linker oligo annealed” (LOA). The melting 
temperature of the overhang between the POA and LOA is prioritised for the split 
design. The designer software selects overhangs with a melting temperature over 
70 °C which consequently leads to an average overhang length of 16 bp depending 
on the GC content. All truncated parts, POAs and LOAs can be recycled for any 




Figure 10: Phase1 – Primer and part design during which the full length DNA part is split into a truncated part 
and part and linker oligonucleotides. 
 
A part linker fusion reaction is performed for each required part junction. These 
reactions are performed in parallel and therefore the time taken to perform the 
assembly is roughly independent from the number of parts necessary for the constructs. 
The part linker fusion reaction is performed through cycles of digestion and ligation. 
Initially an EarI digestion is performed resulting in the truncated part being cleaved 
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from the backbone. Secondly a ligation step is performed in which the corresponding 
POA and the LOA from the subsequent part are ligated to the 5’ and 3’ end of the 
truncated part respectively (Figure 11). In the same ligation step it is also possible for 
the truncated part to be ligated back to its original backbone. To enrich towards the 
desired product (truncated part with ligated 5’ POA and 3’ LOA) samples are 
incubated in a thermocycler which alternates between 37°C and 16°C corresponding 
to the optimum temperatures for digestion and ligation respectively. This enrichment 
through cycling is possible due to the nature of EarI (type IIS endonuclease) which 
cuts outside its own recognition site. As a result, the part linker fusion formed lacks 
EarI sites and therefore is removed from the digestion/ligation cycling. Only the 
residual truncated part inserted into its original EarI-harbouring backbone is able to 
enter the subsequent cycles of digestion.  Part linker fusions are then purified from the 
backbone fragments via gel electrophoresis followed by DNA extraction. 
 
 
Figure 11: Phase 2 - The part/linker fusion reaction. During this reactions are prepared through cycles of EarI 
digestion/ligation. 
 
The assembly reaction is a simple one pot reaction of constant time independent of 
the number of parts being assembled. Equimolar amounts of each part linker fusion 
are mixed and incubated at room temperature for 30 minutes. Parts anneal through 
the complementary 16 bp overhangs generated between the LOA and POA (Figure 
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12). The assembly reaction is then used to transform Escherichia coli and 
transformants screened for correctly assembled vectors.  
 
 
Figure 12: Phase 3 - The assembly reaction. During this reaction purified part/linker fusion products assemble as 
a result of complementary 16 nucleotide single stranded overhangs to generate final vector construct. 
 
1.6.2 Further advances in accelerating the build cycle 
 
Biosynthetic pathway construction capabilities can be further enhanced through the 
utilisation of techniques which are complementary to DNA assembly. A number of 
these can be directly tied to the decreasing cost of DNA synthesis86 allowing large 
libraries of constructs to be built and characterised. A significant amount of research 
has been carried out particularly into the characterisation and construction of libraries 
of promoters87,88 and terminators89, 90, prediction of RBS strengths91 and the effect of 
genome location on gene expression levels92,93, 94 . Each of these approaches can be 
used in parallel with combinatorial DNA assembly strategies to fine tune gene 
expression levels and optimise pathway flux. 
In parallel, techniques such as CRISPR/Cas995 and MAGE96 have facilitated rapid 
and precise modifications of the host organisms genome.. The CRISPR/Cas system is 
an adaptive bacterial and archaeal immune system that can be utilised for rapid 
genome engineering.  The system utilises a guide RNA (sgRNA) to guide the 
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endonuclease Cas9 to the targeted genome location where it catalyses a double strand 
break. During the repair of this break (usually through homologous recombination 
although non-homologous end joining is also possible), DNA introduction or 
deletion can be achieved. This approach has been used to engineer a number of 
organisms including E. coli, P. putida, B. subtilis and S. cerevisiae 97. The system has 
also been adapted for multiplexed gene deletions and insertions 98, 99 as well as gene 
downregulation using a Cas9 protein which has been engineered to maintain DNA 
binding capacity without endonuclease activity (dCas9). The modified dCas9 protein 
can be targeted to the gene of interest to block transcription (CRISPR interference - 
CRISPRi)100. Such a strategy was recently used in C. glutamicum to downregulate 
three genes in order to maximise L-lysine and L-glutamate production101. It was 
found that such an approach resulted in yields comparable to those achieved through 
gene deletion, however the above strategy only took 3 days in comparison to a 
potentially time consuming and cumbersome gene deletion strategy. This approach 
has been further expanded to fuse dCas9 to an activator allowing for gene 
upregulation (CRISPR activation - CRISPRa)102 facilitating the rapid up and 
downregulation of cellular pathways to optimise production formation.   
Multiplexed automated genome engineering (MAGE) is a popular method for the 
generation of focused libraries at the genome level. This is achieved through the 
simultaneous introduction and incorporation of synthetic single stranded 
oligonucleotides at the DNA replication fork to introduce desired mutations96. To 
demonstrate the power of the technique enhancement of lycopene production in E. 
coli was previously targeted. The RBS of twenty genes previously shown to involved 
in lycopene production103 were manipulated to modulate translational efficiency and 
four genes known to negatively impact lycopene production were targeted for 
knockout through the introduction of nonsense mutations. This approach resulted in a 
five-fold increase in lycopene production in 3 days. Whilst the production levels 
were lower than previously reported studies in which E. coli was rationally 
engineered103,104, the time savings were significant. The MAGE technique has 
recently been adapted for use in S. cerevisiae105 further expanding its potential 
utilisation in microbial engineering.  
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1.7 Enhancing the test stage 
 
1.7.1 Complementing DNA assembly with omics approaches 
 
The utilisation of synthetic biology tools for the engineering of industrial microbes is 
accelerating the ability to construct large numbers of engineered microbes during the 
build stage of strain engineering. However, the ability to screen these strains and 
vitally generate the information required to guide subsequent rounds of engineering 
is not progressing at the same rate. Whilst the success or failure of the engineering of 
a host will always be judged through the titer, rate and yield of product achieved by 
the engineered organism, high throughput screens which are directly linked to target 
product formation are unlikely to provide the required information to efficiently 
identify pathway bottlenecks and thus define targets for strain improvement. 
A number of techniques to quantify cellular metabolite, transcript and protein 
abundances, known collectively as omics, have been developed which could be 
exploited to generate the amount of data required to this issue. The standard 
approaches however, are relatively low throughput (and utilise expensive 
instrumentation) so identification of the correct strategy to complement the build 
stage of engineering an industrial microbe is vital.  
Metabolomics analysis provides the opportunity to explore pathway intermediates 
and potential bottlenecks however if competing pathways are directing intermediates 
away from the engineered pathway then bottleneck identification is not straight 
forward. Analysis of mRNA has rapidly developed with methodology in place 
allowing for the analysis of an organisms entire transcriptome in a single 
experiment106, 107. This is often implemented following the introduction of a pathway 
to ensure transcription of the pathway genes. mRNA levels however do not 
necessarily indicate the amount of protein being produced, with factors such as RBS 
strength, codon usage and mRNA secondary structures influencing how efficiently 
the mRNA is translated into protein.  
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Efficient pathway flux is often dependent on fine tuning of the amount of protein 
produced at each stage in the pathway since over production of each pathway protein 
results in significant metabolic burden being placed on the cell108, 109. The utilisation 
of accurate and high throughput approaches amenable to multiplexing to monitor 
protein expression can therefore dramatically accelerate strain engineering. 
Proteomics is however more challenging than transcriptomics as proteins cannot be 
amplified nor are they trivial to separate, both factors that can limit the throughput of 
such an approach. Western blot and ELISA are currently the most applied techniques 
for the specific analysis of proteins in unpurified extracts. Western blot analysis 
requires antibodies to be available or produced for each target protein. If quality 
antibodies are available Western Blot is highly specific and sensitive however it is 
limited in quantitation and the ability to examine multiple proteins in parallel. 
ELISA110 in comparison is a quantitative technology but also limited in that a single 
target can only be examined in each assay. Although both techniques are used in day 
to day research due to ease of use and rapid processing, they do not provide the 
specificity or coverage that mass spectrometry based approaches can offer. 
The utilisation of omics based platforms to characterise engineered microbes with the 
goal of identifying targets for strain improvement is still relatively rare. This is 
despite such an approach having proven successful on a number of occasions. For 
example, Pitera et al111 demonstrated the use of a metabolomics based approach for 
the optimisation of a heterologous mevalonate pathway. Metabolomics analysis 
revealed a pathway bottleneck in which a pathway intermediate was being 
accumulated resulting in inhibition of cell growth. This informed the next stages of 
engineering which resulted in debottlenecking of the heterologous pathway and 
optimised flux towards the compound of interest. Transcriptomics analysis coupled 
to in silico modelling meanwhile was used to optimise L-valine production in E. coli, 
resulting in a 126.7% increase in product formation112. Multi-omics strategies have 
also been utilised, for example Brunk et al attempted to combine metabolomics, 
proteomics and predictions from in silico genome scale models to optimise carbon 
flux through the mevalonate pathway for terpenoid biosynthesis in E. coli 113. Omics’ 
approaches have also been utilised not only for the analysis of metabolically 
engineered strains but also for the identification of suitable host strains for further 
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engineering. In one such study a butyric acid producing Clostridium strain was 
identified (Clostridium tyrobutyricum) as a potential host for optimised butyric acid 
production, however limited knowledge of the genetic and metabolic characteristics 
of this strain had hampered metabolic engineering attempts. To address these issues 
genomic and proteome characterisation of the strain were undertaken. This analysis 
elucidated an alternative butyric acid production pathway in this strain in comparison 
to other clostridia species opening the door to the potential engineering of this strain 
to overproduce butyric acid114. A genomics and transcriptomics approach was also 
utilised in conjunction with in silico genome scale modelling to assess seven E. coli 
strains widely used in academic research and the biotechnology industry for their 
abilities to produce 40 chemicals under both aerobic and anaerobic conditions 
identifying certain strains more suited to produce certain chemicals115.   
An early example of using proteome analysis to maximise heterologous production 
in an engineered E. coli strain was performed by Han et al  using two-dimensional 
gel electrophoresis116. It was found that the heterologous overproduction of serine 
rich (11.6% compared to an E. coli average of 5.6% serine) human leptin resulted in 
a significant decrease in abundance of the enzymes involved in serine amino acid 
biosynthetic pathways. They were able to identify one of the downregulated proteins, 
cysteine synthase A (encoded by cysK) and target it for over production. This 
strategy resulted in a two fold increase in cell growth and a four-fold increase in 
leptin production. To further exemplify the approach the cysteine synthase 
overproduction strain was shown to be able to produce another serine rich protein, 
interleukin-12 β chain (11.1% serine) at an enhanced level in comparison to the WT 
host. In one of the first examples of using mass spectrometry based proteomics to 
characterise engineered E. coli, Redding-Johanson et al117 used targeted proteomics 
to optimise a heterologous pathway for production of the sesquiterpene amorpha-
4,11-diene. Proteomics analysis revealed that two of the pathway proteins were only 
present at extremely low levels. Through codon optimisation of the gene sequences 
for expression in E. coli and the introduction of a strong promoter upstream of the 
coding sequence they were able to improve production three fold. These two studies 
identify the potential of using an omics approach to pathway optimisation but uptake 
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within the field has been limited as slow throughput and high data-complexity are 
still prohibitive.  
Beyond characterisation of pathway proteins comparative proteomics can also be 
utilised to identify changes in the host proteome due to expression of the 
heterologous pathway. Batth et al118identified the need for proteomics analysis to 
have increased throughput as our ability to rapidly engineer microbes increased. 
They describe a platform for optimised sample throughput which was used to 
quantify 400 proteins from major metabolic E. coli pathways. Nowroozi et al119 used 
targeted proteomics coupled to RBS modulation and a combinatorial assembly 
platform to optimise the mevalonate pathway for isoprenoid production in E. coli. 
Proteomics based approaches have also been used in order to characterise and 
quantify post translational modifications. This technique has gained significant 
traction in the field of polyketide synthase engineering. Through monitoring of the 
peptide which carries the phosphopantetheine modification bottlenecks in engineered 
polyketide function can be identified and optimised120.  
 
1.7.2 Mass spectrometry based protein analysis 
 
Fundamentally all mass spectrometers measure the mass to charge ratio (m/z) of ions 
in the gas phase. From this, information on protein sequence, protein amounts and 
post-translation modifications can be derived. Simplistically, all instruments 
comprise of a sample inlet, which is often preceded by a form of chromatography to 
simplify the sample being analysed, a source in which gas phase ions are generated, a 
mass analyser and a detector. The detector will convert the number of ions reaching 
it - separated based on mass vs charge - into a mass spectrum. 
The introduction of soft ionisation techniques led to highly sensitive mass 
spectrometry based protein and peptide analysis becoming the method of choice for 
analysing biological macromolecules. These techniques allow for the ionization of 
intact proteins and peptides which was not feasible with harsher chemical and 
electron ionisation approaches which had been used previously. John Fenn and 
32 
 
Koichi Tanaka developed Electrospray ionisation (ESI)121 and Matrix-Assisted Laser 
Desorption (MALDI)122 respectively for which they were awarded a share of the 
Nobel prize for Chemistry in 2002 and since this development MS has been a vital 
tool in protein research.  
ESI (described in detail below) ionises the sample from solution and is therefore 
easily coupled to separation techniques such as liquid chromatography whilst 
MALDI sublimates and ionises the samples from a crystalline matrix through laser 
pulsing. MALDI has therefore been preferred for the analysis of relatively simple 
mixtures whilst in-line LC-ESI-MS systems have been preferred for the analysis of 
complex mixtures.  
Mass analysers which can be utilised for protein analysis can be split into four 
primary categories, Time of Flight (TOF) (described below), ion trap, quadrupole 
(Q) and Fourier transform ion cyclotron resonance (FTICR). These analysers can be 
deployed alone or, in some cases, in tandem to exploit the advantages of the various 
strategies for analysis of proteins and peptides. In this study an electrospray 
quadrupole time of flight (Q-TOF) mass spectrometer was the instrument used for all 
protein analysis.  
The development of these ionisation techniques and high resolution mass analyser 
coupled to advancements in protein/peptide separation, genome sequencing and the 
availability of protein database search tools have accelerated the advancement in the 
field of mass spectrometry based proteomics. 
 
1.7.2.1 Proteins to peptides 
 
Workflows for the identification and quantification of peptides from a complex 
mixture can generally be split into two main categories: Gel based and gel free 
techniques. In gel based strategies the proteins are first separated by 2D 
electrophoresis (2DE), stained and the proteins quantified by spot intensity. The 
desired spot is then excised, enzymatically digested into peptides and analysed via 
MS in a single step. The approach has been reported to suffer from limited dynamic 
33 
 
range with a systematic study of Saccharomyces cerevisiae highlighting that usually 
only the most abundant proteins can be observed using this approach123. In an 
attempt to address this issue, strategies such as more sensitive gel staining procedures 
have been developed124. 
Gel free mass spectrometry based protein quantification methodologies for the 
analysis of cellular extracts, such as those generated from an engineered industrial 
microbe, standardly utilise the ‘shotgun’ or bottom up technique125 in which proteins 
are firstly digested into peptides typically between 5 and 14 amino acids in length 
and then fractionated prior to MS analysis (Figure 13).  
 
Figure 13:  Proposed workflow for the mass spectrometry based quantification of target proteins from the cell 
extract of a strain engineered for utilisation in an industrial bioprocess.   
 
The enzyme used for proteolysis in most approaches is trypsin which hydrolyses the 
peptide bond at the carboxyl side of the basic amino acids lysine and arginine, except 
when either are followed by proline.  Efficiency and reproducibility of this initial 
step is vital if meaningful proteomics data is to be obtained126.  For trypsin to 
efficiently cleave the protein into peptides, samples are denatured, reduced and 
alkylated prior to digestion. Denaturation and reduction are often performed in 
parallel through a combination of heat and treatment with a reducing agent such as 1, 
4-dithiothreitol (DTT). To further reduce the potential for protein renaturation prior 
to digestion cysteine residues are alkylated, standardly through the addition of 
iodoacetamide. Commercial preparations of trypsin used for proteomics acquisitions 
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are standardly modified through reductive methylation of lysine residues to prevent 
autolysis which can result in the carry through of trypsin peptides into the analysis127. 
Due to the complexity of samples following tryptic digestion (thousands of peptides 
from a proteome sample at varying abundances) in line liquid chromatography, either 
high pressure liquid chromatography or as is the case in this study, ultra-high 
pressure liquid chromatography (UPLC), is standardly used to fractionate the sample 
and reduce the complexity of the sample entering the mass spectrometer. Reverse 
phased (RP) chromatography is generally the separation method of choice for 
proteomics based analysis. This approach employs a non-polar stationary phase such 
as C18 analytical column chemistry and a polar mobile phase comprised of aqueous 
solution and organic solvent. It allows peptide separation based on hydrophobicity 
and therefore the most water soluble peptides pass through the column quickest. 
 
1.7.2.2 Electrospray ionisation 
 
Electrospray ionisation (ESI) is a soft ionisation technique in which the analyte of 
interest is solubilised in a volatile buffer or solvent system. It is a technique which 
has been used to ionise a number of analytes from small organic and inorganic 
molecules to large polymers, nucleic acids and proteins. It is particularly suited to 
coupling to separation techniques such as liquid chromatography and has been one of 
the most popular ionisation methods for protein and peptide analysis. 
There are three main steps in the production of gas phase ions from solution through 
electrospray ionisation: (1) Production of charged droplets at the capillary tip; (2) 
Droplet shrinkage through solvent evaporation and charge induced droplet fission 
resulting in small highly charged droplets capable of producing gas phase ions, and 
(3) the production of gas phase ions from these droplets. 
The solution containing the analyte is passed through a conductive capillary under 
the influence of an electric field which is generated through having a large potential 
difference (~5 kV) between the capillary and the entrance to the mass spectrometer 
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which is standardly 0.3 – 2 cm from the capillary. This results in the charged analyte 
solution forming a Taylor cone, from which highly charged droplets are omitted.  
The resultant droplets reduce in size due to solvent evaporation resulting in increased 
charge density. The increased charge density will result in the generation of a 
Coulombic repulsion which at a certain droplet radius exceeds the cohesive surface 
tension resulting in the splitting of the droplet. This process of repeated droplet 
fission results in very small charged droplets which are the precursor to gas phase 
ions. 
Two mechanisms have then been proposed for the formation of gas phase ions. The 
ion evaporation model suggests the process of droplet fission continues until the 
droplet size has decreased to ≤10 nm and charged analytes can be directly desorbed 
into the gas phase at a point in which repulsion between ions at the surface of the 
droplet overcomes the cohesive force of the surface tension. It is believed for 
molecular species carrying a low number of charges that this mechanism is 
dominant. For molecular species carrying multiple charges it is believed that the 
charge residual model is dominant, in this model droplet generation would result in 
droplets containing one analyte molecule. The ion is not directly desorbed in this 
model, instead solvent evaporation continues until all the solvent is lost and the ion 
enters the gas phase128. 
 
1.7.2.3 Time of flight mass analysers 
 
Time of flight (TOF) mass analysers are one of the oldest ion separation techniques. 
However, despite first being described in 1946129 it was not until 1995 that they 
gained considerable popularity130. The approach relies on the separation of ions 
through the time taken for them to reach a detector in order of increasing mass to 
charge ratio. In its simplest form the approach relies on the acceleration, by an 
electric field, of a set of ions through a field free drift region within a linear vacuum 
tube to towards the detector. Ions that have differing m/z but acquire the same kinetic 
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energy will achieve a different velocity and therefore take differing amounts of time 
to reach the detector. 
This can be shown through firstly using the equation to calculate kinetic energy (Ek) 
for any mass (Eqn. 1).  




Equation 1: Calculation of kinetic energy 
Where Ek is the kinetic energy after acceleration, m is the mass of ion and v is the 
velocity. Following the initial acceleration, the velocity of the ion remains constant 






Equation 2: Calculation of velocity 
Where d is the distance travelled and t is the time taken for the ion to traverse the 
field free region and reach the detector. Introduction of v into Eqn. 1 results in: 




Equation 3: Introduction of velocity calculation into kinetic energy equation 





Equation 4: Equation solved for mass 
This equation is the basic time of flight relationship, for a given kinetic energy and 
distance the time of flight is proportional to the square of the mass 131. 
Significant improvements in the resolution of TOF mass analysers has been achieved 
through the introduction of a “reflectron” within the flight tube132. This is a device 
which uses an electric field to first reduce the velocity of the ions to zero before 
reversing the ions back into the field free region. This approach not only increases 
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the length of the drift region but also corrects for any variations in the kinetic 
energies of the ions during the initial acceleration. This is achieved as ions with the 
same m/z but higher kinetic energies penetrate further into the reflectron and therefor 
taking longer to be reflected.  
 
1.7.2.4 Peptide identification 
 
Having measured the m/z and the intensity of the analysed peptides, primary 
sequence information is also standardly generated for the peptides analysed. This is 
achieved through tandem mass spectrometry (MS/MS and MS2) in which two stages 
of MS are utilised. Initially the mass spectrometer scans all eluting precursor 
peptides recording mass and intensity. Peptides are selected for fragmentation 
through collision with an inert gas (nitrogen, argon or helium standardly) generating 
product ions in either a data dependent (fragmentation of specific peptides) or data 
independent (fragmentation of all peptides) manner. Following this fragments are 
associated to peptides which are assembled into proteins and the identifications 
statistically validated133. 
Data dependent acquisitions (DDA) rely on a serial process of peptide selection 
followed by fragmentation. A fixed number of peptides (usually 3-8) from a survey 
MS scan are selected for fragmentation. The selected peptides are fragmented, and 
data collected on the product ions over a period of time or until a defined ion current 
is breached. During this time all information on co-eluting peptides which were not 
selected for fragmentation is lost. These cycles of precursor and product ion analysis 
continue throughout the runtime. In an attempt to produce the highest quality 
fragmentation data standardly the most abundant peptides will be selected and 
therefore a key limitation of this approach is the potential loss of information on less 
abundant or less well ionised peptides.  
An alternative to data dependent acquisitions, known as MSE, was developed by 
Silva and co-workers and commercialised by Waters Corporation134, 135. In this data 
independent approach, no precursor identification is required. During this type of 
38 
 
acquisition, the quadrupole guides all ions into the collision cell which the instrument 
alternates between high energy and low energy over the course of the run. During the 
low energy scan data is generated on the m/z and retention time of the eluting peptide 
whilst during the high energy scan fragmentation data is collected. As this method is 
completely data independent there is no bias towards highly abundant peptides 
meaning data is collected for all peptides potentially maximising the number of 
proteins quantifiable.  
Post-acquisition MSE data processing is then employed in order to link fragments to 
their precursors, defining peptide sequences and associating them to proteins for 
identification. In this study all identifications were carried out using the identify 
algorithm in Protein Lynx Global Server (PLGS) software version 3.03 developed by 
Waters Corp. This software utilises peptide retention time, precursor and fragment 
ion intensity, charge states and precursor and fragment ion accurate masses for 
protein identification136. 
Data from an MSE experiment is collected as three functions. A low energy function 
(Function 1), a high energy function (Function 2) and lockmass function (Function 3) 
which comprises of a reference compound infused throughout the run for accurate 
mass correction. An initial ion detection is performed from Function 1 and 2. First an 
algorithm, Apex 3D, is used to subtract noise and integrate ion current signals across 
the chromatographic elution. The output of this algorithm is a list of ions with 
intensities above a user defined threshold137. The second algorithm, Pep3D, collapses 
isotopes and charge states of both precursor and product ions into an Exact Mass and 
Retention Time (EMRT). The EMRT is a peptide of unknown sequence which is 
characterised by its mass, retention time and intensity.  Fragment ions are then 
tentatively associated with their precursors based on elution profiles. It is likely that 
multiple precursors will co-elute from the column and therefore product ions will be 
associated to all potential precursors until later in the process.  
Associated product and precursor ions are then filtered, with low molecular weight 
peptides - standardly below 750 Da under low energy and 350 Da under high energy 
- side lined to ensure highly specific initial protein identifications. Although most 
proteins will generate tryptic peptides smaller than 750 Da these have high sequence 
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similarity and therefore low specificity.  Product ions with higher intensities than 
their predicted precursor are also filtered at this stage.  
Prior to data searching a decoy database of in silico generated peptides is generated 
to allow for calculation of the false discovery rate (FDR). PLGS automatically 
constructs this database through generating one random sequence for each protein in 
the database to be searched. The random sequence contains the same number of 
amino acids as the original protein and would generate the same number of tryptic 
peptides however the order of the amino acids is randomised. Identical search 
parameters are then used to search both databases and the FDR calculated as a 
percentage by dividing the number of protein identifications from the decoy database 
by the total number of protein identifications (identifications for the decoy plus 
identifications from the protein database). 
The software then begins database searching, which is performed in three stages, 
known as passes. In the first pass the software cycles through the data removing 
EMRT’s which it considers to be peptides derived from the most confident protein 
identifications. This process continues until the rate of protein identification from the 
decoy database exceeds the user defined FDR. During pass two a subset database 
containing only proteins which were identified in pass one is created, however 
additional search parameters such as missed tryptic cleavages, variable peptide 
modifications and in source fragmentation are assigned to previously unassigned 
peptides that could have come from the proteins identified in the first pass. During 
the final pass all remaining precursor information is used to search the full database, 
however now total product ion intensity is allowed to exceed precursor ion intensity 
which can be a signature of in source fragmentation of highly labile peptides136.    
It is vital that a comprehensive protein database is constructed for the strain being 
characterised. This database should contain all proteins produced by the parental 
strain, heterologous proteins expressed as a result of strain engineering, trypsin if 
used for digestion and any proteins introduced during the sample preparation such as 
lysozyme for cell lysis. In this study the UniprotKB database 
(http://www.uniprot.org/) and the E. coli K12 proteome database from Uniprot were 
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downloaded for interrogation with MSE data. The E. coli database had heterologous 
expressed protein sequences manually added when necessary.  
 
1.7.2.5 Relative and absolute protein quantification 
 
Quantification of proteins from complex mixtures can be achieved in a relative or 
absolute manner. Absolute quantitation techniques require the addition of internal 
standards such as synthetic peptides at known concentration which are designed to 
mimic the peptide of interest. In this approach, the peptide is synthesised with a 
stable isotope present within one amino acid of the peptide. This should result in the 
synthetic peptide and the target peptide having similar properties in terms of 
chromatography, ionisation and fragmentation but remain distinguishable due to the 
difference in mass.  
Relative quantitation approaches can be divided into two main categories, isotope 
based and label free. Isotopic labelling can be performed through a number of 
techniques with the most popular including Stable Isotope Labelling by Amino Acids 
in Cell Culture (SILAC)138, Isotope-coded Affinity Tag (iCAT)139 or Isobaric Tags 
for Relative and Absolute quantification (iTRAQ)140. These techniques rely on either 
the incorporation of labelled amino acids into the protein during cell growth 
(SILAC), chemical labelling of proteins prior to digestion (iCAT) or enzymatic 
labelling of the peptides following digestion (iTRAQ). A primary advantage of these 
techniques in comparison to label free methodologies is that the samples being 
analysed are mixed, either prior to digestion (SILAC and iCAT) or prior to LC-MS 
analysis (Figure 14). This means that variations in sample preparation and 
chromatography that may exist sample to sample will not have as a profound effect 
on the data collected. Despite the success of these techniques label-free quantitation 
is becoming a more popular alternative due to limitations in the scope of labelled 
approaches, the increased time and complexity of sample preparation, the 




Figure 14: Comparison of typical quantitative proteomics techniques.  Boxes in black and white represent two 
experimental conditions which require to be compared. Horizontal line represents sample mixing. At each stage 
where samples are processed in parallel – i.e. not mixed – quantification errors which are not compensated for 
may occur. 
 
Label free methodologies in comparison are likely to be quicker and more cost 
effective due to the avoidance of additional sample processing steps and the cost of 
labelling reagents however as each sample is analysed in isolation robust digestion 
and LC methods require to be in place prior to analysis of complex mixtures. Label 
free methodologies rely on quantification through either spectral counting or signal 
intensity of the detected peptides.   
Relative quantification through spectral counting is achieved through the comparison 
of the number of MS/MS peptide spectral matches from the same protein. This is 
based on the assumption that the number of peptide spectral matches is a correlation 
of total protein amount as more abundant proteins will generate more proteolytic 
peptides. Therefore, an increase in protein abundance results in an increase in protein 
sequence coverage, the number of identified unique peptides and the total number of 
identified MS/MS spectra. Liu et al. explored the correlation between sequence 
coverage, peptide number and spectral count (number of total identified MS/MS 
spectra) and protein abundance. This was achieved through spiking a yeast soluble 
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protein extract with specific quantities of six proteins, the protein mixes were then 
trypsin digested and the peptides analysed. It was found that only spectral count gave 
a strong correlation to relative protein abundance (r2 = 0.9997)142.  The accuracy of 
the approach was further improved through the definition of a normalised spectral 
abundance factor (NSAF) which also considers protein length. As larger proteins will 
tend to contribute more peptide/spectra than shorter ones the NSAF for a given 
protein is calculated as the number of spectral counts (Sc) identifying that protein 
divided by its length (L) divided by the sum of Sc/L for all proteins in the 
experiment143. 
When an ion is detected with a particular m/z information on intensity and retention 
time is also recorded. It was found that signal intensity from ESI correlates to ion 
concentration144. The potential to use this signal intensity based approach for 
protein/peptide quantification was initially explored through the analysis of 10 fmol 
– 100 pmol myoglobin digest via nano-LC coupled to LC/MS/MS145. The 
chromatographic peak area was extracted and calculated for five of the identified 
peptides and shown to increase with increasing concentration. Combination of peak 
areas and plotting against protein concentration resulted in a linear correlation (r2 = 
0.991) showing that the peak areas and concentration strongly correlates. This 
approach was further validated - by the same authors - in complex mixtures through 
the addition of horse myoglobin to human serum. 
A number of factors require to be considered to ensure reliable protein quantification 
through peak intensity. These include highly reproducible LC retention times and the 
collection of sufficient data points across the curve to calculate peak area which can 
be an issue in MS/MS data dependent acquisitions as the MS scans used to collect 
peak area information are not collected during periods in which MS/MS information 
is being collected for protein identification. Experimental variation caused by sample 
preparation or injection variation and drifts in retention time and m/z can be reduced 
through data normalisation using spiked standards, abundant housekeeping proteins 
or the analysis of total ion area. Computational methods which align retention times 
across multiple samples, consider background noise and normalise peak abundance 
have been used to address these concerns. The ability to quantify multiple proteins 
within a cellular lysate extract following genetic engineering is a promising strategy 
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which allows for not only the determination of potential bottlenecks within the 
biosynthetic pathway but also the potential to examine unexpected effects 
engineering may have had on the host organism.  The optimisation of tools such as 
the inABLE DNA assembly platform will allow for the rapid construction and 
introduction of synthetic pathways into host organisms and technologies such as 
proteomics are required to characterise the success or failure of these pathways and 
therefore direct the next round of engineering in a predictable manner. Through 
coupling combinatorial pathway construction, determination of product formation 
and a label free proteomics based strain interrogation approach the optimum 
abundance of each pathway protein can be understood. This understanding leads to 
more predictable pathway optimisation which would not be possible without the 
combination of these approaches. 
 
1.8 Aims and Motivations 
 
In this PhD, I will aim to address the primary issues cited by end users as to why 
bioprocesses are not more readily taken up – their development is too slow, too 
unpredictable and too expensive. This will be achieved through the development of a 
DNA assembly technique optimised for combinatorial pathway construction whilst 
making it feasible to rapidly construct and test many modified organisms. Although 
assays or screens provide information on the complete system they often do not 
provide the level of information required to guide the next stages of engineering. I 
will therefore focus on the development of a robust strain analysis tool which 
provides the level of information required to guide subsequent stages of strain 
optimisation. Proteomics gives the ability to analyse the engineered organism to a 
level which will result in the predictability that can only come from having an in 
depth understanding of the dynamic biological system. The combination of a DNA 
assembly technique optimised for rapid and efficient pathway construction and a 
proteomics platform for analysis of the engineered microbes will result in the 




2. Materials and Methods 
 
2.1 Materials and reagents 
 
All chemicals and solvents were purchased from Sigma Aldrich or VWR unless 
otherwise stated. Escherichia coli strains Top10 (Thermo Fischer) and BW25113 
(Invitrogen) were used for plasmid construction and vector screening. All DNA 
modifying enzymes were purchased from New England Biolabs unless otherwise 
stated. Mass spectrometry grade trypsin was purchased from Thermo Fischer and 
prepared as per the manufacturer’s instructions.  
 
2.2 E. coli strains and plasmids 
 
2.2.1 E. coli strains 
 
Strain (Reference/supplier) Genotype Application 
Top10 (Invitrogen) mcrA, Δ(mrr-hsdRMS-mcrBC), 
Phi80lacZ(del)M15, ΔlacX74, deoR, 
recA1, araD139, Δ(ara-leu)7697, 
galU, galK, rps (SmR), endA1, nupG 
Cloning strain 
NEB 10-beta (NEB) araD139 ∆(ara-leu)7697 fhuA lacX74 
galK (f80 ∆(lacZ)M15) 
mcrA galU recA1 endA1 nupG rpsL 
(StrR) ∆(mrr-hsdRMS-mcrBC) 
Cloning strain 
BL21 (DE3) (Studier et al.146) F– ompT gal dcm lon hsdSB(rB–mB–
) λ(DE3 [lacI lacUV5-T7p07 ind1 
sam7 nin5]) [malB+]K-12(λS) 
Protein expression 




ΔlacZ4787(::rrnB-3) hsdR514 rph-1 
Parental strain for reverse 
glyoxylate shunt screening host 





Plasmid name  Description  Reference 
Assembly T1 pMB1 ori, AmpR, CampR, KanR, TetR This work 
3 bp overhang assembly 
product 
pMB1 ori, TetR This work 
LOA secondary structure 
assembly product 
pMB1, KanR This work 
Assembly Cellulase 1 pMB1 ori, AmpR, truncated ADH1p, alpha factor secretion signal, β-glucosidase a This work 
Assembly Cellulase 2 pMB1 ori, AmpR, truncated ADH1p, alpha factor secretion signal, β-glucosidase b This work 
Assembly Cellulase 3 pMB1 ori, AmpR, truncated PGK1p, alpha factor secretion signal, 
Endo/exoglucanase, TPS1t 
This work 
Assembly Cellulase 4 pMB1 ori, CampR, truncated CYC1t, ZeoR, AmpR, Cen4/ARSH4 This work 
Assembly Cellulase 5 pMB1 ori, AmpR, PGK1p, alpha factor secretion signal, Endo/exoglucanase, TPS1t, 
ADH1p, alpha factor secretion signal, β-glucosidase a, CYC1t, ZeoR 
This work 
Assembly Cellulase 6 pMB1 ori, AmpR, PGK1p, alpha factor secretion signal, Endo/exoglucanase, TPS1t, 
ADH1p, alpha factor secretion signal, β-glucosidase b, CYC1t, ZeoR 
This work 
Nested Pr-Ss vector 
 
pMB1 ori, AmpR, CampR, β-glucosidase, CYC1t, 2-micron ori, KanMX  This work 
Assembly efficiency vector 1 pBR322 ori, AmpR, CampR This work 
Assembly efficiency vector 12 pBR322 ori, AmpR, KanR This work 
eGFP expression vector pMB1ori, CampR, ProC, eGFP This work 
PN vector 1 pMB1 ori, KanR (SapI flanked), AmpR This work 
PN vector 2 pMB1 ori, KanR, ProC, eGFP, Syn ter (SapI flanked) This work 
pET21 MTKa/b pBR322 ori KanR, LacI, T7pr, MTKa, MTKb This work 
pET21 MCL pBR322 ori KanR, LacI, T7pr, MCL This work 
pET21 ICL pBR322 ori KanR, LacI, T7pr, ICL This work 
pRGS_3.1 pBR322 ori KanR, pRecA, MTKa/b, MCL, ICL This work 
pRGS_3.2 pBR322 ori KanR, pA, MTKa/b, MCL, ICL This work 
pRGS_3.3 pBR322 ori KanR, pOSMY, MTKa/b, MCL, ICL This work 
pRGS_3.4 pBR322 ori KanR, pRecA, MTKa/b, MCL, ICL This work 
pRGS_4.1 pBR322 ori KanR, pRecA, MTKa/b, ICL, MCL This work 
pRGS_4.4 pBR322 ori KanR, pOSMY, MTKa/b, ICL, MCL This work 
pRGS_4.5 pBR322 ori KanR, pA, MTKa/b, ICL, MCL This work 
pRGS_5.1 pBR322 ori KanR, pL, MCL, MTKa/b, ICL This work 
pRGS_5.3 pBR322 ori KanR, pRecA, MCL, MTKa/b, ICL This work 
pRGS_5.5 pBR322 ori KanR, pOSMY, MCL, MTKa/b, ICL This work 
pRGS_5.7 pBR322 ori KanR, pA, MCL, MTKa/b, ICL This work 
pRGS_6.1 pBR322 ori KanR, pOSMY, MCL, ICL, MTKa/b This work 
pRGS_7.1 pBR322 ori KanR, pA, ICL, MTKa/b, MCL This work 
pRGS_7.2  pBR322 ori KanR, pOSMY, ICL, MTKa/b, MCL This work 




2.3 Microbiology techniques 
 
2.3.1 Culture media preparation 
 
2.3.1.1 LB liquid media  
 
37 g L-1 LB (Merck) prepared in RO H2O. 
 
2.3.1.2 LB agar 
 
37 g L-1 LB agar (Merck) prepared in RO H2O. 
 
2.3.1.3 SOC liquid media 
 
20 g L-1 Tryptone, 5 g L-1 yeast extract, 0.344 g L-1 NaCl, 0.185 g L-1 KCl, 
2.4 g L-1 MgSO4, 3.6 g L
-1 glucose. 
 
2.3.1.4 Ingenza minimal media 
 
Stock Salts Solution (5X) 
10 g L-1 (NH4)2SO4,  
73 g L-1 K2HPO4 
10 g L-1 NaH2PO4 · 2H2O  





Trace Elements (500X) 
0.5 g L-1 CaCl2.2H2O 
10.03 g L-1 FeCl3 
0.18 g L-1 ZnSO4.7H2O 
0.16 g L-1 CuSO4.5H2O 
0.15 g L-1 MnSO4.H2O
 
0.18 g L-1 CoCl2.6H2O 
22.3 g L-1 Na2EDTA.2H2O 
 
To prepare 1 L minimal media 
200 mL 5X Stock salt solution 
20 mL Glucose 50% (w/v) 
2 mL 1M 500X Trace elements 
 
Optional: 15 g L-1 Select agar (Sigma) 
 
2.3.1.5 Yeast nitrogen base 
 
10x stock preparation 
0.67 g L-1 Yeast nitrogen base (Sigma) 
0.5 g L-1 Glucose 
Working stock prepared through dilution in sterile H2O prior to use 
 
2.3.2 Antibiotic preparation 
 
Ampicillin, chloramphenicol, kanamycin and tetracycline were purchased from 
Sigma. Ampicillin and kanamycin were prepared in H2O, whilst chloramphenicol 
and tetracycline were prepared in 100 % [v/v] and 70 % [v/v] ethanol respectively. 
Stocks were prepared at 1000 x concentration and stored at – 20 °C. Working 
concentrations of each antibiotic found in Table 4.  
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Table 4: Antibiotic working concentrations. 
 
2.4 DNA manipulation 
 
2.4.1 Purification, isolation and quantification 
 
Plasmid DNA was isolated using either plasmid mini or midi kits (Qiagen). DNA 
fragments were purified using Monarch DNA Gel Extraction Kit or PCR & DNA 
clean up kit (NEB). All DNA was quantified using the Qubit fluorometer HS DNA 
quantification kit (Thermo Fischer). Manufacturer’s guidelines followed for each kit. 
 
2.4.2 Digestion and Ligation 
 
All digestions were performed using restriction endonucleases purchased from New 
England Biolabs (NEB). Reaction conditions were defined by the manufacturer’s 
recommendations. 
DNA ligations were performed using NEB Quick Ligation kit. As standard a 5:1 
molar excess of insert to backbone (total 100ng DNA) was used in a final reaction 
volume of 20 µl with 1 µl Quick Ligase and 1x Quick Ligase buffer. Reactions were 






All oligonucleotides for PCR were synthesised by Sigma-Genosys and reconstituted 
to a concentration of 100 µM in molecular biology grade H2O. Working stocks of 
PCR primers were generated through a further dilution in molecular biology grade 
H2O to 10 µM.   
PCR was routinely performed using Phusion high fidelity polymerase (NEB) using 
the following reaction conditions: 1x Phusion HF buffer, 200 µM dNTPs, 0.5 µM 
forward and reverse primer and 10ng template DNA in a total reaction volume of 
50µl. Thermocycling conditions: Initial denaturation – 98 °C for 30 seconds, 
followed by 30 cycles of 98 °C for 5 seconds, 45 °C – 72 °C for 30 seconds, 72 °C for 
15 seconds per kb and a final extension of 5 minutes.  
 
2.4.4 Competent cell preparation 
 
E. coli strains were made electrocompetent through streaking out cells from a master 
cell bank onto a LB agar plate supplemented with antibiotics as appropriate. The 
plate was incubated overnight at 37 °C to obtain single colonies.   
A single colony was picked into 100 mL LB minus NaCl and incubated overnight at 
37 °C 250 rpm. The following morning the culture was back diluted into 800 mL LB 
minus NaCl to an OD600 of 0.1. The culture was grown at 37 °C until an OD600 of 0.5 
– 0.6 was reached at which point cells were chilled on ice for two hours. Following 
this stage all manipulations were performed at 4 °C or lower using ice chilled 
reagents.  
Cells were pelleted through centrifugation (4000 rpm, 4 °C, 10 minutes) and the 
supernatant discarded. The cells were washed twice through resuspension in 200 mL 
ice cold RO H2O followed by centrifugation (4000 rpm, 4 °C, 10 minutes) and 
removal of the supernatant. Following the second H2O wash the pellet was 
resuspended in 40 mL ice cold 20 % (v/v) glycerol and centrifuged (5000 rpm, 4 °C, 
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15 minutes). The pellet was then resuspended in 8 mL ice cold 20 % (v/v) glycerol 
and 50 µl aliquots prepared. The aliquots were stored at – 80 °C prior to testing.  




Electrocompetent cells (50 µL) were mixed with 1 µL of DNA in a 1 mm gap 
electroporation cuvette (Molecular BioProducts) and electroporated using a BioRad 
GenePulser™. Following a single pulse of 1.7 k, at a capacitance of 25 µFD and 
resistance of 200 Ω, the cells were recovered in 1 mL SOC. This was incubated at 
37 °C, 250 rpm for 1 hour before an appropriate dilution of the cells were plated onto 
LB-agar supplemented with the appropriate antibiotic.   
 
2.4.6 Heat shock transformation 
 
Chemically competent cells (50 µl, NEB 10β) were mixed with 1 – 5 µl DNA and 
placed on ice for 30 minutes. Cells were heat shocked at 42 °C for 30 seconds and 
then placed on ice for 5 minutes. 950 µl SOC media was added to cells and 1 hour 
recovery performed at 37 °C, 250 rpm. An appropriate dilution of the cells was 
plated onto LB-agar supplemented with the appropriate antibiotic.   
 
2.4.7 Calculation of transformation efficiency 
 
The transformation efficiency of electrocompetent cells was determined through 
transformation using 50 pg of pUC18 (NEB) following the standard protocol. 
Following the recovery, a percentage (10%, 1%, 0.1% and 0.01%) was plated onto 
LB-Kan. Following overnight incubation (37 °C) the number of colonies were 
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counted, and the transformation efficiency calculated using Equation 5. A 




µ𝑔 𝑜𝑓 𝑝𝑈𝐶19 ×  % 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛
 
Equation 5 – Calculation of transformation efficiency. 
   
2.4.8 Site directed mutagenesis 
 
Site directed mutagenesis to remove incompatible restriction sites (standardly SapI 
and EarI) from DNA targeted for assembly via inABLE DNA assembly was 
performed following the protocol provided with the QuickChange II Site-Directed 
Mutagenesis Kit from Agilent. In brief two primers containing the desired mutation, 
flanked by unmodified nucleotide sequences were designed and used in a PCR 
reaction as indicated below.  
5 µl 10X reaction buffer 
X µl (50 ng) of dsDNA template 
1 µl (10µM) primer #1  
1 µl (10µM) primer #2  
1 µl of dNTP mix (50x, 200 µM final concentration of each) 
1 µl of PfuUltra HF DNA polymerase (2.5 U/µl) 
ddH2O to a final volume of 50 µl  
Thermocycling conditions: Initial denaturation – 94 °C for 30 seconds, followed by 
12 cycles of 94 °C for 5 seconds, 50 °C for 30 seconds, 72 °C for 1 minute per kb of 
plasmid length. The PCR product was then digested at 37 °C for 1 hour using 1 µl 
Dpn I restriction enzyme (10 U/µl) to remove methylated plasmid starting material. 2 
µl of the digested material was used to transform Top10 cells via electroporation and 
the resulting transformants screened for the expected mutation by restriction 
digestion and Sanger sequencing.  
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2.4.9 Capillary electrophoresis 
 
DNA was analysed through electrophoresis using an Agilent 2200 Tapestation 
instrument following the manufacturer’s instructions. In brief, samples were prepared 
by adding 1 µL of DNA to 10 µL of the appropriate sample buffer (either D1000, 
D5000 or Genomic DNA depending on the size of the DNA being analysed). The 
samples were vortexed for 1 min using an IKA vortexer with PCR tube adaptor at 
2000 rpm prior to loading onto the Tapestation instrument. Results were analysed 
using the Agilent 2200 Tapestation Analysis software 
 
2.5 inABLE DNA assembly  
 
2.5.1 Truncated part and primer design 
 
Part sequences were entered into the inABLE® Bio Python part designer program 
which splits the gene into a TP, POA, and LOA. PCR primers for amplification of a 
SapI flanked truncated part are also generated during this stage. The POA is 
composed of annealed part oligo short (POs) and part oligo long (POl) sequences 
whilst annealing of the linker oligo short (LOs) and linker oligo long (LOl) 
oligonucleotides generate the LOA. The oligonucleotides were synthesised by 
Sigma-Genosys and TP’s were either synthesised by GenScript or PCR amplified. 
 
2.5.2 Preparation of oligonucleotides for part linker fusion reaction 
 
Phosphorylation of the 5’-end of each oligo previously designed (LOl, LOs, POl and 
POs) is required to allow efficient ligation with the truncated part during the 
part/linker fusion preparation. Annealing of the respective LOl, LOs, POl and POs 
was carried out to generate partially double stranded linkers harbouring specific 16 
bp overhangs required for the assembly reaction between part/linker fusions. 
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Stock solutions (100 µM) of each oligonucleotide were first prepared by 
resuspending the lyophilized samples into water. Each primer pair (long and short) 
was then phosphorylated and annealed using T4 polynucleotide kinase (NEB) as 
detailed in Table 5. 
 
Reagent Volume (µl) Final Concentration 
Oligo long (100 µM) 10 10 µM 
Oligo short (100 µM) 10 10 µM 
PNK Buffer (10x) 10 1x 
ATP (10 mM) 10 1 mM 
T4 PNK (10 U/µl) 2 0.2 U 
DTT (1 M) 0.5 5 mM 
PEG 8000 (50% w/v) 10 5% w/v 
Molecular grade water 47.5 - 
Total Volume 100 - 
Table 5: Reaction mixture for the phosphorylation of the inABLE oligonucleotides. 
 
The reaction was incubated at 37°C for 30 minutes, followed by inactivation of the 
enzyme at 65°C for 20 minutes in a thermocycler. The reaction was then heated at 
90°C and oligonucleotide annealing was achieved by gradually lowering the 
































Hold 4 °C 
Table 6: PCR program for oligonucleotide annealing to generate POA and LOA fragments 
The resulting annealed part oligonucleotides (POA) and annealed linker 
oligonucleotides (LOA) were then stored at -20°C prior to use.   
 
2.5.3 Truncated part amplification 
 
When required, truncated parts were amplified using Phusion high fidelity 
polymerase (New England Biolabs) and the PCR primers previously designed 
(Section 2.5.1). Each PCR reaction was performed with multiple replicates in order 
to generate sufficient material for the part linker fusion reactions. Following PCR 
reactions samples were analysed by agarose gel electrophoresis. The expected bands 





2.5.4 Part linker fusion reactions 
 
Part linker fusions were prepared by ligating the 5’-end of the truncated part TP with 
its corresponding part POA and the 3’-end of the truncated part with the LOA from 
the following part through cycles of EarI or SapI mediated digestion and T4 DNA 
ligase catalysed ligation.  
The reactions were performed in a total volume of 50 µL and were incubated in a 
thermocycler. Each reaction comprised of 50 nM truncated part, 0.2 µM POA, 0.2 
µM LOA, 1x NEB Buffer 4, 1 mM ATP, 12.5 U SapI/EarI and 500 U T4 DNA 
ligase. A ten-fold molar excess of LOA and POA to the truncated part was used to 
promote ligation between the truncated part and linkers during each ligation cycle.  
Cycles of SapI/EarI digestion and ligation were achieved by alternating the 
temperature between 37°C and 16°C, which correspond to the optimum temperatures 
for the EarI digestion and for the ligation using the T4 DNA ligase respectively 
(Table 7). 
 

















Hold at 4°C 




Upon completion part linker fusions were standardly run on a 1% agarose gel, the 
expected bands excised, and DNA extracted (Section 2.4.1). 
 
2.5.5 Assembly reactions 
 
Assembly reactions were performed through mixing 0.1 pmol of each purified part 
linker fusions together in the presence of 1 x NEB buffer 2 and 5% (w/v) PEG 8000.  
Reactions were incubated at 37 °C for 30 min prior to transformation. 
 
2.5.6 Exonuclease III treatment 
 
Following completion of the part linker fusion reaction cycling, 0.5 µl Exonuclease 
III (50 U), 6 µl NEB buffer 1 (10x) and 3.5 µl H2O was added to each reaction (50 
µl, 50 nM truncated part). The digestion reactions were incubated for 30 minutes at 
37 °C before the enzyme was inactivated through incubating at 70 °C for 20 minutes. 
 
2.6 Protein techniques 
 
2.6.1 Protein expression  
 
Overnight LB-Kan cultures of BL21 (DE3) harbouring expression vectors were 
grown at 37 °C and 250 rpm to an optical density at 600 nm (OD600) of 0.6. Protein 
expression controlled by the T7 promoter of the plasmid pET21 was induced by 
addition of 1 mM IPTG (final concentration) and cultures were further incubated at 
37°C and 250 rpm. Samples (1 mL) were taken prior to induction and after 4 and 24 
hour’s incubation post induction.  
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The time-point samples from each strain were then processed for SDS-PAGE 
analysis. The cells were lysed using the BugBuster protein extraction (Merck) 
reagent supplemented with 15 mg/mL Lysozyme (Sigma) and 3.4 U/µL Benzonase 
Nuclease (Sigma) following the manufacturer’s instructions.  
Following lysis, the fractions were separated through centrifugation (13, 000 rpm, 10 
minutes). The soluble fraction was transferred to a new tube and the insoluble 
fraction re-suspended in the same volume of water as the volume of lysis buffer 
previously used.  
 
2.6.2 SDS PAGE analysis 
 
Samples were prepared for SDS-PAGE analysis through mixing 20 µl of each 
fraction to be analysed with 80 µl SDS-Sample buffer (25 µl 4x Bolt LDS Sample 
Buffer (Thermo Fisher), 10 µl 9 % (w/v) DTT and 45 µl H2O). The mixture was 
heated for 5 minutes at 95°C prior to analysis. 
20 µl of each SDS-sample preparation was then loaded on to SDS-PAGE 4-12% Bis-
Tris gels to analyse the protein content of the soluble and insoluble fractions  
Gel electrophoresis was performed in a dual Bolt mini (Life Technologies) tank 
using Bolt 4 – 12% Bis-Tris gels in a 1x MES running buffer, Gels were ran at 165 V 
for 38 minutes with a ladder run on each gel (Novex Sharp Pre-stained Protein 
Standard, Thermo). Separated proteins were visualised through Coomassie blue 
staining (Instant Blue, Expedeon). 
 
2.6.3 Protein purification 
 
Protein purification was performed using Ni-NTA spin columns (Qiagen). One gram 
of cell pellet was resuspended in 3 mL of 50mM HEPES buffer pH 7.5 and cells 
lysed via sonication (15 seconds on/45 seconds off, 5 minutes total, 45% amplitude). 
The cell free extract clarified by centrifugation (13, 000 rpm, 20 minutes 4 °C) and 
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600µl of the soluble fraction loaded onto a Ni-NTA column equilibrated with 600 µl 
50 mM HEPES pH 7.5, 300 mM NaCl, 20 mM Imidazole. The column was 
centrifuged for 5 minutes at 1600 rpm and the flow through collected and stored on 
ice. The column was washed twice with 600 µl 50 mM HEPES pH 7.5, 300 mM 
NaCl, 50 mM Imidazole with centrifugation for 2 minutes at 2900 rpm after each 
wash. The purified protein was eluted from the column in two elution steps using 50 
mM HEPES pH 7.5, 300 mM NaCl, 600 mM Imidazole. The process was repeated 
using a re-equilibrated column loaded with the flow through from step 1.  
The four elution fractions were pooled in 12 mL HEPES pH 7.5 before being 
concentrated to 300 µl using a 15 mL 10 kDa molecular cut off filter (Merck), 
centrifuged at 3900 rpm, 30 minutes, 4°C. The purified protein was stored as a 10% 
(v/v) glycerol stock at – 80 °C prior to analysis.  
 
2.6.4 In solution protein digest 
 
For LC-MS analysis cells were pelleted through centrifugation (5, 000 rpm, 15 
minutes, 4 °C), the supernatant was discarded and the cell pellet frozen at - 20 °C 
prior to analysis. Cells were resuspended in Tris-HCl buffer (0.4 M, pH 7.8) and 
lysed via sonication as previously described.  
The cell lysate was clarified through centrifugation (13, 000 rpm, 30 minutes, 4 °C) 
and the supernatant used for protein precipitation. To a starting volume of 200 µl, 
400 µl methanol was added and the sample mixed via vortexing. To this solution 100 
µl chloroform was added and the sample mixed through vortexing. The samples were 
then centrifuged at 13, 000 rpm for two minutes and the top aqueous layer removed 
through pipetting.  400 µl of methanol was then added and the sample vortexed. The 
sample was centrifuged (13, 00 rpm, 3 minutes) and as the methanol removed 
through pipetting without disturbing the protein pellet. The pellet was then air dried 
for 15 minutes.   
Protein pellets were re-suspended in 100 µl 6M urea through vortexing and 
sonication (Sonic bath 2 minutes). Protein concentrations were determined using the 
59 
 
Qubit fluorometer protein assay kit (Thermo) and normalised (~1 mg total protein in 
100 µl). 5 µl of DTT (200 mM) was added to each sample to reduce disulphide 
bonds and samples were incubated at room temperature for 60 minutes. Alkylation 
was performed through the addition of 20µl iodoacetamide (200 mM), samples were 
mixed through vortexing and incubated in the dark at room temperature for 1 hour. 
The urea concentration was then diluted through the addition of 775 µl LC-MS grade 
H2O. Sequencing grade trypsin (Pierce) prepared in ice cold LC-MS grade H2O at a 
final concentration of 0.2 µg/mL) was added at a ratio of 1:50 and samples incubated 
overnight at 37 °C. The digestion reaction was quenched through the addition of 
acetic acid to lower the pH below 6. 
Prior to analysis peptides were purified using c18 SEP-Pak columns (Waters). 
Columns were flushed with 5 mL solution B (35% acetonitrile, 65% H2O, 0.1 formic 
acid) followed by 10 mL solution A (2% acetonitrile, 98% H2O, 0.1% formic acid). 
Peptide was then added and allowed to settle into the column. 10 mL of solution A 
used to wash peptides prior to elution using 2 x 1mL solution B. Purified peptides 
concentrated 20 x in a speed-vac. 
 
2.7 Reverse glyoxylate shunt library construction and screening 
 
E. coli Top10 was used as the host for all vector construction and BW25113 (ΔgltA 
ΔprpC) was used as a host to screen the vector library. All plasmids used in this study 
were prepared using the inABLE™ DNA assembly methodology. The MCL and 
MTK genes from Rhodobacter sphaeroides (B9KLE8) and Methylococcus 
capsulatus str. Bath (Q607L8/9) were codon optimised for E. coli expression whilst 
the WT E. coli ICL coding sequence was utilised. Genes were synthesised and sub-
cloned as fragments compatible with the inABLE™ platform by DNA2.0. 
E. coli strains used for vector construction and inABLE optimisation were grown in 
LB media supplemented with the appropriate antibiotic. Strains harbouring rGS 
constructs were screened in Ingenza minimal media supplemented with glucose (10 g 
L-1), succinate (10 mM), kanamycin 50 µg/mL and select agar if required. For liquid 
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phase assays starter cultures were grown in LB media overnight at 37 °C in rotary 
shakers at 250 rpm. Fresh cultures containing Ingenza minimal media supplemented 
with glucose (10 g L-1), succinate (10 mM) and kanamycin 50 µg/mL were 
inoculated to an OD of 0.1 using washed cells. OD measurements were conducted 
using a HACH spectrometer operating at 600 nm with measurements taken over 
eighty hours. Samples for proteomics were collected during mid log phase. For solid 
phase screening cells from starter cultures were washed using RO H2O and diluted to 
allow plating of ~500 cells. Plates were incubated at 37°C in a static incubator. 
 
2.8 Glucose oxidase peroxidase assay 
 
Strains to be analysed were grown for 24 hours in YNB-Glucose media at 30°C, 250 
rpm. OD600 of overnight cultures was measured and cells pelleted through 
centrifugation, 3000 rpm for 5 minutes. The resulting supernatants (40 µl) were 
incubated for 1 hour with 40 µl of substrate (1 mM substrate prepared in 100 mM 
NaOAc pH 4.5) in a 96-well microtiter plate at 37 °C. The reaction was the stopped 
through the addition of 20 µl 1M hydrochloric acid. 20 µl of 1M Tris solution was 
then added to each well followed by the addition of 80 µl assay mixture to detect 
glucose release. The assay mixture was comprised of 0.5 mM ABTS, 20 U HRP and 
40 U glucose oxidase. The microtiter plates were sealed and incubated at 37 °C for 
twenty minutes before the absorbance at 420 nm was measured. A background level 
of glucose was determined for each supernatant following the same protocol but 
replacing the substrate with 100 mM NaOAc pH 4.5. Activity normalised based on 
OD600 readings of overnight cultures. 
 






Tryptically digested MassPrep digestion standard 1 and Leucine Enkephalin 
purchased from Waters. Trypsin-digested BSA MS Standard (CAM-modified) 
purchased from New England Biolabs. Mass spectrometry grade solvents were 
purchased from Fischer Chemical. 
 
2.9.2 Sample preparation 
 
Lyophilised MassPrep Standard mix 1 is an equimolar mix of four tryptically 
digested proteins (50 pmol of each). To prepare the standard for analysis the mix was 
reconstituted through the addition of 100 µl 0.1% formic acid, and vortexing until all 
material was completely re-suspended. 
Lyophilised trypsin-digested BSA standard from NEB was reconstituted in 250 µl 
0.1% formic acid through vortexing until all material was re-suspended giving a final 
concentration of 2 µM. 
Leucine Enkephalin was used for lockmass correction at a concentration of 800 
pg/µL in 75:25 H2O:ACN + 0.1% FA. 
 
2.9.3 Liquid chromatography  
 
All UPLC separations were performed on an Acquity UPLC system using a BEH 
C18 Column, 130Å, 1.7 µm, 1 mm X 100 mm analytical column (Waters 
Corporation). Solvent A was composed of 0.1% formic acid in water and Solvent B 
0.1% formic acid in acetonitrile. Sample elution was standardly performed at a flow 
rate of 90 µl/minute by increasing the organic solvent from 5% to 40% over 25 
minutes. For analysis of cell lysates the length of LC gradient was increased to 60 
and 120 minutes. The Lockspray was infused throughout the run at a standard rate of 




2.9.4 Mass spectrometer configuration 
 
A Synapt G2 Q-TOF mass spectrometer controlled through MassLynx Version 4.1 
(Waters Corporation) was used for all analysis in this study. The instrument was 
calibrated using a MS spectrum generated from sodium formate from m/z 50 - 1500 
All subsequent acquisitions were lockmass corrected post acquisition using single 
point Leucine Enkephalin reference compound (m/z 556.2771). The reference 
compound was delivered into the mass spectrometer through the LockSpray 
interface. Acquisition occurred every 30 seconds for 0.3 seconds. 
MSE data was collected over the m/z range of using a method created the MS method 
editor in Mass Lynx. In the low energy scan a constant trap collision energy of 4 V 
was applied whilst in elevated energy mode the trap collision energy was ramped 
from 15 V to 40 V whilst the transfer energy was maintained at 2 V for low and high 
energy scans.  
 
2.9.5 Processing of MSE data and database interrogation 
 
MSE data for protein identification was processed using PLGS version 3.03. Data 










2.9.5.1 Processing parameters 
 
Attribute Value 
Chromatographic Peak Width Automatic 
MS TOF Resolution Automatic 
Lock Mass for Charge 1 556.2771 Da/e 
Lock Mass for Charge 2 N/A 
Lock Mass Window 0.25 Da 
Low Energy Threshold 135.0 counts 
High Energy Threshold 30.0 counts 
Elution Start Time Not specified 
Elution End Time Not specified 
Table 8: PLGS processing parameters. 
 
2.9.5.2 Workflow parameters 
 
Attribute Value 
Search Engine Type PLGS 
Databank Variable 
Taxonomy N/A 
Peptide Tolerance 10 
Fragment Tolerance  10 
Min Fragment Ion Matches per Peptide 3 
Min Fragment Ion Matches per Protein 7 
Min Peptide Matches per Protein 1 
Maximum Protein Mass 250000 
Primary Digest Reagent Trypsin 
Secondary Digest Reagent None 
Missed Cleavages 1 
Fixed Modifier Reagents Carbamidomethyl C 
Fixed Modifier Reagent Groups N/A 
Variable Modifier Reagents Oxidation M 
False Discovery Rate 4 
Table 9: PLGS Workflow parameters. 
 
Processed data was used to interrogate either the UniProt KB database or an E. coli 
database downloaded from UniProt and supplemented with rGS protein sequences.  
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3. Adaptation of inABLE™ DNA assembly for biosynthetic 
pathway optimisation 
 




The engineering of microbes for industrial bioprocesses often relies on the 
introduction of potentially complex multi-step heterologous biosynthetic pathways in 
the microbe of choice as a first step. Traditionally the construction of the DNA 
vectors to achieve this would be through multiple rounds of digestion and ligation 
based molecular cloning however in recent years a rise in available DNA assembly 
techniques has accelerated the construction of these pathways and opened the door to 
the combinatorial construction of such pathways. The ability to mix and match 
coding sequences, promoters, terminators, ribosome binding sites and vector 
sequences allows a metabolic engineer to explore a much larger design space in a 
single experiment than was previously feasible. This increases the likelihood of 
identifying an optimal gene combination and expression balance to maximise flux 
through the heterologous pathway and has the potential to greatly accelerate the 
engineering of microbes for bio-based processes. 
 
Ingenza currently uses a combinatorial genetic assembly technology (known 
commercially as inABLE®) for the efficient and selective assembly of complex DNA 
expression vectors encoding, for example, the enzymes responsible for multiple 
biosynthetic transformations within a pathway to produce chemical targets. 
Notwithstanding the advantages of this technique, it is also clear that with suitable 
innovation, this technology could be even more powerful than it is in its current 
form. This chapter focusses on the adaptation and optimisation of this technology 
into a robust platform for the combinatorial assembly of multicomponent pathways. 
In order to achieve this a systematic review of the current technology has been 
65 
 
undertaken and a number of areas which can limit the efficiency of the process 
identified. 
 
The inABLE® technology can be split into three stages, part design and preparation, 
part linker fusion and the assembly reaction (described in detail in Section 1.6.1.6). 
The first step of the procedure involves the identification of the optimum splits 
within each part generating a truncated part and the linker and part oligonucleotides. 
Part linker fusions are then prepared firstly digesting the truncated part with SapI 
generating 3 nucleotide overhangs followed by ligating each truncated part with its 
part oligonucleotide at the 5’end and the linker oligonucleotide of the following 
truncated part at the 3’end, a process which generates sixteen nucleotide 
complementary overhangs between parts. The parts are then combined and 
assembled through these overhangs in a one pot reaction, without the addition of 
ligase. Each stage within the process is amenable to optimisation to improve the 
overall assembly efficiency. Three key areas contributing to assembly efficiency 
have been explored in this chapter, the effect of part number, the effect of homology 
with 3 nucleotide overhangs and the effect of secondary structure in 16 nucleotide 
overhangs.  
 




With increasing pathway complexity, the number of fragments of DNA that require 
to be assembled also increases. Whilst standard digestion/ligation techniques which 
utilise overhangs of - on average - 3 nucleotides allow the annealing of up to three 
fragments of DNA, techniques such as inABLE DNA assembly utilise 16 nucleotide 
overhangs, increasing the number of fragments which can be assembled. Despite the 
ability to assemble a larger number of parts the efficiency of the assembly reaction 
will decrease as part number increases. For example, a recent study characterising 
Gibson assembly found that - in the authors hands - when an assembly of more than 
66 
 
four DNA parts was attempted to generate constructs totalling 4.8 kb below 50% of 
the isolates screened were correct148. To test the effect part number has on assembly 
efficiency, a study was designed to test assemblies containing between 2 and 10 
parts, which is thought to be the upper limit of inABLE assembly process. The 
output of this experiment will guide the choice between the standard and alternative 
inABLE based approaches in future vector construction programs. This may be due 
to the complexity of the vector to be constructed or when a high assembly efficiency 




To explore the effect of part number on assembly efficiency an experiment was 
designed in which assembly efficiency could be directly calculated through counting 
of colonies on a selection plate without the requirement for PCR or restriction 
digestion based characterisation. An initial vector was constructed (Figure 15) which 
consisted of Ampicillin (Amp), Kanamycin (Kan), Chloramphenicol (Camp) and 
Tetracycline (Tet) resistance markers along with a pMB1 origin of replication. This 
vector provided the template DNA for subsequent truncated part design and 
amplification and also acted as a positive control for all subsequent transformations. 
Through selection of transformants on LB plates supplemented with Kan, Amp, 
Camp and Tet it is possible to directly screen for isolated containing the expected 





Figure 15: Map of assembly T1 which was used to determine the effect of part number on assembly efficiency. 
The construct is comprised of four genes which confer resistance to four different antibiotics (kanamycin, 
tetracycline, chloramphenicol and ampicillin) and a pMB1 E. coli origin of replication.  Strains which contain 
correctly assembled construct can be selected for on agar containing the four antibiotics GCC sequences 
annotated on the map identify the introduced scar sequence and define the boundary of the parts assembled.  
The parts required to construct Assembly T1 had previously been designed and 
truncated parts, POA and LOA samples were available from the inABLE inventory. 
In order to test assemblies containing between six and ten parts, additional truncated 
parts were designed by splitting the initial five parts used in Assembly T1 in two sub-
parts. This ensured that regardless of the number of parts being assembled that the 
size of the final construct remained constant, which is important as increasing 
construct size is known to have a negative effect on transformation efficiency149. As 
described previously (Section 1.6.1.6) the inABLE procedure results in the 
introduction of a 3 bp scar (gcc) between parts. The introduction of this scar 
sequence is not feasible in the middle of one of the antibiotic resistance marker 
coding sequences as required for the tests involving 6 to 10 parts. To avoid the 
introduction of a scar within the markers the junction between sub-fragments within 
each part was defined as a codon encoding an alanine residue which could be 





































The ability to utilise the inABLE technique in a scarless manner potentially expands 
the scope of the approach to include techniques where splicing within a coding 
sequence is required such as combinatorial polyketide synthase construction150. A 
specific gcc fragment was selected within the pMB1 origin of replication (P169) for 
the sub-fragment split. Once the split points had been defined the sequences were 
used as input sequences for the part designer software to design the corresponding 
truncated parts, the linker oligonucleotides, the part oligonucleotides and PCR 
primers for the amplification of the truncated parts flanked by EarI/SapI sites 















169 PCRf169 PCRr169  
 
1487 pMB1 origin of replication 
2 1 PCRf1 PCRr1 920 Kanamycin resistance marker 
(KanR) 3 171 PCRf171 PCRr171 1592 Tetracycline resistance marker 
(TetR) 4 
172 PCRf172 
PCRr172 876 Chloramphenicol resistance marker 
(CampR) 
5 385 PCRf385 PCRr385 1045 Ampicillin resistance marker 
(AmpR) 6 
A (1/171/172/385) PCRf1 
PCRr385 4588 KanR/TetR/CampR/AmpR 
7 B (171/172/385) PCRf171 PCRr385 3617 TetR/CampR/AmpR 
8 C (172/385) PCRf172 PCRr385 1975 CampR/AmpR 
9 
P169 (SubP1) PCRf169 
PCRr169 
(SubP1) 





PCRr169 455 3’ section of pMB1 ori 
11 
P1 (SubP1) PCRf1 
PCRr1 
(SubP1) 





PCRr1 455 3’ section of KanR 
13 
P171 (SubP1) PCRf171 
PCRr171 
(SubP1) 





PCRr171 873 3’ section of TetR 
15 
P172 (SubP1) PCRf172 
PCRr172 
(SubP1) 





PCRr172 392 3’ section of CampR 
17 
P385 (SubP1) PCRf385 
PCRr385 
(SubP1) 





PCRr385 440 3’ section of AmpR 
Table 10: PCR reactions to amplify the 18 truncated parts required for exploration of the effect of part number 
on assembly efficiency. 
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The eighteen truncated parts (Table 10) were amplified via PCR (Figures 16 and 17) 




Figure 16: PCR amplification of truncated parts 1-12. Numbering and expected products outlined in Table 10. 
 
 
Figure 17: PCR amplification of truncated parts 13-18. Numbering and expected products outlined in Table 10.  
 
The generated PCR products were used to generate the corresponding part linker 
fusions through ligation of the appropriate POA and LOA following the standard 
procedure (Section 2.5.4). Following purification of the part/linker fusion assembly 
reactions were performed in triplicate with the concentration of each truncated part in 
the reaction maintained at 2 nM. Following the completion of the assembly reaction 
70 
 
the product was used to transform E. coli and isolates harbouring the expected 
assembly product were selected for on LB-Kan, Amp, Camp, Tet plates. In parallel 
to each transformation reaction the assembly product (Assembly T1) was 
transformed at the final molar concentration (2 nM) expected for completion of the 
assembly reaction.  Colonies were counted, and assembly efficiency calculated as a 
percentage of the number of transformants obtained using the positive control 





SD Average assembly efficiency SD 
2 Part Assembly 1001 38.947 0.450  0.018 
3 Part Assembly 324 69.415 0.146 0.031 
4 Part Assembly 131 8.717 0.059 0.004 
5 Part Assembly 40 1.571 0.018 0.001 
6 Part Assembly 9 1.700 0.009 0.002 
7 Part Assembly 3 1.247 0.003 0.001 
8 Part Assembly 6 1.247 0.002 0.000 
9 Part Assembly 0 0.000 0.000 0.000 
10 Part 
Assembly 
0 0.000 0.000 0.000 
Table 11: Colony counts and assembly efficiencies for assembly reactions containing between 2 and 10 parts 
using the standard inABLE procedure. The average colony count and assembly efficiency presented are the result 
of experiments performed in triplicate.  The assembly efficiency was calculated as a percentage of the number of 








A key advantage of the number of DNA assembly techniques which have been 
described in the past 10 years is the ability to assemble a higher number of parts than 
standard digestion/ligation approaches which are limited to 3 parts. However, this 
study highlights the considerable decrease in assembly efficiency as part number 
increases. This reinforces the requirement to move towards an alternative approach 
when vectors comprised of 5 or more parts or combinatorial libraries require to be 
constructed. One disadvantage of the strategy employed in this study is that the 
number of incorrect assemblies generated, and thus assembly accuracy, cannot be 
determined (as any colonies containing incorrect assemblies will not be viable on the 
selection plates). To explore the effect of part number on assembly accuracy the 
construction of a vector which results in a colorimetric response, such as the 



























No. of parts in assembly reaction
















The second stage (part/linker fusion) of the inABLE process relies on efficient 
ligation of part and linker oligonucleotides to truncated parts during the part/linker 
fusion reaction. It is this reaction that generates the complementary 16 nucleotide 
overhangs between parts which are vital in the assembly reaction and as such any 
reaction which inhibits this ligation will impact the overall assembly efficiency. One 
such reaction is the potential for self-ligation of the truncated part through three 
nucleotide overhangs present at the 5’ and 3’ end of the truncated part after SapI/EarI 
digestion (Figure 19).  
 
 
Figure 19: Self ligation of a truncated part through 3 nucleotide overhangs in the part/linker fusion reaction The 
formation of this product has the potential to decrease assembly efficiency as the self-ligated product cannot be 
re-digested by EarI/SapI and cannot ligate the POA or LOA fragments which are required for DNA assembly. 
 
The possibility for this reaction is due to the nature of SapI and EarI as type IIs 
restriction enzymes. Type IIs restriction enzymes recognise asymmetric DNA 
sequences and cleave out with their recognition sites. SapI and EarI cleave in an n + 
1, n + 4 manner which results in a 3 nucleotide overhang (Figure 20). This 
characteristic is vital as it firstly generates three nucleotide overhangs to which the 
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POA and LOA are ligated and secondly means the product of the part/linker fusion 
lacks recognition sites allowing for product enrichment through cycles of digestion 
and ligation.   
 
 
Figure 20: Type IIs restriction endonuclease cleave out with their recognition sites. EarI (and SapI) cuts n + 1, n + 
4 resulting in a 3 nucleotide overhang. The EarI recognition site is boxed and the cleavage site indicated by red 
arrows. 
 
The overhang at the 3’ end of the truncated part is specified as being complementary 
to gcc. The maintenance of this sequence as an overhang means that any linker, 
which are standardised to contain a 5’ gcc overhang, can be annealed to any 
truncated part providing the flexibility that makes the technique suitable for DNA 
assembly. The 5’ overhang however is defined by the sequence of the full length part 
and as the part design software does not take complementary bases within the 3 
nucleotide overhangs into account when defining the split point between the 
truncated part and the linkers, complementary bases between the upstream and 
downstream overhang can be generated following EarI/SapI digestion. The effect of 
complementary base pairs within these overhangs was explored to determine if this is 






                                                                      
To explore the effect of self-ligation of the truncated part during part linker fusion on 
assembly efficiency a two part assembly was utilised (Figure 21). The combination 
of one part containing a pMB1 origin of replication and second part containing a 
Tetracycline resistance marker allows for the simple calculation of assembly 
efficiency through selection of transformants on tetracycline containing media as 
only clones containing the correctly assembled product will be able to propagate.  
 
Figure 21: Expected assembly product used to explore the effect of complementary nucleotides within 3 base 
overhang on assembly efficiency. The construct comprises of a gene which confers tetracycline resistance (TetR) 
and an E. coli origin of replication (pMB1). 
 
Primers were designed for amplification of the TetR truncated part generating 
varying 3 bp overhangs following SapI digestion. As the inABLE workflow specifies 
a consistent 3’ overhang this remained constant and the 5’ overhang was modified. 
Six overhangs generating between three and zero bases of compatibility and also the 
position of the complementary bases within the overhang were explored (Table 12).  
 
 








 xxx Overhang 
compatibility 
Matches 
A gtg gcc 
xx¦ 
gtg 
1 external match 




C ggg gcc 
x¦¦ 
ggg 
2 matches  
(1 external, 1 
internal) 




E tga gcc 
x¦x 
gga 
1 internal match 





Table 12: Position and number of complementary bases flanking truncated part following SapI digestion. 
 
Truncated parts were amplified through PCR, using alternative forward primers to 
introduce the desired 5’ overhang and compatible appropriate POA and LOA 
prepared for each reaction. The amount of each part was maintained at 2 nM in each 
assembly reaction. A positive control reaction was performed in which the expected 
assembly product was diluted to 2 nM.  All assembly reactions and subsequent 
transformations were prepared in triplicate as previously described and assembly 
efficiencies were calculated as a percentage of the number of transformants obtained 









Assembly B (3 matches) 39 41 0.021 0.022 0.005 
52 0.028 
31 0.016 
Assembly C (2 matches 1 internal, 1 
external) 
1440 1448 0.765 0.769 0.068 
1608 0.854 
1296 0.688 
Assembly F (2 external matches) 2006 1642 1.066 0.872 0.151 
1608 0.854 
1312 0.697 
Assembly A (1 external match) 3912 3819 2.078 2.028 0.115 
4024 2.137 
3520 1.870 
Assembly E (1 internal match) 2968 2635 1.576 1.399 0.142 
2312 1.228 
2624 1.394 
Assembly D (0 matches) 13600 12460 7.224 6.618 0.613 
12900 6.852 
10880 5.779 
Table 13: The effect of complementary bases within three base overhangs following EarI/SapI digestion. 






























































































































































Figure 22: The effect of complementary bases within three base overhangs following EarI/SapI digestion. The 




This study highlights the pronounced effect the presence of complementary bases 
within the 3 nucleotide overhangs has on the assembly efficiency. It was found that 
the presence of only one complementary base within these overhangs resulted in a 
decrease in assembly efficiency of 70% whilst the presence of three homologous bases 
resulted in a 99% decrease in the efficiency. It is therefore vital for robust and efficient 
assembly that complementary bases within these overhangs is avoided. To achieve this 
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the number of splits defined by the part design software can be increased allowing for 
identification of a split point that results in zero complementary bases following SapI 
digest – either via manual analysis or software modification - maximising assembly 
efficiency. 
Interestingly the assembly efficiency in this experiment is considerably higher than 
seen for two parts in the previous part number experiment (0.45% versus 7% in this 
experiment with no complementary bases). As the assembly product was transformed 
in parallel in each experiment then this difference in efficiency cannot be attributed to 
the increased vector size or factors affecting E. coli transformation such as cell 
competency or transformation protocol. Analysis of the overhangs in the two part 
assembly revealed one complementary base in the overhangs generated following 
digestion of TPA (Table 10) with SapI. This is likely to be partly responsible for the 
lower efficiency observed in the part number experiment and further highlights the 
requirement to avoid complementary bases when looking to maximise assembly 
efficiency.    
 




During the final stage of the inABLE procedure (the assembly reaction) purified part 
linker fusions are mixed together and assembled through complementary 16 
nucleotide single stranded overhangs (Figure 23). These overhangs are generated due 
to the ligation of appropriate part and linker oligonucleotides to adjoining truncated 
parts. One parameter which has not previously been considered is the presence of 
secondary DNA structure within the 16 nucleotide overhangs. The potential for the 
formation of secondary structures within these overhangs would likely prevent the 
efficient assembly of fragments. This is not currently taken into consideration when 
defining the split point between the truncated part and linkers. The effect of 
secondary structure within these overhangs was explored through alteration of the 
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Figure 23: DNA assembly through POA and LOA annealing. Area in yellow highlights the 16 nucleotide 




Experimental design allowed for assembly efficiency to be directly calculated 
through counting the number of colonies on antibiotic containing agar plates. On this 
occasion a KanR marker cassette and pMBI origin of replication were assembled. 
Since the linker sequence requires to be modified in order to modulate the strength of 
predicted secondary structure the KanR fragment available through the inABLE 
database could not be used due to the promoter being included in the linker. 
Modification of the linker therefore could have an impact on the transcription of the 
aminoglycoside 3'-phosphotransferase gene which confers kanamycin resistance. It is 
therefore possible that the modulation of the linker sequence may impair the 
promoter function and as a result kanamycin resistance in clones containing the 
expected vector. To circumvent this potential issue a new KanR fragment was cloned 
in which forty seven base pairs were added to the 5’ end of the KanR cassette to 
allow for LOA modification without altering the promoter or 5’ UTR and affecting 
transcription/translation. 
Eight LOl and the complementary POl sequences were designed to generate 
secondary structures within the 16 nucleotide single stranded overhang ranging in 
predicted strength from very strong ΔG (-7.47) to no predicted secondary structure 
and a ΔG value of 2.04 (Table 14).   
                                                         LOA  
GCCCTTTGCTTTGCCACGGAACGGTCTGCGTTGTCGGGAAGATGCGTGAT 
 
   GAAACGAAACGGTGCCTTGCCAGACGCAACAGCCCTTCTACGCACTAGAC 
 




LOA overhang sequence GC % Predicted secondary 
structure 
ΔG (kcal. mole-1) 
GAACGGTCTGCGTTGT 56.2 Moderate -3.2 
CAACGGTCTGCGTTGT 56.2 Moderate -4.22 
GAACGCTCTGCGTTGT 56.2 Strong -4.05 
CAACGCTCTGCGTTGT 56.2 Strong -5.06 
GAAGGGTCTGCGTTGT 56.2 None 1.02 
GAAGGGTGTGCGTTGT 56.2 None 2.04 
CAGCGCTCTGCGCTGT 68.8 Very strong -6.15 
CCGCGCTCTGCGCGGT 81.2 Very strong -7.47 
Table 14:  Modification of 16 nucleotide overhang sequence to modulate predicted secondary structure strength. 
 
Truncated parts were amplified through PCR and the appropriate POA and LOA 
prepared for each reaction. The amount of each part was maintained as 2 nM in each 
assembly reaction. A positive control reaction was performed in which the expected 
assembly product was diluted to 2 nM.  All assembly reactions and subsequent 
transformations were prepared in triplicate as previously described. Assembly 
efficiencies were calculated as a percentage of the number of transformants obtained 

















Assembly H Very 
Strong (ΔG = -
7.47) 
200 230 0.136 0.157 0.024 
210 0.143 
280 0.191 
Assembly G Very 
strong (ΔG = -
6.15) 




Strong (ΔG = -
5.06) 




Strong (ΔG = -
4.05) 




Moderate (ΔG = -
4.22) 




Moderate (ΔG = -
3.2) 
13120 11613 8.950 7.922 0.909 
9880 6.739 
11840 8.076 
Assembly E None 
(ΔG = 1.02) 
13040 12937 8.895 8.824 0.188 
12560 8.568 
13210 9.011 
Assembly F None 
(ΔG = 2.04) 
14600 15773 9.959 10.759 0.681 
15680 10.696 
17040 11.623 
Table 15: The effect of the presence of secondary structures within 16 nucleotide overhangs on assembly 
efficiency. Number of colonies present on selective plates and the resulting assembly efficiencies. Assembly 




















































































































































































































The presence of strong secondary structures within linker sequences results in a 
significant decrease in assembly efficiency. An analysis however of one hundred 16 
nucleotide overhangs generated from the LOA sequences currently deposited within 
the Ingenza inABLE database predicted ΔG values between -2.81 and 2.55 kcal. 




Figure 25: Analysis of predicted secondary structure within 16 nucleotide overhangs from 100 LOA sequences in 
the inABLE parts database. 
 
This suggests that the decrease in assembly efficiency observed here will not be 
experienced for any of the linkers characterised. The presence of secondary structure 
however does have a strong impact on assembly efficiency in more extreme cases 
(ΔG < -4 kcal. mole-1) and should be explored as a possible cause, when difficult to 




In this study the effect of the number of parts being assembled, the presence of 
complementary bases within truncated part overhangs following SapI digestion and 
the presence of secondary structure within 16 nucleotide overhangs on assembly 
efficiency were explored. On each occasion combinations of fragments comprising 
origins of replication and antibiotic resistance marker cassettes were utilised to allow 
for the rapid determination of assembly efficiency through selection of transformants 
on plates containing appropriate antibiotics. The results highlight that each of the 
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factors explored can have a pronounced impact on assembly efficiency and should be 
considered when looking to maximise reaction efficiency. Secondary structure within 
overhangs and complementary bases flanking the truncated part can both be 
addressed through careful DNA fragment design however the number of parts being 
assembled is dependent on the construct being assembled. In order to address this, 
the development of an alternative inABLE workflow was initiated.   
   




The key advantage gained from using the inABLE® platform is the selectivity it offers 
in assembling DNA parts, permitting assembly of multiple parts in a single reaction. 
Traditional methods allow for the efficient ligation of 2 (or at most 3) parts – using 
inABLE® up to 9 DNA parts in a single reaction have previously been assembled. 
However, in its current form the technology has limitations. Firstly, to assemble a full 
biosynthetic pathway, combinations of a larger number of genomic regions (>10 parts) 
are desirable. Since the current procedure leads to a construct which is no longer 
compatible with the technology (lacking EarI sites), complex assemblies harbouring 
more than ten parts cannot be generated using the technique. Secondly a powerful use 
of this technology is the ability to perform combinatorial assemblies, for example the 
combination of a gene with multiple regulatory regions (promoters, terminators, 
ribosome binding sites), however as described in Section 3.1.2, as part number 
increases assembly efficiency decreases making the combinatorial construction of a 
vector comprised of multiple fragments unpractical.  
 
To address these limitations the development of a “nested” inABLE technology was 
implemented. The essential innovation in this approach is that an initial DNA vector 
is prepared in pieces from inABLE parts in a form that allows it to be used in 
subsequent assemblies – i.e. a convergent rather than a linear synthesis. The key piece 
of novel enabling technology which forms the basis of this work is the design of DNA 
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parts suitable for “nested” inABLE. In theory such an approach will be able to yield 
assemblies of up to 100 parts or ensure that when constructing vector libraries, the 
final assembly step is as efficient as possible, maximizing library coverage. 
As outlined in Section 3.1.2, a primary limitation of the inABLE technology is that 
as part number increases the assembly efficiency rapidly decreases. In response to 
this issue a step-wise approach in which complex assemblies could be split into 
smaller sub-assemblies followed by a final two or three part assembly was envisaged. 
In its current format the product of an inABLE® assembly cannot be used in 
subsequent assemblies. As described in Section 2.5.4, the part linker fusion reactions 
involve cycles of digestion and ligation using EarI (recognition site - CTCTTC) and 
T4 DNA ligase. Although EarI is standardly used truncated parts are designed so that 
they are flanked by a SapI/EarI recognition site (GCTCTTC) (Figure 26). 
 
 
Figure 26: Comparison of EarI and SapI recognition and cleavage sites. The ability to alternate between the 
utilisation of these enzymes is key when adopting a nested assembly approach. 
 
This gives the possibility to use SapI for a first round of reactions and fuse linkers 
containing the EarI recognition sites to the outmost parts. This would result in the 
product of the first round of assembly being flanked by EarI recognition sites which 





Figure 27: Nested assembly of three DNA parts. Following the first assembly Part A and Part B are flanked by EarI 
recognition sites allowing for combination with other parts in a subsequent inABLE assembly provided EarI is 
used in the part linker fusion reaction. 
 
The ability to switch between EarI and SapI for subsequent rounds of part/linker 
fusions gives the possibility to perform complex assemblies in two steps.   The 
primary advantages of this new approach are the ability to build increasingly 
complex vectors as assemblies would no longer be limited to 10 parts and the 
efficient construction of multipart vector libraries through the use of a final step two 
or three part assembly. To explore these potential benefits, the construction of a 
combinatorial library and a complex vector (>7 parts) were initiated. 
 




To explore the ability to use the nested inABLE approach in order to construct 
complex vectors the construction of Saccharomyces cerevisiae vectors for the 
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liberation of glucose from cellulose was initiated. Cellulose is a structural 
polysaccharide found in plants which is the most abundant organic polymer in the 
biosphere152. It is comprised of β-1,4 linked D-glucose monomers organised into 
ordered crystalline domains and disordered amorphous domains. Efficient 
degradation of this feedstock is thought to require the synergistic action of a 
minimum of three enzyme classes, endoglucanases which cleave β-1,4-glucosidic 
bonds at internal sites within the cellulose fibre, exoglucanases which cleave 
cellobiose from the exposed ends in a progressive manner and β-glucosidases which 
liberate glucose from cellobiose153, 154 (Figure 28). The addition of blends of these 
enzymes to cellulosic feedstocks is not cost efficient for large scale biomass 
processing. Ideally a consolidated bioprocessing approach in which the production 
strain produces its own biomass degrading enzymes, assimilates the liberated sugars 
and produces the chemical of interest would be of industrial interest155.  
 
 









To engineer S. cerevisiae to access glucose from cellulosic material the construction 
of two expression vectors for cellulose degradation was initiated. An 
endoglucanase/exoglucanase fusion protein156 alongside two β-glucosidases 
previously identified from rumen metagenomic data and previously characterised in 
vitro by Ingenza were targeted for concerted expression. Previously, these enzymes 
had been characterised individually but expression in S. cerevisiae or the concerted 
activity of the enzymes had not been explored. In order to offer the best chance of 
successful expression and secretion, the native secretion signals were identified in 
each enzyme using Signal P version 4.0157. The signal peptides were removed and 
replaced by the well characterised S. cerevisiae alpha factor secretion signal158, the 
genes were codon optimised for expression in S. cerevisiae using the algorithm 
provided by Genscript. Following optimisation, the sequences were then adapted for 
the inABLE® DNA assembly process and truncated parts designed, synthesised and 
cloned into compatible vector backbones (Figure 29).  Construction of this vector 
using a standard inABLE based approach would involve an eight part assembly, to 




Figure 29: Design of cellulose degradation gene targets for inABLE assembly. Native signal peptides were 
removed and the genes codon-optimised prior to truncated part and linker design.  
To facilitate using the product of one round of assembly in a subsequent part linker 
fusion reaction several specific oligonucleotides required to be designed. Appropriate 
POs, POl, LOl and LOs oligonucleotides were designed to introduce EarI recognition 
sites flanking the initially assembled truncated parts (Table 16). The oligonucleotides 
designed are standardised so that they are compatible with any nested approach. EarI 
sites present within the S. cerevisiae/E. coli shuttle backbone which would be 
tolerated in the standard inABLE procedure were disrupted through site directed 







Oligonucleotide Sequence  
Description 
POsxxx nested gtgctggtCTCTTCg 
POA fused to 5’ end of first TP in the 
nested assembly, introducing EarI site. 
POA is specific to the 3 nucleotide 
overhang formed following SapI 




LOsxxx nested ggaagaatgtttcat LOA fused to backbone part. Provides 
overhang complementary to POAxxx 
nested. 
LOlxxx nested gccatgaaacattcttccgatatctgcattgttg 
LOs172 nested cgcctggtgggatcctCTCTTCg 
 
LOA fused to the 3’ end of the final TP 
in the nested assembly, introducing EarI 
site. Linker is specific to the backbone 
used to construct the nested vector.  LOl172 nested gcccGAAGAGaggatcccaccaggcgtttaagggcaccaata 
Table 16: Nested primers used for construction of initial nested backbone. The EarI recognition sites which are 
used in the second round of assembly are highlighted in capital letters. 
 
In a first round of assembly intermediate vectors comprising a S. cerevisiae/E. coli 
shuttle backbone, an endo/exoglucanase expression cassette and two β-glucosidase 
expression cassettes were constructed. These were then combined in a second round 
of assembly resulting in two dual expression vectors (Table 17). 
 
Intermediate nested vectors Final Expression vectors 
β-glucosidase A cassette 
(Assembly Cellulase 1) Endo/Exoglucanase/β-glucosidase A 
(Assembly Cellulase 5) β-glucosidase B cassette 
(Assembly Cellulase 2) 
Endo/Exoglucanase cassette 
(Assembly Cellulase 3) Endo/Exoglucanase/β-glucosidase B 
(Assembly Cellulase 6) S. cerevisiae/E. coli backbone 
(Assembly Cellulase 4) 
Table 17: Nested strategy for construction of S. cerevisiae dual expression vectors. 
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Four initial nested vectors were constructed (Figures 30 and 31) following the 
part/linker fusion and assembly methods previously outlined. Critically in this first 
round of part linker fusion reactions, the enzyme SapI was used.  
 
 
Figure 30: Nested intermediate β-glucosidase vectors. Introduced EarI recognition sites highlighted 
 
 
Figure 31: Nested intermediate Endo/exoglucanase and E. coli/S. cerevisiae shuttle backbone vectors. Introduced 
EarI recognition sites highlighted. 
 
Construction of intermediate vectors was confirmed through EarI digestion (Figures 
32, 33, 34 and 35) and sequencing of the junction regions between assembled parts. 
The construction of these vectors was achieved with relatively low efficiency 
(average of 23% of the clones characterised harboured the expected construct). This 
highlights the value of a nested approach as it has previously been shown that as the 
number of parts being assembled increases the efficiency further decreases (Section 
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Figure 32: Screening of nested assembly Cellulase 1 vectors via EarI digestion. Screening of five vectors (lanes 1 - 
5) resulted in one vector (lane 4) which yielded DNA fragments of the expected sizes (3.2 kb and 1.8 kb). 
 
 
Figure 33: Screening of nested assembly Cellulase 2 vectors via EarI digestion. Screening of ten vectors (lanes 1 - 
10) resulted in four vectors (lanes 5, 6, 7 ,8 and 10) which yielded DNA fragments of the expected sizes (3.2 kb 
and 1.8 kb). 
 
 
Figure 34: Screening of nested assembly Cellulase 3 via EarI digestion. Screening of ten vectors (lanes 1 - 10) 





Figure 35: Screening of nested assembly Cellulase 4 via EarI digestion. Screening of one vector (lane 1) resulted in 
one vector (lane 1) which yielded DNA fragments of the expected sizes (3.7 kb and 0.9 kb). 
 
Two final S. cerevisiae dual expression vectors were constructed through 
combination of the nested endo/exoglucanase, β-glucosidase and backbone parts 
(Figure 36).  
 
 
Figure 36: Final S. cerevisiae vectors constructed using a nested approach for concerted expression and secretion 
of an endo/exoglucanase fusion and a β-glucosidase. 
 
Part/linker fusions and assemblies were performed as previously but this time using 
EarI in the part linker fusion reaction and the resulting assembly reactions used to 
transform E. coli as previously described. Ten random clones were picked, the 
corresponding vectors were isolated and the constructs screened via PvuI restriction 
94 
 




Figure 37: Screening of assembly Cellulase 5 vectors via PvuI digestion. Screening of ten vectors (lanes 1 - 10) 
resulted in nine vectors (lane 1 – 3 and 5 - 10) which yielded DNA fragments of the expected sizes (5.4 kb, 2.8 kb 
and 2.0 kb). 
 
 
Figure 38: Screening of assembly Cellulase 5 vectors via PvuI digestion. Screening of ten vectors (lanes 1 - 10) 
resulted in nine vectors (lane 1 – 4 and 6 - 10) which yielded DNA fragments of the expected sizes (5.4 kb, 2.8 kb 
and 2.0 kb). 
 
Screening of isolates following the final nested assembly reaction highlighted that 
90% of the clones characterised contained the expected DNA construct, with >1000 
transformants obtained. It is extremely unlikely that such an efficiency would have 
been achieved for the construction of a vector of this complexity using the standard 
inABLE procedure. This result highlights the application and benefits of a nested 
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approach to DNA assembly when looking to construct vectors comprised of a large 
number (5+) parts. Despite the increased time investment required to construct 
intermediate vectors these can be re-used in subsequent assemblies and this 
investment is further offset by the time saved in identifying positive isolates due to 
increased reaction efficiency. 
The constructed vectors were introduced into an industrial ethanol producing S. 
cerevisiae strain (Ethanol Red, Fermentis)159 following the lithium acetate 
transformation method described by Gietz et al160 generating strains Cellulase 68 and 
69. To characterise rate, intermediates and products of cellulose breakdown, a shake 
flask assay and complementary analytical methodology that had previously been 
developed by Ingenza were utilised.  
The two S. cerevisiae strains engineered for concerted expression of the 
exonuclease/endonuclease fusion and either beta-glucosidase (Cellulase 68 and 69) 
were initially screened at shake flask level using commercial corn mash as a 
substrate. Corn mash is currently used as a primary feedstock for the bioethanol 
industry in the United States. In this process the corn is treated with amylases 
(glucoamylase and α-amylase) to degrade the starch present into glucose. S. 
cerevisiae is then added to assimilate the liberated glucose and produce ethanol161. 
Currently in this process however, the cellulose is not targeted. Analysis of the dried 
distillers grains and solubles (DDGS) which constitutes the remaining feedstock at 
the end of a corn ethanol fermentation contains between 9 and 16 % cellulose by 
weight162.  
The engineered strains and a negative control (the non-engineered parental strain) 
were incubated with and without commercial glucoamylase which is standardly 
added to the process to catalyse the saccharification of starch to glucose. Ethanol 
production throughout the experiment was monitored by CO2 loss. Strains Cellulase 
68 and 69 displayed slightly enhanced ethanol production rate in comparison to the 
parental control in the presence of commercial glucoamylase. A HPLC based 
analytical method was used for quantification of DP4+ (saccharides with four or 
more glucose units), DP3 (maltotriose),  maltose, glucose, glycerol and ethanol at the 
assay end point (65 hours). Whilst Cellulase 68 and 69 did not display increased final 
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ethanol yield, the slightly faster rate of ethanol production rate displayed in this 
experiment is potentially an advantage to end users (Figure 39). 
 
Figure 39: Shake flask assay of Cellulase 68 and 69 (CO2 loss) (Left).  Shake flask assay of Cellulase 68 and 69 (End 




This proof of concept study demonstrates the ability to use a nested inABLE strategy 
in which the product of one assembly reaction is compatible with a second round of 
assembly. The technique is feasible due to the introduction of EarI recognition sites 
in linker sequences during the construction of initial vectors which can then be 
utilised in a second round of part/linker fusion. In this study a vector comprised of 
eight parts, which is on the limit of the standard technology, was built in a nested 
manner with 90% of the clones screened following the final assembly reaction 
containing the expected construct. The utilisation of a nested strategy when 
constructing vectors with over five parts has numerous advantages. Firstly, through 
de-risking the vector construction by splitting it into stages and minimising the 
number of parts in the final assembly reaction assembly efficiency was increased, 
limiting the time taken to identify clones containing the expected isolates. Secondly 
each of the intermediate parts are re-usable, meaning that if, for example, one of the 
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genes in the construct is determined to be sub-optimal it can be replaced with a more 
suitable candidate without having to reconstruct the multi-part construct afresh.  
 




Protein secretion can be a powerful of tool for multiple biotechnology applications, 
for example it may provide a simple and cost efficient downstream purification 
platform avoiding the requirement to lyse cells at scale when looking to develop a 
biologics production strain. Alternatively, when looking to engineer a microbe to 
access polymers such as starch, cellulose or lignin as feedstocks and avoid the 
purchasing of purified enzyme cocktails the engineered organism requires to be able 
to efficiently secrete hydrolytic enzymes to degrade these substrates into accessible 
sugars.  
An N-terminal secretion signal is required to direct the targeted protein into the cells 
secretory pathway. The protein is first transferred into the endoplasmic reticulum 
(ER) either during or directly following translation. In the ER the protein is post-
translationally modified before it is transferred to the Golgi apparatus for further 
modification, sorting and finally secretion. This complex process involves multiple 
steps and can quickly become overwhelmed if the targeted protein is highly 
overexpressed, resulting in misfolded inactive protein. It is difficult to predict the 
optimal secretion signal and promoter strength to maximise the level of protein 
secreted for a given gene, with protein specific optimisation often required163. In 
order to attempt to optimise the abundance of  extracellular target protein, the 
combinatorial construction of a library of S. cerevisiae expression vectors containing 
32 combinations of promoters and secretion signals coupled to a cellulase gene and a 
vector backbone comprised of the required origins of replication and selection 






The construction of the considered library would likely not be feasible through a six 
part assembly due to the assembly efficiency being too low when utilising the 
standard technology. To maximise the final assembly reaction efficiency a nested 
strategy was implemented. To enable library construction a cellulase coding 
sequence, terminator, E. coli backbone and S. cerevisiae backbones were first 
assembled using the nested inABLE methodology (section 3.2.1). The cellulase gene 
from Cytophaga hutchinsonii had previously been cloned in E. coli and identified as 
being an interesting candidate due to its potential dual exoglucanase/β-glucosidase 
characteristics164. The native secretion signal was identified and removed, and the 
gene codon optimised for S. cerevisiae expression prior to truncated part design 
(described in Section 3.2.2.2).  
Four constitutive S. cerevisiae promoters; Alcohol dehydrogenase 1 (ADH1p); 
Phosphoglycerate Kinase 1 (PGK1p); Glyceraldehyde-3-phosphate dehydrogenase 1 
(GAPDH1p) and Profilin 1 (PFY1p) of varying strength were selected from the 
Ingenza inABLE database. Eight secretion signal sequences were identified from the 
Pichia pastoris PichiaPink™ secretion signal collection (Invitrogen). As these 
secretion signal sequences had previously been codon optimised for P. pastoris, the 
wild type sequence was identified from the organism’s genomic DNA and codon 
optimised for S. cerevisiae using the algorithm provided by DNA 2.0. The identified 
secretion signal sequences were added to the promoter specific reverse PCR primer 
(PCRr) (Table 18) allowing for the fusion of the secretion signal sequence to the 
promoter truncated parts. This resulted in the generation of 32 re-usable promoter 









Promoter Secretion signal Modified PCRr primer sequence 
406 
ADH1p 
S. cerevisiae α factor 
ttagatggatccgctcttcgGGCTAATGCGGAGGATGCTGCGAATAAAACTGCAGTAAAAA
TTGAAGGAAATCTCATtgtatatgagatagttgattgtatgc 
407 A. niger α amylase 
ttagatggatccgctcttcgGGCCAAAGCAGGTGCAGCGACCTGCAGACCGTACAGAAACA
AAGACCACCAAGCGACCATtgtatatgagatagttgattgtatgc 
408 A. awamori GLA1 glucoamylase 
ttagatggatccgctcttcgGGCCAAACCAGAACAAACCAAACCAGACAAAGCCAACAAAG
ATCTAAAAGACATtgtatatgagatagttgattgtatgc 
409 Human serum albumin 
ttagatggatccgctcttcgggcAGAGTAAGCAGAAGAAAAAAGAAACAACAAGCTTATAA
AGGTAACCCACTTCATtgtatatgagatagttgattgtatgc 
410 K. marxianus INU1 inulase 
ttagatggatccgctcttcgGGCACTGACTCCTGCCAATGGAAGCAACAAGGAGTATGCTA
ACTTCATtgtatatgagatagttgattgtatgc 
411 S. cerevisiae SUC2 invertase 
ttagatggatccgctcttcgGGCAGATATTTTGGCTGCAAAACCAGCCAAAAGGAAAAGGA
AAGCTTGCAAAAGCATtgtatatgagatagttgattgtatgc 
412 S. cerevisiae M1 killer toxin 
ttagatggatccgctcttcgGGCTACGACTAGATGTAGTAATGTGATGAAAAATAATATACT
GACAGATCTAACTAATACTTGGGTTGGCTTAGTCATtgtatatgagatagttgattgtatgc 
413 G. gallus lysozyme 
ttagatggatccgctcttcgggcACCTTGACAGATACCCAACAAAGCAGTCAATCCCAACAA
GACCAAAACAAGACACATTGGGTCGTTCTTACCCAGCATtgtatatgagatagttgattgtatgc 
Table 18: Design of modified PCRr primers for addition of secretion signal to ADH1 promoter truncated part. 
Introduced secretion signals in capitals. Underlined 3’-end fragment of the selected promoters. Primer design 
carried out following the same strategy for PGK1, GAPDH1 and PFY1 promoters. 
 
The recipient nested vector was constructed comprised of a cellulose coding 
sequence, S. cerevisiae terminator and E. coli/S. cerevisiae backbone parts flanked 
by EarI recognition sites (Figure 40), providing a platform to allow for the 
combination of this construct with the multiple promoter/secretion signal parts in a 




Figure 40: Initial nested vector for promoter secretion signal library construction. Introduced EarI sites 
highlighted in red boxes In a second stage of inABLE assembly promoter/secretion signal combinations can be 
introduced upstream of the Ex1 β-glucosidase. 
 
To build this vector a four part assembly was performed as described in Section 2.5. 
Around fifty colonies were obtained following E. coli transformation of which 10 
were picked at random and screened for successful assemblies via EarI restriction 
digest (Figure 41). The construction of this initial vector was achieved at low 
efficiency with 10% of the clones characterised containing the expected construct. 
 
 
Figure 41: Screening of nested backbone assembly via an EarI restriction digest. Screening of ten vectors (lanes 1 
- 10) resulted in one vector (lane 9) which yielded DNA fragments of the expected sizes (6.1 kb and 1.0 kb). 
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The low efficiency of this four part assembly highlights the requirement to 
implement a nested approach. Sanger sequencing analysis of the vector confirmed 
the expected assembly. The backbone was tested in a second round of inABLE for 
library construction through combination with the 32 promoter secretion signal parts, 
vitally this part linker fusion reaction was performed using EarI. 
To characterise the library 60 colonies were picked and the promoter and secretion 
signal combination present in the construct identified through colony PCR. From the 
sixty clones analysed, nine failed to generate a PCR product either due the isolates 
harbouring a mis-assembled construct or due to the PCR reaction failing. From the 




Figure 42: Identification of promoter secretion signal combinations following library construction through colony 
PCR. From the library of 32 combinations at least one positive was isolated for 28 of the potential constructs 
 
The above library was used to transform S. cerevisiae following the lithium 
acetate/single stranded carrier DNA method outlined by Gietz et al113, with 1.5 µg of 
the library used to transform 108 freshly prepared competent cells. Transformants 
were selected for on YPD-G418 and 100 colonies were initially picked for screening.  
Screening of the library was envisioned through a liquid phase glucose 
oxidase/peroxidase liquid phase assay. This assay relies on the incubation of the 
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culture supernatant - which should contain the secreted enzyme – with cellulose 
model substrates and the detection of liberated glucose. Glucose is detected through 
the oxidation of glucose by glucose oxidase resulting in the formation of and 
hydrogen peroxidase and gluconic acid. Hydrogen peroxidase is in turn used by 
horseradish peroxidase for the oxidation of ABTS which results in a colorometric 
response that can be monitored at 420 nm165 (Figure 43). 
 
 
Figure 43: Screening of cellulase expressing strains through glucose oxidase/peroxidase coupled assay. In this 
approach, culture supernatant is incubated with cellobiose resulting in the formation of glucose through the 
action of the secreted β-glucosidase. 
 
The glucose oxidase assay was performed using both carboxymethyl cellulose and 
cellobiose which are model substrates for both exoglucanase and β-glucosidase 
activities. Despite attempts to optimise both the protein expression and assay 
conditions, reproducible glucose release could not be detected for any of the library 







In order to optimise extracellular protein production, the combinatorial construction 
of a library of vectors containing 32 combinations of promoters and secretion signals 
was designed. The construction of this library however would likely not be feasible 
through a six part assembly due to the assembly efficiency being too low. To enable 
the library construction a recipient vector comprised of the cellulase coding 
sequence, a S. cerevisiae terminator, and E. coli/S. cerevisiae shuttle backbone was 
first assembled using the nested inABLE methodology.  Eight secretions signals 
were fused to the four promoter truncated parts via PCR allowing for a final two part 
assembly, maximising assembly efficiency. 
This final assembly resulted in thousands of transformants with the library diversity 
confirmed through a colony PCR based screen.  A high throughput liquid phase 
assay was designed to characterise the library following the introduction of the 
library into S. cerevisiae. Unfortunately, no activity could be detected for any of the 
constructs. Further work to determine if this result is due to the low activity of the 





In this chapter multiple parameters which can impede efficient multi-component 
pathway construction have been identified. It is clear to maximise assembly 
efficiency, as is often the case when constructing combinatorial libraries, it is 
required to limit the potential for secondary structure formation within linkers and 
avoid the possibility of truncated part self-ligation during part linker fusion. The 
effect of part number on assembly efficiency has also been defined, highlighting the 
requirement for the development of the nested approach when multiple DNA 




The expansion of the standard inABLE technology through a nested approach was 
investigated through the construction of a complex vector (>7 parts) and a 
combinatorial library. Nested linkers which allow for the stepwise assembly of parts 
were designed and tested. The two primary advantages of this approach are the 
ability to construct increasingly complex vectors which may be required when 
building a multi-gene pathway, and the efficient construction of combinatorial 
libraries which is powerful tool in pathway optimisation. These applications have 
been explored and the relevant plasmids and libraries were successfully constructed 
using the nested approach. The efficiency in which these constructs were prepared 
would not have been achieved using the standard technology. Identification of key 
parameters which limit the efficiency of the inABLE DNA assembly platform and 
the implementation a nested assembly workflow are key developments for 




















4. The development of an inABLE 2.0 platform 
 




Despite the advantages described in the previous chapter the throughput and 
efficiency of the inABLE DNA assembly platform is still amenable to optimisation. 
DNA assembly approaches are standardly ranked based on throughput, accuracy, 
flexibility and their amenability to process automation. The further development of 
an inABLE 2.0 platform was envisioned through optimisation of each of these 
parameters.   
A major bottleneck within the current inABLE DNA workflow is the requirement for 
part/linker fusion purification through gel electrophoresis or biotinylated primers and 
streptavidin beads166. These purification approaches have limitations and present a 
bottleneck in the current workflow. The running of agarose gels and excision of the 
DNA of interest is the currently preferred method for isolating the DNA of interest. 
However, this is a cumbersome, low throughput approach with the added 
disadvantage that the DNA extracted from the gel is likely a combination of the 
desired part/linker fusion and fragments lacking one or both linkers which are vital in 
the assembly stage.  
The utilisation of biotinylated primers and streptavidin beads is a potential solution 
to these issues. However, this approach requires an additional stage of processing 
increasing the length of time taken to construct the vector of interest by up to six 
hours. This section describes the development of a method to address this bottleneck 
in the current workflow. It outlines a high throughput approach, easily automated 
through the use of a liquid handling robot which results in the isolation of only the 
DNA of interest whilst degrading the remaining contaminating DNA in the reaction.   
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4.1.1.1 Current methods 
 
At present, gel electrophoresis is the standard method to purify desired DNA from a 
mixture167.  This approach utilizes an electric field for DNA migration through a 
porous agarose gel.  The fragments of DNA travel through the gel at a speed 
inversely proportional to their length.  Therefore, smaller fragments travel further on 
the gel and DNA of the desired size can be identified through comparison with a co-
electrophoresed set of DNA fragments of a known size.  The desired DNA is 
subsequently isolated from the gel through manual excision of the gel fragment and 
extraction of DNA from the gel matrix using commercially available kits (i.e., 
QIAquick gel extraction – Qiagen).  This process however is low throughput and 
provides a bottleneck in the inABLE DNA assembly process. This is also a manual 
process not amenable to automation.  
An additional limitation to this approach is the resolution that can be achieved 
through gel electrophoresis.  The DNA of interest contains 5’ and 3’ linkers (as 
described in Section 1.6.1.6) which constitute an increase in size of ~ 50 base pairs, 
over a DNA part which lacks either the 5’ and/or or the 3’ linker.  The part itself can 
often be ≥ 1000 base pairs in length so this change in size may be only ≤ 5% and 
thereby indistinguishable by gel electrophoresis.  As a result, DNA lacking one (or 
both) of the linkers can readily be carried through into the assembly stage where its 
presence is likely to be detrimental to the efficiency of the assembly reaction. 
To date attempts to accelerate this process have largely focused on the utilisation of 
biotinylated linkers and streptavidin beads168. This approach improves throughput 
and is in theory specific for purification of DNA which contains both 5’ and 3’ 
linkers. The technique relies on the extremely high affinity with which biotin binds 
to streptavidin. Biotinylated primers are available from all major primer 
manufacturers whilst small scale spin columns packed with streptavidin beads are 
produced by multiple companies. Biotinylated oligonucleotides (referred to as 
purification oligonucleotides) complementary to the 16 nucleotide single stranded 
overhangs of inABLE parts can be ordered.  However, it is not feasible to confirm 
whether both 5’ and 3’ biotinylated linkers have been attached to a part.  For 
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instance, presence of only one linker would still result in the DNA part-linker 
binding to the streptavidin.  In order to purify the desired DNA fragment, two rounds 
of purification are required. In the first round a biotinylated oligo specific for the 5’ 
linker is utilised before the process is repeated using a purification oligo specific for 
the 3’ linker. This adds additional steps to the process increasing the time to 
assemble the required vector, an extra cost to purchase the additional purification 
oligonucleotides, the need for two stages of purification, the unavoidable loss of 
product at each stage and the potential for contamination with non-specifically bound 
DNA.  This results in a less efficient, albeit somewhat higher throughput process 
than what is achievable with gel extraction based purification. 
 
4.1.1.2 Exonucleases and phosphorothioate bonds 
 
Exonucleases are enzymes which degrade DNA through hydrolysis of 
phosphodiester bonds in a stepwise manner from the end of the polynucleotide chain, 
as opposed to endonucleases which cleave internally in the chain.  Exonucleases 
cleave nucleotides one at a time from the end of polynucleotide chain in either a 5' → 
3' or 3' → 5' direction. To date, 17 exonucleases have been identified in E. coli169 
which play key cellular roles in DNA repair and recombination, genome stability and 
mutation avoidance.  
Exonucleases cleave phosphodiester bonds from a free DNA end and therefore do 
not degrade supercoiled circular plasmid starting material (although a number are 
able to initiate degradation from nicks in plasmid DNA169). The use of an 
exonuclease treatment instead of the standard gel-based strategy to remove 
contaminating linearised backbone can therefore be envisioned. However, an 
alternative strategy such as counter selection - as detailed in section 4.1.2.1 - will be 
required to select against contamination of the assembly reaction with supercoiled 
plasmid starting material. 
Phosphorothioate bonds – which have been found naturally in species of 
Streptomyces170, 171 are generated through replacing a non-bridging oxygen within 
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the phosphate backbone with a sulfur atom (Figure 44). The introduction of the 




Figure 44: Generation of a phosphorothioate bond through the introduction of a sulphur atom within the DNA 
backbone. 
 
This property can be used to protect DNA of interest from endo- and exonuclease 
attack, and has been utilised to protect DNA in a number of approaches including 
next generation sequencing174 and single stranded DNA recombineeering175, 176 
although not for DNA assembly.  Through the introduction of phosphorothioate 
bonds within the 5’ and 3’ linkers utilised in the inABLE procedure, only DNA 
which has linkers annealed at both ends is protected, while the remaining DNA is 
unprotected from exonuclease degradation. 
Such an approach can offer specificity which cannot be rivalled by gel 
electrophoresis (due to the resolution which can be achieved) and biotin/streptavidin 
purification (a separation with potential for contamination by non-specifically bound 
DNA or a part with a linker attached at only one end).  The process does not involve 
additional steps during ligation of linkers to parts and replaces the gel electrophoresis 
stage with the addition of an exonuclease and incubation for a maximum of 30 
minutes.  This enzyme addition and incubation has the potential to be extremely high 





4.1.2.1 Backbone counter selection 
 
The simplest method to accelerate the assembly process is to simply avoid 
purification of the part/linker fusion. A concern for such an approach is that 
standardly the part including the backbone will carry the same E. coli origin of 
replication and antibiotic resistance marker as the final assembly plasmid. If the 
corresponding part linker fusion reaction does not reach completion, plasmid starting 
material will not be removed through gel extraction and will be carried into the 
assembly reaction without an agarose gel based purification. The presence of the 
unwanted cloned backbone part in the assembly reaction will result in a high 
percentage of transformants containing this vector starting material rather than the 
assembly product. 
One potential solution to this issue is the use of a double antibiotic selection 
approach. In such a strategy an additional antibiotic marker fragment would be 
included in each assembly reaction and selection on agar containing both this 
antibiotic and the one on the vector backbone would select against carry through of 
starting material. However, this approach requires the inclusion of the additional part 
in each assembly reaction, reducing assembly efficiency whilst the maintenance of 
two antibiotic resistance markers puts an unnecessary metabolic burden on the host. 
An alternative strategy to address the issue of backbone contamination is through the 
introduction of a counter-selectable marker into the truncated part carrying vector as 
this fragment of DNA will not be present in the desired final assembly product. The 
SacB gene from Bacillus subtilis which encodes a levansucrase177 can be used to 
confer sucrose sensitivity in E. coli178. To explore the potential to use the sacB gene 
as counter selection against TP vector starting material contamination the sacB gene 
was cloned into the vector TP59 (KanR, pBR322 fragment) generating vector TP184 
(Figure 45). Importantly the sacB gene is cloned into the carrying vector fragment 
and therefore is not present in final assembly product. Contamination of the assembly 
reaction with starting material (TP184 plasmid) therefore, in the case of an 
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incomplete part linker fusion reaction, can be counter selected against through the 
addition of sucrose (10% [w/v]) in transformation selection media. 
 
 
Figure 45: TP184 vector containing counter selectable SacB marker cloned adjacent to the chloramphenicol 
marker in the carrying vector.  
 
Activity of the sacB gene in vector TP184 was confirmed by E. coli transformation 
and the absence of growth on LB-Kan supplemented with 10% [w/v] sucrose 
(Suc10). As expected, dilutions of the reaction selected on LB-Kan resulted in cell 
growth (Figure 46).  
 
 
Figure 46: Selection of E. coli cells harbouring the SacB containing TP184 on LB-Kan and LB-Kan with 10% [w/v] 





To explore gel purification free inABLE DNA assembly coupled to counter selection 
of the potentially contaminating backbone a two part assembly was performed, 
combining TP184 and TP171 which results in the construction of a vector which 
confers resistance to kanamycin and tetracycline.  Three purification approaches 
were tested to determine assembly efficiency when an agarose gel based purification 
step is omitted. As well as the standard purification, a silica-membrane-based 
purification (PCR purification) and direct use of fragments without any purification 
were also explored. Transformants were selected for on LB-Tet + Kan and LB-Kan 
supplemented with Suc10 and the number of colonies counted (Figure 47).  
 
 
Figure 47: Characterisation of the utilisation of the SacB counter selection in a Gel free inABLE approach. Three 
purification approaches were compared: a silica-membrane-based purification (PCR purification), direct use of 
fragments without any purification and the standard gel extraction based purification. Average colony counts 
are the result of triplicate experiments. 
 
Selection of transformants on LB-Kan + Tet and LB-Kan + Suc10 results in a similar 
number of transformants confirming that that SacB counter selection is a suitable 
















PCR purification LB- Kan+Suc10
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assembly reaction. However, using a silica membrane spin column to purify part 
linker fusions rather than gel extraction results in a decrease in the number of 
transformants by 83% whilst performing no purification following the part linker 
fusion reaction results in a drop by 97%. The avoidance of an agarose gel based 
purification will enhance the throughput of the procedure, however, the dramatic 
drop in efficiency means that such an approach is not compatible with a multi-part 
assembly strategy as is often required when constructing biosynthetic pathways.  
Despite the observed decrease in efficiency such a strategy may be a promising tool 
when looking to construct relatively simple constructs (2-3 parts) in a high 
throughput manner as many as thousands of isolates harbouring the expected 
construct were obtained without the requirement to purify the DNA fragments via gel 
electrophoresis which offers significant time savings and allows for the automation 
of the process.   
To increase the number of parts that can be assembled in a gel-free assembly a novel 
approach was devised which combines an exonuclease treatment to degrade 
contaminating DNA coupled to phosphorothioate based protection of part linker 
fusions as means to purify DNA within the current DNA assembly workflow.  
 
4.1.2.2 Exonuclease identification 
 
Identification of a suitable exonuclease depends on its substrate specificity, 
directionality and sensitivity to phosphorothioate bonds. SapI digestion of a truncated 
part results in the generation of 5’ overhangs comprising of three nucleotides to 
which part and linker oligonucleotides are annealed generating 16 nucleotide 3’ 
overhangs (Section 2.5.2). The backbone from which the truncated part is cleaved 





Figure 48: A. Overhangs generated following SapI digestion with 5’ and 3’ ends annotated. B. Overhangs 
generated following POA and LOA annealing with 5’ and 3’ ends annotated and introduced phosphorothioate 
bond highlighted. 
 
Since the logical point to introduce phosphorothioate bonds is at the end of the 16 
nucleotide 3’ overhangs (Figure 48b) the exonuclease of choice should act in a 3’ to 
5’ manner and be unable to cleave phosphorothioate bonds allowing for the 
protection of correctly ligated part linker fusions. Through inversion of the POA and 
LOA it is also feasible to generate 5’ 16 nucleotide extensions (Figure 49) and 
therefore 5’ to 3’ exonuclease unable to cleave phosphorothioate bonds were 
included in the search. 
 
 
Figure 49: Inversion of POA and LOA sequences to generate 5' overhangs. The ability to generate 5’ overhangs 
expands the number of exonuclease that can be explored.  
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A review of available exonuclease characteristics (Table 19) immediately identified 
Exonuclease III from E. coli as a particularly interesting candidate as it prefers 
substrates with blunt or recessed 3’ termini with the 3’ extensions over 4 bases or 
longer essentially being resistant to cleavage.  
 
Exonuclease Polarity Initiates on DNA with Phosphorothioate 
cleavage 5’ ext 3’ ext Blunt Nick 
Exonuclease I 
3’-5’ 
No +/- +/- NR - 
Exonuclease III Yes +/- Yes Yes - 
Exonuclease T No Yes +/- NR - 
BAL-31 Yes Yes Yes Yes NA 
Exonuclease V 
Both 
Yes Yes Yes No NA 
Exonuclease VII +/- +/- No No + 
Exonuclease 
Lambda 5’-3’ 
+/- Yes Yes No - 
Rec-JF +/- No +/- No - 
Table 19: Characteristics of Exonucleases available from New England Biolabs. +/-: activity greatly reduced 
relative to preferred substrate.  
 
An initial test using Exonuclease III was carried out to determine if this enzyme 
would efficiently degrade a SapI digested truncated part (Figure 50a) and secondly if 
the ligation of part and linker oligonucleotides (at this stage without 
phosphorothioate modification) would render the fragment of DNA resistant to 




Figure 50: Treatment of the possible outcomes of a part linker fusion with Exonuclease III. A. Truncated part 
digested from backbone, gel extracted and subjected to exonuclease treatment (No POA or LOA attached). B. 
Part/linker fusion reaction performed with TP/POA/LOA (1), TP/LOA (2) or TP/POA (3). 
 
The results of this initial study show that as expected exonuclease III has the 
capability to degrade truncated parts completely lacking both POA and LOA (Figure 
50a), annealed to only the LOA (Figure 50b-2) or the POA (Figure 50b-2) whilst the 
full length part linker fusion (without phosphorothioate bonds) appears to be resistant 
to degradation (Figure 50b-1). This is of particular interest as with the current gel 
electrophoresis based protocol it is not possible to distinguish between part linker 
fusions and fragments of DNA lacking either POA, LOA or both. In the current 
approach these contaminating fragments are carried through into the assembly 
reaction potentially decreasing assembly efficiency.  
The remaining exonucleases identified as having attractive characteristics were 
screened through the digestion of part linker fusion reactions performed using POA 
and LOA fragments with phosphorothioate bonds, In the case of 3’- 5’ exonucleases 
POA and LOA sequences were only modified to introduce the phosphorothioate 
bonds. For 5’ – 3’ the POA and LOA sequences were inverted generating 16 
nucleotide 5’ extensions rather than the standard 3’ extensions, with a 
phosphorothioate bond again introduced between the final two bases of the 16 
nucleotide overhang. The products of the exonuclease treatment were analysed via 
gel electrophoresis to determine if the exonucleases tested were able to remove the 





Figure 51: Digestion of phosphorothioate protected part/linker fusion reactions with candidate 5' - 3' and 3' - 5' 
exonucleases. The desired exonuclease reaction would result in the removal of the backbone fragment (1.9 kb) 
whilst the protected part linker fusion (5.3 kb) remains undigested.  
 
Only Exonuclease lambda and Exo III displayed the required characteristics. As 
Exonuclease lambda operates in a 5’ to 3’ direction - and to utilise this enzyme the 
entire LOA and POA inABLE back catalogue would require to be reconfigured - the 
most suitable candidate identified from this initial characterisation all further tests 
were performed using E. coli Exonuclease III. 
 
4.1.2.3 Exonuclease treatment 
 
The drop in efficiency observed when part linker fusions are not gel extracted is 
likely due to the carryover of contaminating DNA fragments present in the 
part/linker fusion reaction into the assembly reaction. This DNA includes the vector 
backbone and unbound POA and LOA fragments both of which are removed through 
gel electrophoresis. These fragments will compete in the assembly reaction with the 
construction of the desired vector.  
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Exonuclease III treatment without the use of phosphorothioate bonds was explored to 
determine if this alone is sufficient to remove contaminating DNA and maintain or 
even enhance assembly efficiency. As described previously, a review of the 
characteristics of Exonuclease III suggest that it should be suitable to remove 
contaminating DNA from the reaction without digesting the part linker fusion 
(removing the requirement for phosphorothioate bonds). This is due to its preferred 
substrates being blunt or recessed 3’ termini with 3’ extensions over 4 bases or 
longer reported as being resistant to cleavage179. These characteristics should prevent 
the degradation of the part/linker fusion which contains 16 nucleotide 3’ extensions 
whilst contaminating vector backbone (recessed 3’ termini) would be removed from 
the reaction.  
To explore the potential to use an exonuclease treatment alone to purify part linker 
fusions a two part assembly comprised of TP171 and TP184 was utilised which 
confer resistance to tetracycline and kanamycin respectively. Part linker fusions were 
treated with Exonuclease III (Section 2.5.6) and either purified by agarose gel, 
purified using a PCR spin column or not purified following exonuclease treatment. In 
parallel the inABLE procedure was performed as standard using agarose gel based 
purification. The resulting assembly reactions were used to transform E. coli, the 
transformants selected for on media supplemented with tetracycline and kanamycin 

























































































1 0 0 0
1 5 0 0
2 0 0 0
 
Figure 52: The effect of exonuclease treatment on assembly efficiency. Following exonuclease treatment, three 
purification approaches were compared: a silica-membrane-based purification (PCR purification), direct use of 
fragments without any purification and the standard gel extraction based purification. The average number of 
colonies present on LB Kan + Tet selection plate are the result of triplicate experiments. 
 
Treatment of part linker fusion reactions with Exonuclease III under the conditions 
tested above resulted in a pronounced decrease in assembly efficiency. In this 
experiment the standard inABLE procedure yielded ~ 1400 colonies carrying the 
expected assembly. When an exonuclease treatment was used followed by 
purification via agarose gel the number of transformants dropped to ~ 450 colonies, a 
decrease in assembly efficiency of 68 %. The efficiency further decreases when the 
exonuclease treatment is followed by a PCR clean up and no purification (up to a 





Figure 53: Analysis of part linker fusions and assembly products following Exonuclease treatment. Exonuclease 
treatment has successfully removed the backbone fragments (A) however the resulting part/linker fusions 
appear to be unable to assembly. This can be observed through the lack of higher molecular weight bands 
present in lanes 3 – 8 in image B.  
 
Analysis of part linker fusion reactions by gel electrophoresis (Figure 53a) following 
exonuclease treatment gel analysis confirmed that, as expected, the contaminating 
backbone fragment was completely digested whilst it appeared that the part/linker 
fusion remained undigested. However, analysis of the assembly reaction products via 
agarose gel suggested that when treated with Exonuclease III the two DNA 
fragments do not assemble as seen for the standard inABLE workflow (Figure 53b). 
It is hypothesised that this is due to degradation of the 16 base overhang by 
Exonuclease III. Whilst 16 base overhangs are not the preferred substrate it is likely 
to occur as a secondary reaction at a reduced rate compared to backbone degradation. 
To avoid the issue, the utilisation of phosphorothioate bonds to protect these 16 base 






4.1.2.4 Coupling phosphorothioate containing linkers with an Exonuclease III treatment 
 
The previously attempted two part assembly utilising three purification approaches 
was repeated utilising modified phosphorothioate containing linkers. A single 
phosphorothioate bond was introduced at the 3’ of each LOl and POl used in the 
assembly reaction. Linker preparation and part linker fusion reactions were 
performed as standard.  Following completion of the cycling reaction, part linker 
fusions reactions were divided, and half treated with Exonuclease III whilst the 
remaining samples were stored on ice prior to purification. As previously, three part 
purification approaches were explored and transformants were selected for on LB + 

















































































































































1 0 0 0
1 5 0 0
2 0 0 0
L B  -  K a n  +  T e t
L B  K a n  +  S u c 1 0
 
Figure 54: The effect of coupled phosphorothioate protection and exonuclease treatment on assembly efficiency. 
As previously, three purification approaches were compared: a silica-membrane-based purification (PCR 
purification), direct use of fragments without any purification and the standard gel extraction based purification. 
Average CFU are the result of experiments performed in triplicate. 
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Comparable numbers of transformants were observed when transformants were 
selected on LB- Kan + Tet in comparison to Kan and Suc10 containing media whilst 
no transformants were observed on negative control plates as previously observed.  
In the absence of an exonuclease treatment, a decrease in assembly efficiency when a 
gel extraction was not performed was observed (64% decrease in efficiency when a 
spin column purification was performed and a 92% decrease in efficiency when no 
purification was performed). However, when an exonuclease treatment was 
performed, coupled to phosphorothioate treatment and the fragments gel purified the 
assembly efficiency did not decrease highlighting that the presence of the 
phosphorothioate bonds prevents overhang degradation. Critically, when an 
exonuclease treatment and phosphorothioate linkers was coupled to spin column 
purification the assembly efficiency was maintained. Therefore, through the removal 
of the backbone DNA fragment and/or aberrant part linker fusions the assembly 
efficiency is maintained without the requirement to run an agarose gel. This is a key 
result as it opens the door to process automation whilst not having to sacrifice 
assembly efficiency. 
To determine if this strategy is scalable beyond two parts the effect on assembly 
efficiency of Exonuclease III treatment in conjunction with PCR purification (the 
most promising gel free work flow from the two-part assembly) was then explored to 
combine five DNA part-linker fusions to confirm the approach was suitable for the 
assembly of more complex vectors. A five-part assembly was then conducted in 
triplicate using the protocol as described for the two-part approach. The standard 




Figure 55: Comparison of standard inABLE and Gel free inABLE assembly for five DNA fragments. Four DNA 
fragments containing antibiotic resistance markers and one containing an E. coli of replication were assembled. 
The average number of transformants was calculated from experiments performed in triplicate. 
 
Analysis of the number of transformants carrying the expected assembly product 
(Figure 55) and the part linker fusion and assembly products via capillary 
electrophoresis (Figure 56) highlights that the gel free approach is suitable for the 
assembly of larger numbers of DNA fragments without sacrificing DNA assembly 
efficiency. The ability to automate this process offers the potential to significantly 
enhance process efficiency. 
 
 
Figure 56: Analysis of part linker fusions and assembly products from a standard and gel free five part construct 
via capillary electrophoresis. The five fragments assembled P1, P171, P172, P385 and P169 can be observed a 
single band for both the standard and gel free inABLE. Analysis of the assembly products highlights the 



















4.1.2.5 The effect of phosphorothioate bonds alone on assembly efficiency 
 
It was hypothesised that the introduction of a phosphorothioate bond alone may 
result in an increase in assembly efficiency. The present workflow does not require 
the addition of ligase during the assembly reaction and attempts to include ligase in 
the assembly reaction results in a modest increase in assembly efficiency, but a 
pronounced increase in the number of incorrect assemblies.  Therefore, the current 
process relies on in vivo ligation of the assembly product to repair nicks present in 
the assembled construct.  These nicks are also a potential target for cellular 
exonucleases.  E. coli Exonuclease III - for example - is able to initiate degradation at 
plasmid nicks in a 3' → 5' manner169.  The introduction of phosphorothioate bonds at 
the 3’ end of the POl and LOl has the potential to confer to resistance to cellular 
exonucleases at nicks present in the assembled vector in vivo. 
An experiment was therefore performed in which five DNA fragments were 
assembled, four of which confer resistance to an antibiotic and one an E. coli origin 
of replication allowing selection of cells containing the expected assembly on media 
supplemented with four antibiotics. Part linker fusion reactions were performed using 
either standard linker or phosphorothioate modified linkers. All fragments were 








Figure 57: Comparison of the effect of phosphorothioate bonds alone on assembly efficiency. Part linker fusion 
reactions were performed using either standard linker or phosphorothioate modified linkers and all fragments 
were purified via the running of an agarose gel followed by gel extraction. The average number of transformants 
was calculated from experiments performed in triplicate. 
 
No significant difference in assembly efficiency were observed when comparing 
standard to phosphorothioate containing linkers (Figure 57). This result suggests that 
the utilisation of phosphorothioate linkers alone does not provide a noticeable 
advantage when assembling five fragments of DNA, however such an effect may be 
noticeable when a higher number of fragments are assembled as the number of nicks 
present in the assembly product is directly correlated to the number of parts being 
assembled.  
 
4.1.2.6 The effect of Exonuclease treatment and phosphorothioate bonds on assembly 
accuracy 
 
In each of the previous examples the assembly of DNA fragments conferring 
antibiotic resistance or containing origins of replication allowed for a direct 
comparison of assembly efficiency through the number of colonies present on 
selection plates containing the appropriate antibiotics. However, this approach does 
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not allow for the study of assembly accuracy, i.e. the ratio of correctly assembled 
products to misassemblies, as cells carrying misassemblies will not be viable on the 
selection plate. 
To explore assembly accuracy a four-part assembly (one fragment containing an 
antibiotic resistance marker and origin of replication and three comprised of a gene 
and associated regulatory regions) which had previously proven difficult to construct 
using the standard inABLE approach was explored. Three workflows were 
compared, the standard inABLE procedure, phosphorothioate bonds only and 
coupled exonuclease treatment and phosphorothioate bonds. All fragments were 
purified via gel electrophoresis with assembly reactions and E. coli transformation 
performed as described previously. Transformants were screened via colony PCR 
and the ratio of correctly assembled fragments to misassemblies presented as 
assembly accuracy (Figure 58).  
   
 
Figure 58: The effect of phosphorothioate bonds and coupled phosphorothioate/exonuclease treatment on 
assembly efficiency. The standard inABLE procedure was compared to phosphorothioate bonds only and coupled 
exonuclease treatment and phosphorothioate bonds.  All fragments were purified via gel electrophoresis and 






























In the absence of both phosphorothioate bonds and exonuclease treatment an average 
assembly efficiency of 2.3% was achieved which is comparable to previous results 
when trying to build this construct. The introduction of phosphorothioate bonds into 
the linker sequences resulted in a slight increase in assembly efficiency to 26.4%, 
however when phosphorothioate bonds were coupled to exonuclease treatment the 
assembly accuracy rose to 93.3% (Table 20). 
 




















Standard inABLE (-) (-) 0 4.7 3.3 2.3 
Phosphorothioate Bond  (+) (-) 32.2 20.7 8.1 26.4 
Coupled 
Phosphorothioate Bond 
+ Exonuclease III 
Treatment 
(+) (+) 90 96.7 4.7 93.3 
Table 20: The effect of phosphorothioate bonds and coupled phosphorothioate/exonuclease treatment on 




The utilisation of phosphorothioate linkers and exonuclease treatment in this study 
has shown the ability to maintain assembly efficiency whilst removing the 
requirement to run an agarose gel, greatly reducing the length of time to build the 
required constructs whilst also increasing the predictability and robustness of the 
procedure and permitting automation of the process.  The new approach is 
completely compatible with the current inABLE workflow, not requiring changes to 
the part and primer design, the previously cloned truncated parts or the part linker 
fusion or assembly reactions. Only the linkers are modified to include 
phosphorothioate bonds.  As described in the above work, the presence of these 
bonds can then be utilised to purify the part-linker DNA using an exonuclease 
treatment.  Specifically, this provides a DNA purification method that results in 
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greater process efficiency through higher throughput and specificity in reduced time 
while permitting automation of the entire process by eliminating the need for gel 
electrophoresis. This is a key breakthrough in the development of a second 
generation inABLE procedure and is subject to US patent application number – 
15901431 (METHOD FOR ASSEMBLY OF POLYNUCLEIC ACID SEQUENCES 
USING PHOSPHOROTHIOATE BONDS WITHIN LINKER OLIGOS, 2018) 
 




One of the most time consuming stages of the inABLE DNA assembly process is the 
cycling of digestion and ligations reactions that are utilised to generate a part linker 
fusion, which takes a total of 335 minutes. The cyclic nature of this reaction is 
feasible, as described previously, due to the characteristics of SapI which as a type 
IIs restriction enzyme cuts out with its recognition site. This means that the 
part/linker fusion is void of SapI recognition sites and essentially removed from the 
reaction. Through cycling between rounds of digestion and ligation it is possible to 
enrich towards the product of interest. This is a similar strategy to one employed in 
golden gate based DNA assembly strategies to enrich towards the product of interest. 
This process currently involves six rounds of digestion and six rounds of ligations 









Stage Lid Temperature: 42°C 
Temperature (°C) Time 
(minutes) 
1 37 90 
2 16 30 
3 37 30 
4 16 15 
5 37 15 
6 16 15 
7 37 15 
8 16 10 
9 37 15 
10 16 10 
11 37 60 
12 16 30 
Total 335 minutes 
Table 21: The cycles of digestion and ligation in a standard part linker fusion reaction. Digestion is performed at 
37 °C which is the optimal temperature for EarI and SapI activity whilst ligation is performed at 16°C, the optimal 
temperature for T4 DNA ligase. 
 
Due to its stability, SapI is characterised by NEB as an enzyme which is not 
recommended for digestions of longer than one hour180. Therefore, in order to 
determine if any advantage is gained from the cycling of digestion and ligation a 




4.2.2.1 Assembly efficiency 
 
To explore the effect of digestion/ligation cycling on assembly efficiency, the 
construction of two vectors was explored in parallel, one of which conferred 





Figure 59: Vectors constructed to determine the effect of the number of digestion and ligation cycles on 
assembly efficiency. Two vectors were constructed to explore this, the first vector (A.) was constructed through a 
two part assembly and confers resistance to Camp and Amp whilst the second (B.) confers resistance to Kan and 
Amp. 
 
Following each ligation reaction cycle, samples were removed from the thermocycler 
and the SapI and T4 DNA ligase present in the reactions heat inactivated through 
incubation at 65 °C for 20 minutes. Part linker fusions were first visualised on an 
agarose gel to monitor the presence of starting material in the reaction (Figure 60). 
The presence of visible staring material would highlight an incomplete part/linker 
fusion reaction suggesting additional rounds of digestion and ligation are required.  
 
 
Figure 60: Visualisation of part linker fusion reaction products following each ligation cycle. 
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The appropriate DNA fragments were gel extracted and assembled following the 
standard procedure. Through the construction of vectors harbouring double antibiotic 
resistance markers assembly efficiency was calculated through the number of 





The number of colonies present on selection plates at each time does not increase 
significantly throughout the time course experiment (Figure 61). This result and the 
visual analysis (Figure 60) of the part linker fusions suggest that there is no 
Table 22: The effect of the number of digestion/ligation cycles on assembly efficiency. Colony counts were 
determined following transformation of assembly product and selection on plates containing the appropriate 
antibiotics to confirm successful vector assembly 
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enhancement in assembly efficiency achieved through cycling between ligation and 
digestion. This is likely due to the reported low stability of SapI in the reaction 
resulting in it being inactive following the first cycle of incubation at 37 °C. This 
reduction in the number of cycles can significantly enhance the throughput of the 
inABLE DNA assembly platform. 
 
 
Figure 61: Average number of colony forming units from triplicate experiments on selection plates following 
each ligation stage within the part linker fusion reaction 
 
4.2.2.2 Assembly accuracy 
 
A limitation with the above strategy is that due to the double antibiotic selection 
approach only cells transformed with the expected construct will be viable on the 
selection media. This approach allows for calculation of assembly efficiency but not 
accuracy, which is a key aspect of any DNA assembly approach. To explore the ratio 
of positive assemblies to mis-assemblies a screen based on the expression of 
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enhanced green fluorescent protein (eGFP) was implemented. In this study a 
constitutive E. coli promoter (ProC)181, an enhanced GFP variant from the pSEVA 
plasmid collection182 and an E. coli backbone comprised of a CampR marker and a 
pMB1 origin of replication were assembled (Figure 62). 
 
  
Figure 62: Target vector construct comprised of three DNA fragments. Only cells containing the expected 
construct will be viable on chloramphenicol containing media and produce eGFP. 
 
The minimal conditions identified in the assembly efficiency test (1 cycle of 
digestion and 1 cycle of ligation) were directly compared to the standard part linker 
fusion reaction. Following the part linker fusion and assembly reactions, 
transformants were selected for on chloramphenicol containing plates. Only 
transformants containing the expected construct would be viable on this media and 
fluoresce when the plates are visualised using a Safe Imager 2.0™ blue light 
transilluminator (Invitrogen). In parallel, a negative control construct was prepared in 
which the promoter was purposely omitted. This was performed to ensure that read 
through from a promoter in the E. coli backbone (such as the one controlling 












fluorescence. When this negative control construct was introduced into E. coli and 














Standard 123 117 107.7 18.3 99.0 16.6 92.0 
118 103 
82 77 
Minimal 112 106 94.3 12.6 84.3 15.5 89.4 
87 76 
84 71 
Table 23: Colony counts following transformation of assembly product, selection on plates containing the 
appropriate antibiotics and visualisation of GFP output to confirm successful vector assembly. 
 
As observed in the assembly efficiency experiment the number of colonies present 
on selection plates between a minimal and standard cycling regime does not increase 
significantly. In this experiment however, the presence of transformants on the 
selection plate is not 100% indicative of a fully assembled construct. Crucially, a 
similar number of fluorescing colonies is observed in both standard and minimal 
cycling regimes, highlighting that the implementation of a minimal cycling approach 








This study highlights that reducing the number of cycles in the part linker fusion 
reaction does not have a significant effect on either the efficiency or the accuracy of 
the inABLE DNA procedure however the reduced cycling time can dramatically 
increase the throughput of the procedure. As previously described SapI is not 
recommended for digestions of longer than one hour, meaning that following the first 
round of incubation at 37 °C the SapI is unlikely to be active in subsequent rounds of 
digestion. Secondly, in the part linker fusion reaction a 10 to 1 molar excess of the 
linkers to the truncated part is present. Therefore, during the ligation reaction, 
ligation of the linkers to the truncated part should be favoured over re-ligation of the 
truncated part into the vector backbone. It is important to note that EarI is expected 
to be more stable in the part linker fusion reaction. However, since EarI has a 
recognition site 1 bp shorter than SapI (CTCTTC and GCTCTTC respectively) its 
use places more stringent sequence requirements on fragments which can be 




The ability to reduce the part linker fusion reaction from almost six to two hours can 
have a significant effect on the timeline with which vectors can be constructed using 
the inABLE platform and also further open the door to automation. One could 
assume an additional acceleration in vector construction by coupling this approach 
with a faster growing host than E. coli such as Vibrio natriegens which has recently 
been characterised as a molecular biology host with a doubling time of <10 
minutes183. 
 
4.3 Multiple rounds of SapI mediated assembly through protection of SapI 




One limitation of the current inABLE technology is that the product of one assembly 
reaction cannot be directly used in a second round of assembly. This limits the 
potential to, for example, add additional genes to a previously assembled 
heterologous pathway. This is a result of the utilisation of type IIs restriction 
enzymes in the part linker fusion reaction the nature of which result in no recognition 
sites being present in the final assembly product. The BioBricks platform (reviewed 
in Section 1.7.1.2) for example addresses the issue through the use of a four 
restriction endonuclease approach in which pairs of enzymes cleave different sites to 
produce compatible cohesive ends. Following ligation, a non-cleavable scar is 
formed while active sites flank the assembled DNA and can be used to add further 
fragments. This four enzyme strategy however places significant sequence 
constraints on the parts being assembled meaning fragments will often require to be 
modified to mutate non-compatible sequences prior to assembly. The Golden Gate 
assembly has also been adapted for iterative DNA assembly as described in the 
MoClo and Golden braid methodologies184, 185 both of which rely on alternative use 
between two type IIs enzymes in a multi-level system that allows the products of one 




One possible approach within the inABLE workflow (as described in section 3.2) is 
to alternate between two type IIs enzymes for each round of assembly (i.e. 1st round 
using SapI and append linkers containing EarI recognition sites for a second round of 
assembly). This approach has previously been exemplified and is compatible with 
the inABLE DNA assembly framework as each truncated part is flanked by a SapI 
site and by default also an EarI site. Whilst this approach allows for the addition of 
parts to previously constructed plasmid without resorting to PCR you are limited to 
two rounds of assembly as it is not possible to use SapI containing linkers during the 
EarI mediated second round of part linker fusion since they would be cleaved. The 
part sequence also requires to be void of both EarI and SapI recognition sites 
decreasing the flexibility of the approach.  
 
The possibility to mediate sequential rounds of SapI mediated DNA assembly 
through the introduction of SapI sites protected by phosphorothioate bonds in a first 
round of assembly on linker fragments was therefore explored as a potential solution. 
Following replication of the assembly product in E. coli the phosphorothioate bonds 
will be lost making SapI sites available for a second round of assembly. Such an 
approach can be repeated for unlimited rounds of assembly.  A similar approach has 
recently been implemented for DNA assembly approaches which use the  Dcm 
methylation sensitive type IIs restriction endonuclease BsaI such as in the Golden 
Gate strategy and its derivatives186.  This approach utilises the introduction of BsaI 
sites on a synthetic fragment of DNA. It has been shown that the methylation of 
either of the cytosines the BsaI recognition site GGTCTC confers resistance to BsaI 
cleavage187, in the same way that restriction enzyme-producing organisms protect 
their own DNA through the expression of site specific methylases. This can be 
leveraged to prevent cleavage of BsaI recognition sites contained on linker sequences 
in an initial round of assembly. The protection of the BsaI sites is then lost following 
introduction of the assembly product into an E. coli host which does not maintain the 
methylation pattern freeing BsaI sites for subsequent rounds of assembly. As SapI or 
EarI are not reported to be sensitive to DNA methylation the potential to utilise the 
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4.3.2.1 Protection of SapI recognition sites via phosphorothioate bonds 
 
Recently, Zhao et al 188 explored the effect of phosphorothioate or 2’-O-Methyl 
nucleotide substitutions on the cleavage efficiency of six type II endonucleases. It 
was found that introduction of nucleotide substitutions can modulate the efficiency of 
enzymatic cleavage in a position dependent manner. Only moderate inhibition from 
phosphorothioate bond introduction was observed regardless of the position of the 
substitution in the case of XhoI and XbaI enzymes. Significant reduction in 
enzymatic cleavage was observed when the phosphodiester bond cleaved by the 
restriction endonucleases SpeI and EcoRI was substituted with a PS bond. Finally, 
complete inhibition of cleavage bond for PstI and SphI was observed once again 
when the bond cleaved was modified to a PS bond. In general, 2’-O-Methyl 
nucleotide substitutions appeared a more robust method for restriction endonuclease 
site protection and this modification could be explored further for use in SapI 
protection in the future.  No similar study has been performed using SapI or other 
type IIs restriction endonucleases.  
To explore if SapI recognition sites can be protected through the replacement of 
phosphodiester bonds with phosphorothioate bonds a total of eight, 100 bp DNA 
fragments were synthesised containing a central SapI site and each bond within the 
recognition site and the cleavage sites comprised of either a phosphorothioate or 







PS_1 5’-GGCAGTTATTGGTGCCCTTAAACGCCTGGTGGGATCCG*CTCTTCGGGCTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGG -3’ 
PS_2 5’ - GGCAGTTATTGGTGCCCTTAAACGCCTGGTGGGATCCGC*TCTTCGGGCTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGG – 3’ 
PS_3 5’ - GGCAGTTATTGGTGCCCTTAAACGCCTGGTGGGATCCGCT*CTTCGGGCTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGG – 3’ 
PS_4 5’ - GGCAGTTATTGGTGCCCTTAAACGCCTGGTGGGATCCGCTC*TTCGGGCTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGG – 3’ 
PS_5 5’ - GGCAGTTATTGGTGCCCTTAAACGCCTGGTGGGATCCGCTCT*TCGGGCTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGG – 3’ 
PS_6 5’ - GGCAGTTATTGGTGCCCTTAAACGCCTGGTGGGATCCGCTCTT*CGGGCTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGG – 3’ 
PS_7 5’ - GGCAGTTATTGGTGCCCTTAAACGCCTGGTGGGATCCGCTCTTC*GGGCTATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGG – 3’ 
PS_8 5’ – GGCAGTTATTGGTGCCCTTAAACGCCTGGTGGGATCCGCTCTTCGGGC*TATATCTCCTTCTTAAAGTTAAACAAAATTATTTCTAGAGGG – 3’ 
Table 24: DNA fragments used to explore protection of EarI/SapI recognition sites (in bold) through the 
introduction of phosphorothioate bonds. Recognition site in bold and phosphorothioate bonds denoted by *. 
 
Analysis of digestion products by capillary electrophoresis revealed that EarI/SapI 
sites are only successfully protected through the introduction of phosphorothioate 
bonds at the cleavage site (Figure 64, lanes 9 and 18), introduction of the bond at any 
site within the recognition sequence has no noticeable effect on SapI or EarI activity. 
 
 
Figure 64: Capillary electrophoresis analysis of products following SapI and EarI digestion. Lanes 1-9 show, 1 – 
No phosphorothioate bond; 2 – PS_1, PS_2, PS_3, PS_4, PS_5, PS_6, PS_7, PS_8; digested with SapI. 10-18 
digested with EarI and 19-28 H2O controls 
 
This initial result opens the door to potentially implementing a “phospho-nested” 
DNA assembly strategy. Further study of alternative modifications to inhibit 
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SapI/EarI modification may further expand the flexibility of this approach for 
iterative rounds of DNA assembly. 
 
4.3.2.2 Design of initial phospho-nested approach. 
 
An initial two part assembly was implemented to explore a potential “phospho-
nested strategy”. In previous nested approaches specific POA and LOA sequences 
were ordered to introduce EarI recognition sites to be utilised in a second round of 
DNA assembly (Section 3.2). These sequences were modified to now introduce 
phosphorothioate protected SapI recognition sites rather than EarI sites (Table 25).  




      Cgg*gCTTCTCGtgtccaccgtgaaaagcc 




denoted by * 
POAxxx - 
nested 
                            gtgctggtGCTCTTCg*ctg 
ctatagacgtaacaaccacgaccaCGAGTTGcgac*gac 
Table 25: DNA fragments used to explore protection of EarI/SapI recognition sites through the introduction of 
phosphorothioate bonds. SapI recognition site in bold and bonds denoted by * 
 
As seen above, one limitation of this approach is the requirement to add additional 
scar sequences with each round assembly. The reason for the further scar sequence 
introduction is that phosphorothioate bonds require to be introduced during DNA 
synthesis. The bonds cleaved in a scarless system would be not generated during 
DNA synthesis rather through the ligation of the linker to the truncated part during 
the part linker fusion reaction at which point it is not possible to introduce a 
phosphorothioate bond.   
This is not an issue with the annealing of the LOA in which a GCC scar is added 
using the standard technology and therefore parts are designed so this does not cause 
issues (for example it is standardly introduced directly following a stop codon in a 
gene part). However, the introduction a scar during the ligation of the POA has the 
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potential to be problematic. The annealing of a POA to a truncated part is generally 
scarless. This is because the addition of any scar at this point is within the sequence 
of the full length part (i.e. within the coding sequence in a gene part) and therefore 
requires to be avoided. This is a limitation of the proposed “phospho-nested” 
approach and requires careful fragment design to ensure any scar sequences 
introduced do not have a negative effect on construct performance.  
To alleviate the issue during this proof of principle study the DNA fragment 
previously constructed for the exploration of the effect of 16 bp overhang secondary 
structure on assembly efficiency (Section 3.1.4) was utilised in this experiment. This 
part comprises of a KanR marker cassette with a 5’ extension of 49 bp, allowing for 
the introduction of scar sequences during POA ligation without the disruption of the 
5’ UTR which may impact cassette performance.  
Part linker fusion reactions were performed as described previously using “phospho-
nested” linkers (Table 25) with and without phosphorothioate bonds. Selection of 
transformants on plates containing Amp + Kan allowed for the direct comparison of 
assembly efficiency in this two part approach. 
 
 
Figure 65: Comparison of the utilisation of nested linkers containing SapI sites plus or minus phosphorothioate 
protection. Average colony counts following selection of transformants on LB media supplemented with Amp 




It was expected that without the phosphorothioate mediated protection of SapI sites 
within the linkers that the assembly efficiency would dramatically decrease due to 
the cleavage of SapI sites contained within the linker sequences resulting in less 
efficient DNA assembly. However, assembly efficiency was largely maintained with 
or without phosphorothioate introduction (Figure 65). Subsequent treatment of 
assembly reactions with SapI resulted in a complete loss of transformants in the 
assembly products lacking phosphorothioate protection whilst assembly products 
with protection resulted in a similar number of transformants as previously. This 
confirms that the phosphorothioate bonds are conferring resistance to SapI in the 
assembled product (Figure 66).  
 
 
Figure 66: Vector constructed using a “phospho-nested” strategy. This strategy results in SapI recognition sites 
which are protected by phosphorothioate bonds being introduced during the assembly process. Following 
replication of the assembly product in E. coli the phosphorothioate bonds are lost allowing the SapI sites to be 
utilised for a second round of inABLE assembly. 
 
It is likely that a difference in assembly efficiency between the protected and 
standard linker was not observed due to the stability of SapI within the part linker 
fusion reaction. SapI is characterised as a restriction enzyme which is not 
recommended for incubation times of longer than 1 hour180. Therefore, towards the 
end of the part linker fusion cycling program only ligation reactions would be 
Phospho-nested Vector1








SapI (9 45 )
SapI (2 82 4)
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occurring allowing for repair of linkers and formation of the required part linker 
fusions. Analysis of assembly products from both protected and non-protected 
experiments through SapI digestion and DNA sequencing confirmed that even 
without protection the expected construct was being formed and the introduced 
recognitions sites can be utilised for additional rounds of inABLE based vector 
construction.  
 
4.3.2.3 Utilisation for bioengineering 
 
In order to make the phospho-nested approach compatible with the construction of 
biosynthetic pathways whilst maintaining its compatibility with previously cloned 
inABLE truncated parts a revised construction strategy was implemented. 
To utilise this approach for biosynthetic pathway generation a fully functional vector 
would require to be constructed to which additional parts can be added as required. 
Ideally, this should be achieved without the introduction of the associated scar 
sequences in potentially problematic regions. If a similar approach to the previously 
exemplified nested strategy (Section 3.2) was adopted this would not feasible as the 
1st part of the assembly reaction product remains truncated and likely non-functional. 
In addition, scar sequences would be introduced during POA ligation meaning they 
would also impact part performance.  
To avoid this a Phospho-nested LOA comprised of a short synthetic E. coli 
terminator89 flanked by two phosphorothioate protected SapI recognition sites 
specific for the expression vector backbone (CampR/pMB1 ori) was constructed 
(Figure 67). The design of this fragment ensures that each of the parts assembled are 
full length and as such will result in a functional expression vector to be constructed 




Figure 67: Product of phospho-nested assembly reaction. E. coli terminator flanked by SapI recognition sites 
which can be utilised in subsequent rounds of inABLE assembly. 
 
If additional genes require to be added to the construct, then a part linker fusion 
reaction using SapI can be performed. The T7 terminator flanked by SapI sites can be 
relocated to follow the additional genes added in this second round of assembly. This 
approach also ensures that the additional scar sequences which are a result of the 
phospho-nested strategy are introduced out with gene coding sequences or key 
regulatory regions.  
 




           CGG*GCTTCTCGATTGCATTTTTGGGCGAAGCCGCCCAAAAAAATACCGAGAAGCAAC*GGCCTAGACGTAGCG 
LOA containing 
terminator flanked by 
protected SapI sites.  
Table 26: Phospho-nested linker sequences. DNA contains a short E. coli terminator flanked by SapI sites which 
are protected with phosphorothioate bonds (*). 
 
To explore this strategy four DNA fragments were assembled, a KanR marker 
fragment, pMB1 origin of replication, the ProC E. coli constitutive promoter and an 
eGFP coding sequence along for selection of transformants containing the expected 
assembly through resistance to Kanamycin and production of eGFP. The fragments 
were assembled as standard except LOA PN (Table 26) was annealed to the GFP 





Figure 68: Analysis of transformants from Phospho-nested assembly reaction: A. Visualisation of fluorescent vs 
non-fluorescent colonies using blue light transilluminator. B. Fluorescent vs non-fluorescent colonies. 
 
Colonies following transformation were visualised using a Safe Imager 2.0 blue light 
transilluminator and the number of fluorescent colonies to non-fluorescent colonies 
compared.  94% of the colonies characterised were fluorescent suggesting correctly 
assembled constructs (Figure 68). Sanger sequencing confirmed the successful 
introduction of the synthetic terminator flanked by SapI sites after the GFP gene 
confirming the construction of a functional expression vector which is compatible 
with additional rounds of inABLE assembly.  
When additional parts require to be added to this vector TP SapI is again used in the 
part linker fusion reaction. As the previously assembled DNA has replicated in E. 





In this section the use of phosphorothioate bonds for the protection of SapI 
recognition sites with the goal of recursive DNA assembly was explored. Such an 
approach builds on the previously exemplified nested inABLE strategy (Section 3.2). 
This approach has the potential to allow for unlimited rounds of inABLE assembly 
using a single restriction enzyme provided carefully designed DNA fragments are 
employed.   
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The full protection of SapI recognition sites was defined through using short 
synthetic fragments of DNA with phosphorothioate bonds introduced throughout the 
recognition site and also at the cleavage site. It was found that only the introduction 
of a phosphorothioate bond within the cleavage site inhibits SapI digestion. The use 
of protected SapI recognition sites within the inABLE DNA assembly workflow was 
then validated in initial proof of principle experiments confirming the ability to 
construct functional vectors which are compatible with additional rounds of inABLE 
assembly.  The development of the phospho-nested strategy allows for recursive 


















5. Proteomics for metabolic pathway optimisation  
 




The utilisation of mass spectrometry based proteomics approaches for the assessment 
of heterologous pathway implementation has the potential to accelerate the 
engineering of microbes for industrial bioprocesses. Many factors contribute to 
pathway performance which would not be identified when only monitoring product 
titers. For example, a vital consideration when introducing a multi gene pathway is 
the fine tuning of protein production at each stage of the pathway189. Over production 
of each pathway protein can result in significant metabolic burden placed on the cell 
thus diminishing productivity whilst the underproduction of pathway enzymes may 
result in the formation of pathway bottlenecks. The optimal balance of pathway 
proteins is difficult to predict and is therefore often addressed through the 
construction of libraries of genetic elements. The level of expression is manipulated 
through varying factors including promoter strength, copy number, RBS strength and 
gene codon usage. The ability to directly monitor and quantify multiple proteins in 
the engineered system therefore can greatly benefit attempts to optimise heterologous 
metabolic pathways.  
One challenge associated with characterising an engineered strain at the protein level 
is the lack of high throughout techniques which are readily available. The separation 
of a specific protein of interest from the cellular proteome can be time consuming 
and labour intensive as proteins have similar physical characteristics – such as 
molecular weight (mW) and isoelectric point (pI) – and are produced at significantly 
varying concentrations. Immunoblot assays have traditionally been used for the 
selective identification of proteins. These approaches are fast, convenient and for the 
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same protein can be multiplexed, however can prove challenging when multiple 
proteins require to be detected. 
Advances in LC-MS and LC-MS/MS based approaches have allowed for the 
identification and quantification of multiple proteins from cell lysates. Multiple 
techniques for both relative and absolute quantification including the inclusion of an 
internal synthetic peptide and isotopic labelling through the incorporation of labelled 
amino acids into the protein during cell growth (SILAC)138, chemical labelling of 
proteins prior to digestion (iCAT)139 or enzymatic labelling of the peptides following 
digestion (iTRAQ)140. Despite the success of these techniques, label-free approaches 
are often favoured as quick and cost effective options requiring no additional stages 
of sample preparation making it extremely compatible with previously developed 
strain engineering platforms. These approaches also avoid the limitations of labelling 
approaches including the cost of reagents, the efficiency of the labelling reaction and 
limitation of the number of samples that can be analysed.  
In this chapter the implementation of a MS-based platform for the label free 
quantification of multiple pathway proteins will be explored. The implementation 
will initially focus on the robust identification of target proteins using the MSE 
platform before attempting relative quantification of target proteins from engineered 
microbes.  The successful implementation of such a strategy has the potential to 
complement the previously exemplified pathway construction tools and accelerate 




5.1.2.1 High and Low Energy scans 
 
The MSE protein analysis approach developed by Waters Corporation, is a data 
independent approach in which there is no precursor peptide selection for 
fragmentation and instead the instrument alternates between high energy and low 
energy scans. During the low energy scan the m/z and retention time of the intact 
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eluting tryptic peptide is collected and as such the collision energy is set to minimise 
fragmentation within the collision cell. It should be noted that fragmentation of a 
peptide can also occur within the source and therefore parameters such as cone 
voltage should also be considered during optimisation. During the elevated energy 
scan the goal is to collect information on fragment ions and therefore the collision 
energy should be such that the intact peptides are efficiently fragmented. However 
unlike in a data dependent acquisition (DDA) when the collision energy for any 
given precursor is defined by the m/z and the charge in an MSE experiment multiple 
precursors may be co-eluting from the column over a range of m/z and charges. A 
collision energy ramp is therefore implemented which is suitable to fragment 
peptides spanning the range of m/z and charges expected from a tryptic digest. As 
there is no mass selection, bias towards the identification of highly abundant peptides 
is reduced and fragmentation data is generated for all eluting peptides.  
During an MSE acquisition three functions are generated within the raw data file by 
the Mass Lynx software. Function one comprises of low energy information, 
function two contains high energy data whilst function three contains lockmass data 
which is a reference compound infused throughout the run and used for data 
correction post acquisition.  
To perform an initial study of generating MSE data using a single peptide a sample of 
luteinizing hormone-releasing hormone (LHRH) was analysed through LC-MSE on a 
Synapt G2 instrument. Low and high energy data generated showing the parental ion 




Figure 69: High (upper) and low (lower) energy scans of LHRH on a Synapt G2 instrument mimicking a MSE 
analysis which utilises high and low energy scans to generate intact and fragmentation data on analysed 
peptides. 
 
5.1.2.2 MSE based protein identification – Single protein 
 
To further explore MSE data acquisition, tryptically digested BSA was purchased 
(NEB) and analysed using LC-MSE on a Synapt G2 instrument and the resultant MSE 
data analysed for protein identification in PLGS (Reviewed in Section 1.7.2.4) with 
the data searched against the SwissProt protein database. A lockmass of Leucine 
Enkephalin (Leu-Enk) was infused throughout the run and used for post-acquisition 
mass correction with chromatographic separation of the peptides achieved over 30 
minutes. Over triplicate experiments the average sequence coverage achieved was 
31%. An example of the PLGS protein identification output for this analysis is found 




Figure 70: Example output of PLGS processing of MSE data generated from the analysis of a commercially 
available tryptic digest of BSA.  
 
5.1.2.3 MSE based protein identification – Multiple proteins 
 
To further expand on this initial MSE based protein identification proof of principle a 
MassPrep standard was purchased form Waters Corporation. This is an equimolar 
mix of four tryptically digested proteins; alcohol dehydrogenase from S. cerevisiae 
(UniProt P00330 and P00331), phosphorylase b from rabbit muscle (UniProt 
P00489), bovine serum albumin (UniProt P02769), and enolase from S. cerevisiae 
[UniProt P00924 and P00295]). The mixture was analysed using the same workflow 



















Products Products RMS Mass 
Error (ppm) 
P00330 ADH1_YEAST 36668 6.2739 20 25 44.38 3.05 133 7.6165 
P00489 PHS2_RABIT 97096 6.7954 39 82 44.8 3.92 287 8.0808 
P00924 ENO1_YEAST 46642 6.1538 16 36 29.5 4.08 90 7.5545 
P02769 ALBU_BOVIN 69248 5.7583 23 64 32.7 4.45 110 9.3348 
Table 27: Output of PLGS analysis of data generated through MSE characterisation of MassPrep protein standard 
which comprises of peptides generated from the tryptic digestion of S. cerevisiae alcohol dehydrogenase and 
enolase, rabbit phosphorylase B and BSA.  
 
The data was searched against the SwissProt protein database and returned 
identifications for the four target proteins. The proteins characterised ranged in size 
from between 37 kDa and 97 kDa with an average protein coverage of 38% achieved 
(Table 27). This was achieved in a single analysis using as little as 180 ng of protein 




In this section a data independent protein identification workflow has been 
implemented and proof of concept protein identifications performed for a single 
protein and a mix of four proteins. The MSE acquisition approach was implemented 
on a Synapt G2 instrument with the appropriate chromatography and the data 
analysis steps to analyse MSE data for protein analysis also implemented. This initial 
work provides the framework for the analysis of increasingly complex mixtures 











To explore the use of the data independent proteomics workflow to guide strain 
engineering approaches the implementation of a reverse glyoxylate shunt in E. coli 
was identified as test case. The glyoxylate shunt avoids the decarboxylation steps of 
the TCA cycle and therefore allows the production of TCA cycle intermediates from 
acetyl-coA without carbon loss. The operation of this pathway in an acetyl-CoA 
producing direction however had not been described until Mainguet et al in 2013190. 
The introduction of a rGS from malate to isocitrate into E. coli requires the 
expression of two heterologous enzymes, Methylococcus capsulatus malate 
thiokinase (MTK) and Rhodobacter sphaeroides malyl-CoA lyase (MCL), along 
with the overexpression of the native E. coli isocitrate lyase (ICL) (Uniprot numbers 
Q607L8/9, B9KLE8 and P0A9G6 respectively). The introduction of this synthetic 
pathway into E. coli was demonstrated through the conversion of four carbon TCA 
intermediates such as malate and succinate into oxaloacetate plus two molecules of 
acetyl-CoA without carbon loss (Figure 71). Common sugars are standardly 
metabolised to acetyl Co-A through the decarboxylation of pyruvate and therefore, 
the ability to produce acetyl-CoA without the loss of carbon associated with the 
standard route through pyruvate is of interest for the production of a number of 
industrially useful compounds including fuels, fatty acids and isoprenoids. In this 




Figure 71: Conversion of four carbon TCA intermediates such as malate into oxaloacetate plus two molecules of 




5.2.2.1 Generation of purified rGS protein extracts  
 
To validate the ability to detect the enzymes involved in the rGS through an MSE 
approach each protein was independently purified. To allow for purification of the 
three target proteins, vectors were assembled using the standard inABLE procedure 
to incorporate an N-terminus histidine tag comprised of ten histidine residues (His10). 
The His10 tag was introduced through the use of modified linker oligos. Design of 






























Table 28: Design of linker oligos for incorporation of N-terminal His tag. His tag highlighted in capitals. 3’ end of 
gene underlined. 
 
E. coli expression vectors were constructed through a standard two part inABLE 
assembly using the His10 sequence containing linkers which are specific to each gene 
truncated part (Figure 72).  
 
 
Figure 72: E. coli vectors constructed to introduce N-terminal His tag to reverse glyoxylate shunt enzymes. 
Restriction sites used for screening annotated on maps. 
 
Part linker fusions were performed, and gene parts assembled with a pET21 
backbone part in a two part assembly. Constructs were screened via restriction 




Figure 73: Agarose gel screening of rGS vectors through restriction digest. Expected bands (kb): MTKa/MTKb – 
5.9, 1.5; MCL – 5.4, 0.7, 0.1; ICL – 6.0, 0.5. 
 
The E. coli expression strain BL21 (DE3) was transformed with the three vectors and 
a single colony picked from each transformation plate to test for protein expression 
(Figures 74, 75 and 76). 
 
 
Figure 74: SDS-PAGE analysis of soluble and insoluble fractions from expression of MTKa and MTKb. Target 
proteins highlighted by red boxes. Protein expression was induced with 1 mM IPTG and cells incubated at 37 °C 
post induction.  
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Figure 75: SDS-PAGE analysis of soluble and insoluble fractions from expression of MCL. Target protein 





Figure 76: SDS-PAGE analysis of soluble and insoluble fractions from expression of ICL. Target protein highlighted 
by red box. Protein expression was induced with 1 mM IPTG and cells incubated at 37 °C post induction. 
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Since MTKa/MTKb and MCL were primarily expressed in an insoluble form 
expression work was repeated at a lower post induction temperature. The reduced 
temperature may result in an increase in protein solubility due to slower protein 
synthesis resulting in enhanced protein folding191. The expression protocol and 
sample preparation were the same as described earlier in this section with the 
exception that once cultures reached OD600 0.6 they were immediately placed on ice 
prior to IPTG addition and incubated at 16 °C post induction (Figures 76 and 77).  
 
 
Figure 77: SDS-PAGE analysis of soluble and insoluble fractions from optimised expression of MTK a/b. Target 
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Figure 78: SDS-PAGE analysis of soluble and insoluble fractions from optimised expression of MCL. Target protein 
highlighted by red box. Protein expression was induced with 1 mM IPTG and cells incubated at 16 °C post 
induction. 
 
Following expression condition optimisation soluble protein was detected for the 
three targets by SDS-PAGE. Optimised conditions were used for culture scale up to 
provide biomass for protein purification. Protein purification was performed using 
NiNTA spin columns (Section 2.6.3) and SDS-PAGE analysis of the resulting 
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Figure 79: SDS-PAGE analysis of fractions from MTKa and MTKb purification. Purified protein can be observed in 
the elution fraction 1. 
 
 
Figure 80: SDS-PAGE analysis of fractions from MCL purification. Purified protein can be observed in elution 
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Figure 81: SDS-PAGE analysis of fractions from ICL purification. Purified protein can be observed in elution 
fractions 1 and 2. 
 
SDS-PAGE analysis highlighted a considerable amount of target protein present in 
the column flow through fraction (Lane 3). This is likely due to overloading of the 
columns which are limited to a binding capacity of 300 µg. Purified protein 
concentration was measured using the BCA assay192 and protein extracts stored at -
80 °C as a 10% (v/v) glycerol stock prior to in solution tryptic digestion. 
 
5.2.2.2 MSE characterisation of purified rGS proteins 
 
Equimolar amounts of the four purified rGS proteins (MTKa/b, MCL and ICL) were 
mixed and then reduced, alkylated and digested with trypsin as described in section 
2.6.4. The resulting peptides were separated using a chromatographic gradient of 35 
minutes (Figure 82) as previously described and analysed via MSE. A Lockspray of 






Figure 82: Chromatographic separation of tryptic peptides generated from an equimolar mix of purified target 
proteins - MTKa/b, MCL and ICL. 
 
The resulting data was analysed using PLGS with data searched against a custom E. 
coli K-12 Uniprot database with His-tagged versions of the four reverse glyoxylate 
shunt proteins manually added. Interrogation of the database identified each of the 
proteins with an average sequence coverage of between 78% and 91% achieved from 
three technical replicates (Figure 83). An example protein sequence coverage for 
each target is shown in Figure 84. 
 
 






Figure 84: Peptide coverage maps for each of the target proteins. Generated from MSE characterisation of an 
equimolar mix of the four purified targets. Blue indicates a peptide match, red a partial peptide match, green a 
modified peptide match and yellow a partial modified peptide match.  
 
5.2.2.3 MSE characterisation of rGS1 overexpression strain 
 
To expand on this successful identification of the purified targets the ability to 
identify one of the target proteins against an E. coli proteome background was 
explored. To study this an E. coli strain engineered to overexpress ICL through IPTG 
induced T7 based expression was utilised. On this occasion the cells were lysed, and 
the entire cellular proteome digested, following the in solution tryptic digestion 
protocol described in Section 2.6.4. The resulting peptides were separated over a 
chromatographic gradient of 120 minutes and analysed using Synapt G2 mass 
spectrometer configured for MSE acquisition (Figure 85). The resulting data was 
analysed using PLGS and searched against the custom database generated in Section 
5.2.2.2 to confirm that identification of a single target proteins from an E. coli cell 





Figure 85: Chromatographic separation of E. coli proteome tryptic peptides over 120 minutes. The strain 
characterised is engineered for the overexpression of E. coli ICL. 
 
The analysis of this data via PLGS resulted in the identification of 173 E. coli 
cellular proteins. From these identified proteins, ICL had the highest sequence 
coverage with 93.5% (Figure 86). 
 
 
Figure 86: Isocitrate lyase protein coverage. Blue indicates a peptide match, red a partial peptide match, green a 
modified peptide match and yellow a partial modified peptide match. 
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In this study proteins were identified which ranged in size from 8 to 155 kDa and 
isoelectric points from 3.75 to 11.8 (Figure 87). The average number of peptides per 
protein identification in this dataset was 12.6 and no protein was identified from a 
single peptide whilst only 11% were identified from four or less peptides. The 
average protein coverage of the 173 proteins identified was 44.1%. 
 
 
Figure 87: Molecular weight and isoelectric point of proteins identified from E. coli lysate by MSE analysis. 
 
Analysis of the identified proteins revealed 20 which are involved in E. coli central 
carbon metabolism (Table 29). These proteins are likely to be of particular interest 
when engineering cellular metabolism as they are involved in the oxidation of main 
carbon sources whilst all natural metabolites produced by E. coli are derived from 12 
precursors which are either intermediates of central carbon metabolism or co-factors 
including NAD(P)H and ATP193. 
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P06994 MDH_ECOLI Malate dehydrogenase  32317 89.4231 TCA 
P08324 ENO_ECOLI Enolase 45495 71.2297 Glycolysis 
P00891 CISY_ECOLI Citrate synthase 48031 66.5105 TCA 
P06958 ODP1_ECOLI Pyruvate dehydrogenase E1 component  99474 66.3657 Glycolysis 
P06977 G3P1_ECOLI Glyceraldehyde 3-phosphate dehydrogenase A  35379 63.9394 Glycolysis 
P08200 IDH_ECOLI Isocitrate dehydrogenase [NADP]  45727 61.0577 Glyoxylate cycle 
P11665 PGK_ECOLI Phosphoglycerate kinase  40961 58.0311 Glycolysis 
P31217 PMG1_ECOLI Phosphoglycerate mutase 1  28407 53.4137 Glycolysis 
P07459 SUCD_ECOLI Succinyl-CoA synthetase alpha chain  29627 51.7361 TCA 
P30148 TALB_ECOLI Transaldolase B  35066 48.7342 PPP 
P11604 ALF_ECOLI Fructose-bisphosphate aldolase class II  38991 48.6034 Glycolysis 
P27302 TKT1_ECOLI Transketolase 1  72156 45.5505 PPP 
P00350 6PGD_ECOLI 6-phosphogluconate dehydrogenase_ decarboxylating 51449 43.1624 PPP 
P07460 SUCC_ECOLI Succinyl-CoA synthetase beta chain  41366 43.0412 TCA 
P10444 DHSA_ECOLI Succinate dehydrogenase flavoprotein subunit  64381 38.7755 TCA 
P07014 DHSB_ECOLI Succinate dehydrogenase iron-sulfur protein  26752 34.0336 TCA 
P00864 CAPP_ECOLI Phosphoenolpyruvate carboxylase  99000 27.9728 TCA 
P22259 PPCK_ECOLI Phosphoenolpyruvate carboxykinase [ATP]  59606 27.2222 Gluconeogenesis 
P78258 TALA_ECOLI Transaldolase A 35636 18.3544 PPP 
P14178 KPY1_ECOLI Pyruvate kinase I 50697 17.0213 Glycolysis 





The aim of this section was to establish that the MSE workflow was suitable for the 
identification of heterologously expressed proteins. To achieve this a purification 
strategy for the 4 target proteins was successfully designed through the introduction 
of a N-terminal His tag and Ni-NTA affinity chromatography. The purified targets 
were mixed in equimolar amounts and in-solution tryptic digestion performed. The 
peptides were analysed via the previously exemplified MSE workflow and the data 
used to interrogate a custom E. coli protein database that was supplemented with the 
heterologous proteins. This resulted in the successful identification of each of the 
target protein with up to 91 % protein coverage.   
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An E. coli cellular lysate from a strain engineered to over express once of the target 
proteins (ICL) was then lysed. Protein expression was induced, the cells lysed and 
the cellular proteins tryptically digested in-solution. The analysis of this lysate 
resulted in identifying the target protein with a protein coverage of 93.5%.  In 
addition to this a further 172 E. coli cellular proteins were identified spanning a 
range of molecular weights, isoelectric points and cellular functions in a single 
experiment.  
 





Inherent to the successful re-engineering of metabolic pathways to make high value 
chemicals is the development and utilisation of technologies that aid both their 
construction and the optimisation. Earlier chapters of this PhD have described 
methodologies to rapidly assemble biosynthetic pathway. This study will aim to 
complement this approach through applying MSE proteomics directly to the 
optimisation of a metabolic engineering approach. In the previous section of this 
chapter a workflow was developed for the identification of target proteins from 
cellular extracts. This will now be expanded to attempt label free quantification of 
pathway proteins using strains engineered to express the previously described reverse 
glyoxylate shunt. A library of genetic configurations designed to modulate the 
amount of each pathway protein will be screened for flux through the pathway using 
both solid and liquid phase analysis. Strains will then be characterised via MSE with 
the goal of identifying pathway bottlenecks and the identification of an optimal 







5.3.2.1 Construction of library to modulate gene expression 
 
The fine tuning of heterologous protein production levels is a key aspect to be 
considered when looking to optimise biosynthetic pathway implementation. This 
approach can be used to avoid the accumulation of pathway intermediates and limit 
the burden on the host cell67,194. In the case of the reverse glyoxylate shunt the 
expression of four heterologous enzymes requires to be balanced (MTK α/β, MCL 
and ICL). 
Multiple strategies can be implemented in order to modulate protein production 
including, strength of transcriptional promoter, RBS sequence, transcriptional 
terminator sequence, plasmid copy number and codon optimisation. In this study the 
three genes were designed to be expressed from a single plasmid in a synthetic 
operon.  Four constitutive promoters, standardly used for heterologous protein 
production, of varying strength were implemented (lambda phage pL, E. coli AspC, 
E. coli RecA and E. coli OSMY). To further modulate the amount of protein being 
produced the order of the three genes within the synthetic operon was shuffled 
(Figure 88). Previous studies on the order of genes within a synthetic operon have 
suggested that as the distance between the start of a gene and the end of the operon 
increases (“transcriptional distance”) so does the level of expression. This is due to 
genes at the start of the operon having more time to be translated during transcription 
of the remainder of the operon 195.  
 
Figure 88: Promoter strength and order of genes within the synthetic operon explored. Each potential 
combination was constructed resulting in 24 combinations. 
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A high throughput inABLE based combinatorial DNA assembly methodology was 
implemented to construct the 24 possible vectors.  In this study plasmid copy number 
and ribosome binding site (RBS) upstream of each gene were kept constant.  
 
5.3.2.2 Solid and liquid phase screening of library  
 
To assess the effect of gene order and promoter strength on the reverse glyoxylate 
shunt activity in vivo an E. coli screening strain was obtained. The construction of 
this strain was achieved through the deletion of citrate synthase (gltA) and 2-methyl 
citrate synthase (prpC) which has previously been reported to have minor citrate 
synthase activity196 generating a glutamate auxotroph as previously described190. To 
confirm the generated strain displays the expected phenotype, glutamate auxotrophy 
was assessed through plating the Glu- strain (gltA prpC) onto LB rich media and 
minimal media +/- glutamate. The auxotroph was unable to grow on minimal media 
lacking the glutamate addition confirming the expected auxotrophy (Figure 89).  
 
 
Figure 89: Confirmation of glutamate auxotrophy in Glu- (ΔgltA ΔprpC) strain through growth LB rich media and 




An initial vector for expression of the three genes comprising the rGS under the 
control of the pRecA promoter was introduced into the resulting strain (ΔgltA 
ΔprpC) and the complementation of glutamate auxotrophy through channelling 
carbon across the rGS was confirmed by the ability of the resulting strain to grow on 
glucose minimal media supplemented with succinate (Figure 90).  
 
 
Figure 90: Metabolic pathway for complementing glutamate auxotrophy through the reverse glyoxylate shunt. 
 
The introduction of an empty vector failed to rescue the auxotrophy and growth was 
not detected.  As the cell is unable to produce glutamate through any other route than 
the reverse glyoxylate shunt the growth rate on this media is a direct consequence of 





Figure 91: Complementation of succinate auxotrophy via the rGS. A1: Initial rGS expression construct. B1: Plating 
of Glu- strain harbouring rGS expression vector +/- succinate. A2/B2 Repeated with negative control. 
 
This was exploited as an initial screening platform to characterise the vector library 
in a solid phase screen.  Following selection on glucose minimal media plates 
supplemented with succinate, forty of the largest colonies were isolated and the 



























6.1 pOSMY MCL-ICL-MTK 
7.1 pA 
ICL-MTK-MCL 
7.2  pOSMY 
Table 30: Genetic characterisation of fastest growing libraries members identified from solid phase screen 
 
This initial approach identified 14 strains with unique genetic configurations which 
were able to grow on minimal media supplemented with succinate and therefore 
channel carbon through the reverse glyoxylate shunt. A negative control strain 
containing an empty vector was again unable to proliferate on this media. Whilst the 
results of this initial study suggested that multiple genetic configurations result in an 
active rGS the optimal gene order or promoter for rGS activity was difficult to 
define. In fact, each of the four promoters implemented was observed and only the 
operon order ICL::MCL::MTK was not detected.    
To further characterise the 14 strains identified in the first round of screening the 
growth profile of each strain in minimal media supplemented with glucose and 
succinate was observed (Figure 92). This approach allowed ranking of isolates 
however once again no pattern of optimal genetic configuration and therefore 
optimal balance of pathway proteins was easily identifiable. In fact, the three strains 
which displayed the quickest growth rates (4.1, 4.4 and 5.1) differed gene order and 
promoter (Table 30). Strain 5.1 carries a strong promoter and the MCL gene in 
operon position one suggesting that high expression of this protein may be required 
for optimised flux. However, in strains 4.1 and 4.4 the MCL gene is in position three 




Figure 92: Growth curves of 14 library members identified in solid phase screen. Growth curves the result of 
triplicate experiments generated in minimal media supplemented with glucose and succinate. Strain ID found in 
Table 30. 
 
Three strains (5.1, 5.7 and 6.1) were selected for further analysis of heterologous 
protein abundance. One slow grower, one intermediate and one fast grower were 
taken forward for initial MSE based quantification of rGS protein levels to determine 
if an optimal protein abundance at each stage in the pathway could be identified and 
secondly how the genetic configuration affected protein output.   
 
5.3.2.3 Heterologous pathway protein quantification 
 
The three strains selected (rGS 5.1, rGS 5.7 and rGS 6.1) displayed differing growth 
rates in the liquid phase assay (rGS5.1 > rGS 6.1 > rGS5.7) (Figure 92) and contain 
differing genetic configurations (Table 30), however no clear correlation between 
growth rate, promoter strength and operon order could be deciphered. Analysis of the 
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soluble fractions generated from the three strains prior to tryptic digestion through 
SDS-PAGE was complicated by the target proteins having similar sizes, for example 
Malyl–CoA lyase (37 kDa), Malate thiokinase β-subunit (31 kDa) and Malate α-
subunit (44 kDa). A tentative hypothesis would be that based on the SDS-PAGE, 
strain 5.1 – the fastest grower – is producing higher amounts of MCL than the other 
strains characterised by the band present above 32 kDa in lanes 1 to 3 in the SDS-
PAGE which is not present in the other lanes (Figure 93). However, without target 
specific antibodies this is difficult to confirm.  
 
 
Figure 93:  SDS-PAGE analysis of the three rGS expressing strains proteomes prior to tryptic digestion. Strain A, B 
and C relate to rGS 5.1, rGS 5.7 and rGS 6.1 respectively. 
 
Tryptically digested cellular proteomes from biological triplicates of the three strains 
were prepared for MSE analysis as previously described. The data was collected as 
previously however in order to allow for relative protein quantification the resulting 
data was processed using the Progenesis QI for Proteomics platform (Nonlinear 
Dynamics) for label free relative protein quantification.  
Relative protein quantification was performed using the Hi-3 methodology described  
by Silva et al135.  Quantification was carried out following peptide and protein 
identification and was achieved through averaging the abundance of the three most 
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abundant peptides per protein giving a value for the protein signal. This averaged 
value allowed for relative quantification of the same protein across runs. It is 
possible - with the addition of a calibrant - to convert this number into an absolute 
value.  
In this study relative quantification between strains was performed. Following 
protein quantification proteins with a P value > 0.05 and a max fold change < 2 were 
omitted. This resulted in 32 quantified proteins including the four reverse glyoxylate 
shunt proteins for analysis. To act as a technical replicate a pool prepared from all 
the samples analysed was run in triplicate throughout the experiment to monitor for 
column condition, sample degradation or other factors that may impact the analysis. 
The max fold change in the four rGS proteins from this pool analysis was 1.8 fold. 
As an additional control the chloramphenicol acetyltransferase which is expressed 
from the plasmid acting as a selection marker was also quantified giving a max fold 
change of 1.7 between samples. 
Results from each run were grouped per strain, the abundance normalised across runs 
and relative average abundances calculated for each of the target proteins (Figure 
94). These results suggest that the least active strain (rGS 5.7), produces high levels 
of isocitrate lyase but low levels of the other rGS proteins whilst the most active 
strain (5.1) appears not to overproduce any one of the pathway proteins and instead 
displays a more balanced pathway protein output.   
 
 
Figure 94: Average normalised relative abundances generated from the three reverse glyoxylate shunt 
expressing strains explored in this study. 
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To further characterise the differences in protein abundance between the strains 
analysed, the fold difference in each protein between the strains was calculated. It 
was found that the highest fold change observed for any of the proteins quantified 
was a 33.76 fold increase in malyl-CoA lyase abundance between the most active 
strain (5.1) and the least active strain (5.7) (Table 31). This result suggests that the 




Table 31: Maximum relative fold changes in the target rGS proteins observed between engineered strains. The 
largest fold change observed was a 33.76 fold increase in MCL abundance in strain rGS5.1 (the best performing 
strain) in comparison to rGS5.7 (the worst performing strain) 
 
5.3.3.4 Identification of pathway bottleneck through individual gene downregulation 
 
To further explore this hypothesis, a series of vectors were constructed to simulate 
the under expression of each pathway enzyme and the effect this has on carbon flux 
through the reverse glyoxylate shunt.  The pathway was split between two plasmids 
one of which included a high copy origin of replication (pBR322 ~15-20 copies197) 
and strong promoter whilst the other included a lower copy ori (p15a ~ 10 copies198) 
and a weak promoter. Each of the genes were introduced independently to the high 
copy promoter vector to determine the effect of individual gene up regulation on 
carbon flux. A control construct in which the full operon was expressed from the 
high copy plasmid was constructed in parallel. The resultant vectors were introduced 
into the Glu- strain and, as previously, screened on minimal media supplemented 
with glucose and succinate (Figure 95).  
Target Protein Max fold change in abundance Strain with highest abundance Strain with lowest abundance
ICL 17.04 rGS5.7 rGS5.1
MTKα 15 rGS5.1 rGS5.7
MTKβ 5.74 rGS5.1 rGS5.7




Figure 95: The effect of individual gene downregulation on the ability of strains to channel carbon through the 
rGS. Growth on a minimal media agar plate supplemented with glucose and succinate was only achieved when 
MCL was expressed using a strong promoter from a high copy number plasmid. 
 
These results show that growth on this media and therefore flux through the reverse 
glyoxylate shunt was only achieved for the positive control strain and when the MCL 
gene was expressed from the high copy/strong promoter construct. This result 
supports the finding from the MSE based analysis, highlighting that high levels of 
expression of MCL is key for successful carbon channelling through the reverse 




A key consideration when embarking on a metabolic pathway engineering project is 
the fine tuning of expression of heterologous pathway proteins to optimise strain 
performance. Through modulation of protein levels, unnecessary metabolic burden 
can be avoided whilst also ensuring pathway intermediates do not build up. In this 
study the reverse glyoxylate shunt was used as a test case to exemplify the utilisation 
of proteomics coupled to high throughput screening and synthetic biology 
approaches to accelerate metabolic engineering programs. This study highlights the 
177 
 
greater depth of knowledge that can be garnered from techniques such as LC-MS 
based proteomics and how this knowledge, which would not be generated from 
traditional product formation assays, can be used to guide subsequent rounds of 
metabolic engineering.   
In this section a library of vectors designed to modulate the levels of expression of 
the enzymes involved in the introduction of reverse glyoxylate shunt into E. coli 
were characterised. This characterisation combined with the use of solid and liquid 
phase analysis with label free protein quantification to identify pathway protein 
abundances and correlate these abundances to pathway performance. It was found 
through label free protein quantitation that the best performing strain had a 33-fold 
increase in malyl-CoA lyase abundance in comparison to the worst performing 
isolate suggesting the abundance of this enzyme is key for pathway performance. 
This finding was confirmed through the simulated under-expression of each pathway 
protein, which confirmed that MCL required to be highly expressed to facilitate flux 





















The replacement of conventional processes to manufacture valuable industrial 
products and the selection of optimal biosynthetic routes requires the construction, and 
in most cases subsequent context-dependent evaluation, and optimization of 
multicomponent biosynthetic pathways to generate commercial end products. This 
PhD has focused on the development of an industrial platform for microbial strain 
improvement which addresses the persistent limitations associated with today’s 
iterative and empirical approaches. To achieve this, I have developed a DNA assembly 
platform which is optimised for both accuracy and efficiency and coupled this 
approach to mass spectrometry based proteomics techniques and direct screening 
methods to identify strains with improved process efficiency. 
The DNA assembly technique is state of the art, enabling the optimised combinatorial 
assembly of DNA fragments for large scale gene/pathway assembly and optimisation. 
To achieve this a systematic overview of the previous inABLE technology was 
undertaken and key factors limiting DNA assembly identified and addressed. Despite 
this, the process still required the purification of DNA fragments through gel 
electrophoresis, which limits the potential to automate the process. To address this key 
technical hurdle a novel purification platform based on phosphorothioate bond 
mediated DNA protection and exonuclease degradation of contaminating DNA was 
developed. It was found that the DNA of interest could be purified through 
exonuclease addition, removing the requirement to run agarose gels, greatly enhancing 
process efficiency and ensuring the technique is amenable to process automation. The 
introduction of this step did not reduce assembly efficiency in comparison to gel 
electrophoresis and in fact was found to increase assembly accuracy in previously 
difficult to assemble constructs.  
This innovation and optimisation has resulted in a strategy which can be considered 
alongside the Gibson78 and Golden Gate80 approaches - two of the most widely used 
DNA assembly approaches199 – as the method of choice for combinatorial assembly 
of DNA. As the cost of DNA synthesis continues to decrease86, the cloning of a single 
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gene will become a process which is no longer carried out by the researcher and instead 
is outsourced to DNA synthesis providers. This highlights the fact that it is increasingly 
important that DNA assembly techniques are optimised for the large scale production 
of combinatorial libraries as the complete chemical synthesis of these libraries will 
likely remain cost prohibitive for the foreseeable future.  The ability to mix and match 
target genes with regulatory regions to identify levels of expression which results in 
optimal flux through the required pathway without placing unnecessary burden on the 
host organism has proven a successful strain engineering strategy33, 200. The platform 
developed in this thesis provides the ability to build combinatorial DNA libraries 
rapidly and accurately in an automated manner and has the potential to greatly 
accelerate strain engineering programs. A patent has been applied for to protect this 
invention and work has now been initiated on the automation of the process through 
transferring the optimised protocol onto a liquid handling robot.  
Obvious synergy exists between this approach and label free quantitative proteomics 
coupled to versatile, solid phase screening and selection. The generation of 
information on pathway protein abundances in combination with target production and 
cellular growth rate has been used previously to identify clear and focused targets for 
the next stages of pathway optimsiation73,117. In this thesis, methods were developed 
to identify engineered cells of interest, pathway bottlenecks and guide subsequent 
rounds of pathway optimisation. The label free MSE platform, initially described by 
Silva et al134,135, was identified as a suitable approach for the flexible analysis of 
protein abundances in engineered microbes. Robust liquid chromatography, MS and 
data analysis methods were developed to identify and quantify multiple key cellular 
proteins from engineered strain lysates. The approach was applied to the 
implementation of a reverse glyoxylate shunt in E. coli and this strategy coupled to 
liquid and solid phase screening approaches allowed for the ranking of strain 
performance and the identification of pathway bottlenecks limiting flux through the 
pathway.  
MSE analysis highlighted a 33-fold increase in abundance of one pathway protein – 
MCL from R. sphaeroides - when comparing a well performing strain against a poor 
performing strain. The findings from the MSE analysis were then confirmed through 
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simulated under expression of each pathway enzyme in vivo where it was shown that 
only when the MCL was overexpressed was flux through the pathway observed.   
This study highlights the greater depth of knowledge that can be garnered from 
techniques such as LC-MS based proteomics and how this knowledge, which would 
not be generated from traditional product formation assays, can be used to guide 
subsequent rounds of metabolic engineering. Future work will focus on expanding the 
scope of this approach to study not only heterologous proteins but also the effect the 
introduction of the biosynthetic pathway has had on the host proteome. This data 
would then be used to inform the next stages of strain optimisation.  
This thesis aimed to address the primary issues cited by end users as to why 
bioprocesses are not more readily taken up – their development is too slow, too 
unpredictable and too expensive. The integration of the methodologies described in 
this study for pathway engineering and analysis have the potential to address these 
concerns through the creation of a step change in the speed and predictability with 
which microbes can be engineered for industrial applications. Ingenza is currently 
applying this platform to synthetic biology programs for the bio-production of plastic, 
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